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Abstract 
 
It is widely recognised that most proteins are subject to some form of post 
translational modifications such as glycosylation. Glycosylation has been shown to 
impact correct protein folding, protein stability, solubility, to aid in cell recognition 
and to help regulate cell processes. A deeper understanding into the effect of altered 
glycosylation patterns on cellular processes such as, cell recognition and protein 
function is necessary. Therefore, the development of new sensitive and accurate 
technologies that may be used to detect, separate and quantify glycans and 
glycoproteins is of increasing importance. 
The objective of this work was to develop prokaryotic Cry proteins as novel 
carbohydrate-binding molecules that could be potentially used as ligands for the 
affinity based detection and separation of glycans and glycoproteins. Recombinant 
proteins tCry1Ac and CryD3 were designed based on the Cry1Ac toxin from 
Bacillus thuringiensis. tCry1Ac and CryD3 were cloned into pQE60 which contained 
a 6x histidine tag. The expression of tCry1Ac and CryD3 was carried out in E. coli 
JM109. tCry1Ac and CryD3 were purified by immobilised metal affinity 
chromatography (IMAC) with additional GalNAc/galactose washes to remove 
persistent contaminating proteins from E. coli. tCry1Ac and CryD3 carbohydrate 
binding abilities were examined by Enzyme linked lectin assay (ELLA). tCry1Ac 
was found to have specificity to GalNAc and the Tn antigen while CryD3 had 
specificity to α1-3, galactose. Site directed mutagenesis was carried out on the 
predicted binding sites of tCry1Ac and CryD3. Residues N480, Q483, Y487 and 
N521 for tCry1Ac and N45, Q48, Y52 and, N86 for CryD3 were mutated to alanine, 
expressed, purified and their carbohydrate specificity examined. The N86A mutant 
was the only protein that showed significant activity, binding to GalNAc and 
galactose on an ELLA. This suggests that the binding site for GalNAc and galactose 
in tCry1Ac and CryD3 is the same and may be altered with relative ease by 
mutagenesis. This result also confirmed that residue N86 plays an important role in 
the structure of the binding site and its recognition of the specific sugar as when 
mutated to alanine it changed the specificity from galactose to GalNAc. 
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 Introduction 
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1.1 Protein – Carbohydrate interactions 
Protein – carbohydrate interactions are important in biological processes, in nature 
and in bio-analytical techniques. Many pathogens have developed carbohydrate 
binding proteins which allow them to recognise and target their host. These specific 
interactions are particularly important, and need to be studied to give us a deeper 
understanding of protein – carbohydrate interactions, which will enable the 
development of novel bio-analytical techniques.  
 
1.2 Microbial Carbohydrate Binding proteins; lectins and toxins   
Microorganisms have long been known to exploit host cell-surface glycans as 
recognition sites and receptors for cell attachment and tissue colonization. A large 
number of pathogenic species depend on these interactions for infection (Bektas and 
Rubenstein 2011; Williams and Davies, 2001; Rostand et al. 1997). Viruses, bacteria, 
fungi and protozoa express a variety of carbohydrate binding proteins including 
toxins and lectins (Varki et al. 2009). Many of these microbial lectins were originally 
detected based on their ability to aggregate red blood cells. The first microbial 
hemagglutinin identified was in the influenza virus, and it was shown by Alfred 
Gottschalk in the early 1950s to bind to erythrocytes and other cells though sialic 
acid residues of cell-surface glycoconjugates (Varki et al. 2009). In 1981, the viral 
hemagglutinin was crystallized to determine its structure. These studies accelerated 
the research into other types of microbial lectins (Varki et al. 2009).  
Bacterial surface lectins were first described in the 1970s. These lectins also 
exhibited hemagglutinating activity, but their primary function is to facilitate 
attachment or adherence of bacteria to host cells, a prerequisite for bacterial 
colonization and infection (Varki et al. 2009). Certain bacteria also produce 
carbohydrate-binding protein toxins, whose actions often depend on glycan-binding 
subunits that allow the toxin to combine with membrane glyco-conjugates to deliver 
the functionally active toxic subunit across the membrane (Varki et al. 2009; Kitov et 
al. 2000). A number of secreted bacterial toxins also bind to glycans and are 
summarized in table 1.1. This project is interested in the Cry toxins from Bacillus 
thuringiensis, as they have been identified as having ‘lectin-like’ binding domains, 
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multiple receptors and they do not harm animals or humans. Therefore, these protein 
toxins could potentially be used as novel carbohydrate binding molecules. 
 
Table 1.1: Examples of microbial toxins and their targeted glycosylated site. Cer 
indicates ceramide. Gangliosides are defined using the Svennerholm nomenclature. 
N-acetylgalactosamine (GalNAc), Galactose (Gal), Glucose (Glc), Mannose (Man), 
N-Acetylglucosamine (GlcNAc) 
Microorganism Toxin Proposed receptor sequence Target tissue 
Bacillus 
thuringiensis 
crystal toxins Galβ1–3/6Galα/β1–3(±Glcβ1–
6)GalNAcβ GlcNAcβ1–
3Manβ1–4GlcβCer 
intestinal 
epithelia of 
insects 
Clostridium 
botulinum 
botulinum 
toxins (A–E) 
gangliosides GT1b, GQ1b nerve 
membrane 
Clostridium 
difficile 
toxin A GalNAcβ1–3Galβ1–
4GlcNAcβ1–3Galβ1–4GlcβCer 
large intestine 
Clostridium tetani tetanus toxin Ganglioside GT1b nerve 
membrane 
Escherichia coli heat-labile 
toxin 
GM1 intestine 
Shigella 
dysenteriae 
Shiga toxin Galα1–4GalβCer Galα1–
4Galβ1–4GlcβCer 
large intestine 
Vibrio cholerae cholera toxin GM1 small intestine 
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1.3 Introduction and Background of the Bacillus thuringiensis toxins 
Bacillus thuringiensis (Bt) is a gram positive insect pathogen. It has the ability to 
produce spores with parasporal crystals. These crystals contain toxins that become 
activated when the correct pH and environment is reached in the insect gut (Schnepf 
et al. 1998). These toxins, known as Cry (crystal) or Cyt (cytotoxic) have proven to 
be very important in controlling crop pests and mosquitoes (Bravo et al. 2011). Bt 
was first discovered in 1901 in Japan as the cause of wilt disease in silk worm 
(Bombyx mori) (Bravo et al. 2011). Since then many Bt strains have been identified 
all over the world (Crickmore 2013). Bt strains have been found to be active against 
Lepidoptera, Diptera, Coleoptera, Hymenoptera, Homoptera, Orthoptera and 
Mallophaga insect orders (Schnepf et al. 1998). Some Cry toxins have shown activity 
against nematodes, mites and protozoa (Wei et al. 2003; de Maagd et al. 2001; 
Crickmore et al. 1998; Schnepf et al. 1998). 
Research started by Berliner in 1938, led to the first Bt formulation for use 
against insect pests on crops (Bravo et al. 2011).  This work led to the first study of 
the toxins that were being expressed by Bt. The cry gene toxins were discovered on 
large plasmids flanked by transposable elements (Pigott and Ellar 2007). In the years 
following the focus was to clone these toxins and identify their toxicity to insects as 
well as examining their structure and mode of action (Adang 1991; Sekar et al. 1987; 
Adang et al. 1985). The success of Bt as a bioinsecticide was in the development of 
Bt crops that express a cry gene, which resulted in insect resistant crops (Adang et al. 
1993; Dean and Adang 1992; Adang et al. 1986). The advantage of using Bt toxins is 
that they are specific to a limited number of insect species and there is no toxicity 
against humans or other organisms (Bravo et al. 2011). James, (2010) reported that 
there was more than 58 million hectares of Bt-maize or Bt-cotton grown worldwide.  
The main disadvantage of Bt crops is the appearance of insect resistance to the Cry 
toxins. The emergence of resistance has been well documented for many species 
(Gassmann et al. 2011; Bagla 2010; Storer et al. 2010; Tabashnik et al. 2008; van 
Rensburg 2007; Jurat-Fuentes, Gould and Adang 2000; Ramachandran et al. 1998; 
Moar et al. 1995). From the emergence of resistance many research groups began 
examining the Cry toxins in greater detail, investigating their mode of action and in 
particular the binding of the protein to the insect intestinal cell membrane (Hua et al. 
2001; Jurat-Fuentes and Adang, 2001; Garczynski and Adang 2000; Luo, Banks and 
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Adang 1999). Some of the receptors for Cry toxins on the insect cell membranes 
were isolated through binding studies on the brush border membrane vesicles of 
insects (BBMV’s) (Garczynski and Adang 2000; Hua et al. 2001).  To examine 
toxicity and resistance, domain swapping, mutagenesis and binding studies were 
carried out on several Cry toxins. In particular, significant work was carried out on 
Cry1Ac from the strain Kursatki HD-73 as it was found to be one of the most widely 
used and lethal Cry toxins to insects (Jurat-Fuentes and Adang 2007; 
Krishnamoorthy et al. 2007; Jurat-Fuentes et al. 2003; McNall and Adang 2003; 
Banks et al. 2001; Lee et al. 2001; deMaagd et al. 1999; Jenkins et al. 1999; Singsit 
et al. 1997; Lu et al. 1996; Singsit et al. 1996; Stewart et al. 1996; Masson et al. 
1995; Garczynski and Adang 1995; Sangadala et al. 1994).  
With this research came a greater understanding of the mode of action of Cry 
toxins, the identification of receptors on the insect cell, enhanced toxicity against 
specific insects and the ability to recover toxicity in the case of appearance of 
resistance (Pardo-Lopez et al. 2009). One finding of particular interest, was the 
specific binding of Cry1Ac to an N-Acetylgalactosamine (GalNAc) sugar residue on 
the aminopeptidase N of the insect gut (Rodrigo-Simon, Caccia, and Ferre 2008; 
Knowles, Knight, and Ellar 1991). It is evident that some Cry toxins have taken 
advantage of the recognition of the O-glycosylation on the insect gut and have 
specifically targeted this area (Burton et al. 1999). In recent years the focus of Cry 
toxin research has been to genetically engineer the Cry toxins to enhance toxicity, 
discover new cry genes through qPCR, identify the receptors through proteomics and 
characterise these insect receptors (Hua et al. 2009; Perera et al. 2009; Abdullah et al. 
2009; Bayyareddy et al. 2009; Jurat-Fuentes and Adang 2007). 
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1.4 Toxin nomenclature 
 
The Bacillus thuringiensis delta-endotoxin nomenclature committee was set up in 
1993 in order to update the nomenclature originally devised in 1989 by Hofte and 
Whiteley. This system provided a useful framework for classifying the ever-
expanding set of known genes. However, inconsistencies existed in the scheme due 
to attempts to accommodate genes that were highly homologous to known genes but 
did not encode a toxin with a similar insecticidal spectrum. Crickmore et al (1998), 
proposed a revised nomenclature for the cry and cyt genes. To organise the vast 
amount of data produced by genomic sequencing efforts, a new naming system 
emerged, exemplified by the cytochrome P-450 superfamily nomenclature system 
(Crickmore et al. 1998). The system that they put forward conformed closely to this 
model both in conceptual basis and in nomenclature format. The underlying basis of 
this type of system is to assign names to members of gene superfamilies according to 
their degree of evolutionary divergence as estimated by phylogenetic tree algorithms 
(Crickmore et al. 1998). Roman numerals were exchanged for Arabic numerals in the 
primary rank (e.g., Cry1Aa, Cry1Ab) to accommodate the large number of expected 
new proteins. The definition of a Cry protein put forward by Crickmore et al. (1998), 
is a parasporal inclusion (crystal) protein from B. thuringiensis that exhibits some 
experimentally verifiable toxic effect to a target organism, or any protein that has 
obvious sequence similarity to a known Cry protein (Crickmore et al. 1998). 
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1.5 Cry toxin diversity 
 
The huge variety of known Cry proteins is as a result of continuing efforts to isolate 
and characterise new strains of Bt. It is hoped that this would result in novel toxins 
that could be used for the control of pests. Thousands of strains have been screened 
and there are currently over 150 unique Cry toxins according to the Bt toxin 
nomenclature webpage. http://www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/ 
This huge diversity of cry toxins is believed to be due to a high degree of genetic 
plasticity while many cry genes are flanked by transposable elements that may 
facilitate gene amplification, and in turn developing new toxins. The cry genes are 
found on plasmids, thus horizontal transfer by conjugation may result in the creation 
of new strains with novel cry genes (Pigott and Ellar, 2007). 
Due to the large number of known Cry toxins it has permitted comparative sequence 
analyses and has helped to reveal elements important for both basic toxin function 
and insect specificity. Hofte and Whiteley carried out the first detailed analysis of 
Cry protein sequences in 1989 when 13 Cry proteins were known and assigned to 
one of four groups based on their insect specificity. The sequence alignment of these 
proteins showed a high degree of diversity among the Cry toxins. In most of the 
sequences, however, five blocks of conserved amino acids were discovered. 
Therefore the discovery of new Cry proteins encouraged further analysis by Bravo 
(1997) and de Maagd et al (2001). Most of the toxins examined had some or all of 
the five conserved blocks, which suggested that these regions may be important for 
toxin stability or function.  
Natural resources Canada set up a Bacillus thuringiensis toxin specificity database as 
part of their Microbial control agents project. The ongoing discovery of new Bt toxin 
genes and rapid accumulation of information on their insecticidal activities prompted 
them to construct a relational database on Bt. toxin specificity to make the 
information accessible in a searchable format 
http://www.glfc.cfs.nrcan.gc.ca/bacillus (Frankenhuyzen et al. 2002). 
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1.6 Evolution of the Cry toxins 
 
To date, over 700 cry gene sequences have been identified due to extensive screening 
and sequencing of Bt strains (Crickmore et al. 2011). These sequences have been 
classified according to their amino acid sequence identity in around 70 different cry 
gene groups and the toxins in these groups share less than 40% amino acid identity 
with toxins in other groups (Crickmore et al. 1998, 2011). The Cry toxins are flanked 
by transposable elements which are located on large plasmids in Bt. It is thought that 
this could be one reason for the large range of toxins and their similarities in 
structure. Phylogenetic analysis of Cry toxin sequences showed that the family of 
Cry proteins belong to four non-phylogenetically related protein families (i) the 
family of three domain Cry toxins (3d), (ii) the family of mosquitocidal Cry toxins 
(Mtx), (iii) the family of the binary-like (Bin) and (iv) the cytotoxic (Cyt) family of 
toxins (Bravo, Gill, and Soberón 2005). Among these toxins, the lineage of 3d-Cry 
toxins represents the largest group with more than 53 different subgroups of Cry 
toxins (Crickmore et al. 2011). One particular feature of the 3d-Cry group is the 
presence of protoxins with two different molecular sizes, namely, 65 and 130 kDa. 
Cry1Aa, Cry2Aa, Cry3Aa, Cry3Ba, Cry4Aa, Cry4Ba and Cry8Ea all have their 
crystal structure resolved and this shows a large amount of structural similarity in all 
toxins (Pigott and Ellar 2007). This group of toxins are known by their production of 
bacterial protoxins during sporulation which can be either large 130kDa or short 
protoxins 65-70kDa. The large protoxins are processed by insect gut proteases where 
much of the C terminal and a short fragment of the N terminal end are cleaved, thus 
yielding a protease resistant core that is biologically active (de Maagd et al. 2001).  
Evolutionary analysis of domain I and II reveal that they co-evolved as different 
toxins (Crickmore 2000; Bravo 1997). Analysis of domain III however showed 
domain swapping among several toxins. Therefore domain III swapping among Cry 
toxins could be an active evolutionary development for determining insect specificity 
(de Maagd et al. 2001; Bravo 1997). Wu and co-workers (2007) investigated 
adaptive evolution in Cry toxins and identified several residues that are under 
positive selection. Positive selection favours the retention of mutations that are 
beneficial to a protein. Most of the 24 identified residues were located in domains II 
loop regions or domain III. This may provide some indication that these areas are 
likely to be involved in receptor binding. It was proposed that high divergence in 
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these regions could promote rapid evolution to their target receptors (Wu et al. 2007). 
The diversity of the Cry toxins is speculated to be a result of the independent 
evolution of the three domains with domains II and III under positive selection and 
domain III involved in domain swapping. This generated Cry toxins which have 
similar structure and mode of action but different specificities.  
 
 
1.7 Structure of the 3d-Cry toxins 
 
1.7.1 Cry Toxin Domain I 
 
Domain I is located on the N terminal of the Cry toxin and is a collection of seven 
alpha helices where the central helix is hydrophobic and circled by amphipathic 
helices. (See figure 1.2) This is the helical domain responsible for membrane 
insertion and pore formation. Domain I shares similarities with other pore forming 
toxins (PFTs) such as colicin (see figure 1.1) which further supports that it plays a 
role in pore formation (Bravo, Gill, and Soberón 2008). 
 
Figure 1.1: Crystal structure of colicin N (PDB code, 1A87). The helical bundle 
with structural similarity to Cry toxin domain I is shown in red (Pigott and Ellar 
2007). 
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1.7.2 Cry Toxin Domain II 
 
Domain II consists of three antiparallel beta sheets, where the loop regions are 
exposed (See figure 1.2). These areas are thought to be involved in receptor binding. 
This is supported by the fact that structural similarities have been shown between 
domain II and several carbohydrate binding proteins like vitelline, lectin jacalin and 
the lectin Mpa (De Maagd et al. 2003). 
 
1.7.3 Cry Toxin Domain III 
 
Domain III is a beta sandwich and has been reported to have a role in both receptor 
binding and structure (Pigott and Ellar 2007). Domain III shares structural 
similarities with carbohydrate binding proteins which include the cellulose binding 
domain of 1, 4 beta glucanase C, galactose oxidase, sialidase, beta- glucoronaidase, 
the Carbohydrate Binding Domain (CBD) of of xylanase U and beta-galactosidase 
(Pigott and Ellar 2007). These enzymes generally consist of a catalytic domain linked 
to one or more Carbohydrate binding Molecules (CBMs). The function of the CBM 
is to target the catalytic domain to its polysaccharide substrate (Pigott and Ellar 
2007). This enhances the enzyme’s catalytic efficiency by increasing its effective 
concentration at the substrate surface. This could imply that carbohydrate moieties 
have an important role in receptor binding and toxicity for these toxins.  
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Figure 1.2: Crystal structure of Cry1Aa, Cry2Aa, Cry3Aa, and Cry4Ba. Domain 
I, domain II, and domain III are shown in red, green, and blue, respectively. The N-
terminal protoxin domain of Cry2Aa is shown in yellow (Pigott and Ellar 2007). 
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1.8 Mode of Action of the 3d-Cry toxins 
 
3d-Cry toxins are recognised as pore forming toxins that lyse insect midgut cells by 
osmotic shock. For this to happen the parasporal crystals have to be ingested by the 
larvae, solubilised by the pH of the insect gut and activated by proteases to yield an 
activated toxin. Activated Cry1A subsequently binds to the insect gut through a 
mechanism with Glycosylphosphatidylinositol (GPI) anchored proteins such as 
alkaline phosphatase (ALP) or aminopeptidase-N (APN) and cadherin like protein 
which result in the formation of a pre-pore structure (Bravo et al. 2011; Pacheco et 
al. 2009; Pigott & Ellar 2007; Bravo et al. 2004). 3d-Cry toxins may also bind to 
glycans, glycolipids and certain intracellular proteins (Bayyareddy et al. 2009; 
Krishnamoorthy et al. 2007; Griffits et al. 2005; McNall and Adang 2003). Figure 
1.3 shows the morphological changes in midgut cells of Manduca sexta larvae after 
ingestion of the toxin. Bravo, Jansens and Peferoen (1992) reported that the toxins 
were immunolocalized in the apical microvilli of the midgut cells. Figure 1.3 shows 
the mechanism of action of the 3d-Cry toxins in Lepidoptera at the molecular level. 
Another model for the mode of action of Cry toxins, proposed by Zhang et al (2006) 
illustrates that binding to cadherin is sufficient to trigger an intracellular signal 
transduction pathway leading to cell death.  This intracellular pathway results in 
activation of a G protein with subsequent activation of adenylyl cyclase, raising 
cAMP levels and activating a protein kinase A that in turn leads to cell death without 
involvement of oligomer formation and toxin pore formation. However nontoxic Cry 
toxin mutants were constructed that affected toxin oligomerisation and pore 
formation but this did not affect their binding to cadherin. This illustrates that 
binding to cadherin alone is not sufficient for toxicity (Rodrıguez-Almazan et al. 
2009; Girard et al. 2008; Jimenez-Juarez et al. 2007; Vachon et al. 2002).  
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Figure 1.3: The mechanism of action of Cry (3D) toxins in Lepidoptera at the 
cellular level. Showing the immunolocalization of Cry toxin during toxication 
(Bravo, Jansens, and Peferoen 1992). 
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Figure 1.4: The mechanism of action of 3d-Cry toxins in Lepidoptera at the 
molecular level:  
1. The larvae ingest the Cry protoxin, which is solubilised in the midgut due to high 
pH and activated by gut proteases. 2. The monomeric Cry toxin binds ALP and APN 
receptors; in a low-affinity interaction, the toxin is then located close to the 
membrane. 3. The Cry toxin binds the CAD receptor in a high-affinity interaction 
and this interaction induces proteolytic cleavage of the N-terminal end of the toxin. 
4. The cleaved 3d-Cry toxin oligomerises in a toxin prepore oligomer. 5. The 
oligomeric Cry structure binds to ALP and APN receptors with high affinity. 6. The 
toxin inserts into the membrane causing pore formation (Pardo-Lopez et al. 2012). 
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1.9 Investigating the Receptors of the 3d-Cry toxins  
Much of the research that has been done to date on receptor binding of Cry toxins is 
largely focused on how receptor binding affects toxicity and how the toxicity may be 
increased. Some of the receptors that have been identified are; cadherin receptor 
(CADR), aminopeptidase-N (APN), alkaline phosphatise (ALP), GalNAc on the 
APN or ALP and, 270 kDa glyco-conjugate receptor (GCR) (See figure 1.5). Various 
methods used to analyse receptor binding and pore formation of the toxin have been 
examined including light scattering of liposomes or brush border membrane vesicles 
(BBMV) (Carroll and Ellar 1993; Haider and Ellar 1989), leakage of 86Rb+–K+ and 
leakage of calcein from BBMVs (Rausell et al. 2004; English, Readdy and Bastian 
1991) ,  analysis of single-channel currents in black lipid bilayers (Lorence et al. 
1995; Schwartz et al. 1993), analysis of ion amino acid co-transport (Hendrickx et al. 
1990),  analysis of changes in membrane potential (Munoz-Garay et al. 2006; 
Lorence et al. 1995) and studies of short-circuit currents in midgut tissues (Liebig, 
Stetson and Dean 1995).  
 
As outlined in section 1.7, Domains II and III have been identified as the receptor 
binding domains for the 3d-Cry toxins. A considerable amount of work has been 
done on domain swapping and mutagenesis to analyse the nature of the binding to 
receptors on the insect midgut.  Mutagenesis has been carried out on domain II for 
many Cry toxins (Griffitts et al. 2005; Beron, Curatti, and Salerno 2004; De Maagd 
et al. 1999; Schnepf et al. 1998). Data from these experiments reveal that the 
mutations may have a negative or positive effect on binding and toxicity thus 
demonstrating that the binding of receptors and domain II is very complex. It has 
been observed that all loops of domain II may be involved in receptor binding but not 
for every receptor and not all at the same time (Xiang et al. 2009). The first example 
of domain II loop mutants with increased insecticidal activity was Cry1Ab toxin 
where mutations in loop 2 resulted in higher insecticidal activity against Gypsy moth 
(Limantria dispar) (Rajamohan et al. 1996). The increased insecticidal activity 
correlated with increased binding affinities to BBMV isolated from Gypsy moth 
(Rajamohan et al. 1996). 
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In the case of domain III, there are just a few examples of mutations in two different 
exposed loop regions with some mutants showing a moderate to non-significant 
increase in toxicity against different insect species (Lv et al. 2011; Shan et al. 2011; 
Xiang et al. 2009; Shu et al. 2007). There have only been a small number of studies 
that have mapped the domain III binding regions with ALP and APN (Arenas et al. 
2010; Gómez et al. 2006; Atsumi et al. 2005). However, there has been substantial 
work done on domain III swapping which yielded in some cases hybrid toxins with 
increased toxicity (Bosch et al. 1994). One example the hybrid toxin that contains 
domain I and II from Cry1Ab and domain III from Cry1C; It was found to have more 
than a sixfold higher toxicity against beet armyworm (Spodoptera exigua) compared 
with Cry1C (de Maagd et al. 2000). 
 
 
Figure 1.5: Examples of receptor molecules of Cry1A proteins. CADR, cadherin 
receptor; APN, aminopeptidase-N, ALP, alkaline phosphatase, GalNAc on the APN 
or ALP and GCR, 270 kDa glyco-conjugate receptor (Bravo, Gill, and Soberón 
2007).   
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1.10 Cry1Ac 3d-Cry toxin 
 
Cry1Ac is one of the 3d- toxins produced by Bacillus thuringiensis subsp. Kurstaki 
HD-73 (see Figure 1.7).  Adang et al. (1985) characterised the Cry toxins in Kurstaki 
HD-73 and examined their toxicity to Manduca sexta. In 1986 the cry1ac gene was 
expressed in tobacco plants. This ultimately led to the commercialisation of 
insecticidal products and transgenic crops (Adang et al. 1986). Cry1Ac was chosen 
as the toxin in many transgenic crops because it is extremely lethal to many insect 
species (Adang et al. 1986). It is now known that binding of Cry1Ac toxin to specific 
receptors in the midgut brush border membrane is essential for toxicity.  Resistance 
of Cry toxins correlates to changes in the receptors on the brush border membrane of 
insects (Ferre and Van Rie 2002). In Heliothis virescens (tobacco budworm), 
alterations in the cadherin protein HevCaLP (Jurat-Fuentes et al. 2004; Gahan, Gould 
and Heckel 2001) and the membrane-bound alkaline phosphatise HvALP (Jurat-
Fuentes and Adang 2004) have been reported to be involved in resistance to Cry1Ac 
toxicity.  
 
 
Figure 1.6: Structure of Monosaccharides. Monosaccharides Glucose and 
Galactose with their derivatives GlcNAc and GalNAc (Varki et al. 2009). 
 
As a result of the research into the receptors on insect cells and mutagenesis of 
Cry1Ac it was found that this toxin has some unique binding patterns in comparison 
to other Cry toxins. In an in-direct toxin-binding assay using BBMV’s, the modified 
sugar GalNAc completely abolished toxin binding while GlcNac had no effect 
(Knowles, Knight, and Ellar 1991) (see Figure 1.6). The presence of GalNAc on the 
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toxin-binding protein was confirmed by experiments in which both the toxin and the 
GalNAc-binding lectin soybean agglutinin bound to a 120 kDa protein present in M. 
sexta BBMV’s (Knowles, Knight, and Ellar 1991). The results presented by Burton 
et al. (1999) point out residues N506, Q509 and Y513 to be involved in the binding 
of Cry1Ac both to the carbohydrate GalNAc and to aminopeptidase N. The binding 
of Cry1Ac throughout the larval midgut was examined and it was found that there 
were different binding patterns in regions of the larva i.e. there were regions where 
GalNac did not affect binding (Rodrigo et al. 2008). This provides some evidence 
that the Cry proteins do not recognise one specific receptor and thus would have the 
ability to affect different species of insects.  Xiang et al. (2009), revealed that the 
residue N546 in β18– β19 loop of the Cry1Ac domain III played an essential role in 
its insecticidal activity and binding to insect BBMV.  Proteomic approaches have 
also been employed to identify novel Cry1Ac toxin binding proteins (McNall and 
Adang 2003). Jurat-Fuentes and Adang (2007) used a proteomic approach to study 
Cry1Ac binding proteins and the alterations on these proteins in resistant Heliothis 
virescens larvae. They demonstrated, through 2D gel electrophoresis, lectin blots and 
2D differential in gel electrophoresis (2D-DIGE), that Heliothis virescens 
membrane-bound alkaline phosphatase (HvALP) is a Cry1Ac binding protein and 
putative receptor. Previous proteomic analysis of Cry1Ac binding proteins in the 
Brush Border membrane (BBM) proteome allowed for identification of novel toxin 
binding proteins, including actin and the A subunit of the vacuolar ATPase 
(Krishnamoorthy et al. 2007).  
Detection of Cry1Ac binding to both ATPase and actin suggests the possibility of 
potentially relevant interactions between part of the Cry1Ac toxin and intracellular 
proteins. Kitami et al. (2011) reported that Cry1Ac domain III bound to several 
proteins unrelated to insects in dot blot experiments. Thus even though the main 
receptor for Cry1Ac would seem to be GalNAc these studies have shown that it may 
also have specificity for other proteins or glycoproteins. Kitami et al. (2011), 
postulate that the binding of the unrelated proteins was far away from the binding 
site of GalNAc. These and other studies that were carried out on Cry1Ac were 
mainly focused on its impact on toxicity, insect resistance or effect on other 
organisms (Yang et al. 2008; Jurat-Fuentes and Adang, 2004). The involvement of 
glycoproteins as Cry toxin receptors has been suggested for several toxin membrane 
interactions (Burton et al. 1999). 
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Figure 1.7: Predicted structure of active Cry1Ac. This structure is based on 
previously solved Cry1A structures and submitted to I-TASSER. Domain I is in blue 
(beta barrels), domain II is shown in green while domain III is shown in red. 
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1.11 Carbohydrate Binding Proteins 
The understanding of the significance of glycosylation is expanding rapidly. 
However, progress in understanding cell glycosylation, cell-glycan interactions, host-
microbe interactions and aberrant glycosylation, is relatively restricted by the 
analytical techniques accessible for glycan profiling. Lectins are a general term for 
proteins that may recognise and bind specific glycan structures (Varki et al. 2009).  
They have the ability to bind and separate closely related glycoforms of 
glycoproteins and are increasingly being used in bio-analytical techniques, for 
glycan/glycoprotein enrichment and separation (reviewed in more detail in section 
1.17). The disadvantage of these molecules is the cost and availability as most 
commercial lectins have been isolated whole from plant seeds, fruit, stems and bark. 
Lectins, from these sources, are typically multi-subunit proteins in which the 
subunits themselves may vary or be glycosylated. Thus, it is difficult to produce 
large quantities of plant lectins recombinantly which can give rise to batch to batch 
variation depending on the method of purification. In the past number of years 
prokaryotes have emerged as a good source of novel carbohydrate-binding 
molecules, for example, Escherichia coli, P fimbriae targets Galα1–4Galβ- on the 
urinary tract and Helicobacter pylori, BabA targets Le
b
 on the stomach (Imberty et 
al. 2004, Loris et al. 2003). Unlike plant lectins, bacterial lectins are more suited to 
overproduction in bacterial expression systems. The ability to up-scale production of 
these molecules and simplified downstream purification methodologies could enable 
the use of these lectins for wide reaching applications at low costs. DNA methods 
can be used to further enhance carbohydrate-binding proteins and facilitate their 
implementation in glycol-analytical platforms. An affinity tag, such as 6x histdine 
may be engineered onto the protein to enable downstream purification of the 
recombinant binding protein, to simplify their incorporation or immobilisation onto 
chromatographic or array based platforms. Mutagenesis may also be used on 
recombinant carbohydrate-binding proteins to enhance or alter their binding affinities 
and/or specificities. Potential useful directions for the development and expansion of 
novel carbohydrate-binding protein libraries include those which target common 
glycan terminal structures such as GalNAc and GluNAc.  The binding domains of 
the Cry toxins have the potential to be novel carbohydrate binding proteins. These 
toxins have various receptors in insects, some of which are glycosylated and domain 
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III in the toxins has shown strong structural similarities to other lectins. Cry1Ac has 
shown glycan binding properties, in particular to GalNAc. Investigation into the 
binding of Cry1Ac to GalNac containing glycoproteins for use not as a toxin but as a 
lectin has not yet been explored. It is proposed that Cry1Ac could be used as a novel 
carbohydrate-binding bioligand which could have a number of applications, for use 
in glycan array techniques or in detection and separation of glycans or glycoproteins.  
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1.12 Glycobiology and Glycosylation 
 
1.12.1 Glycobiology 
 
The term glycobiology first came about in the late 1980s to recognize the disciplines 
of carbohydrate chemistry and biochemistry coming together with a modern 
understanding of the cell and molecular biology of glycans and, in particular, their 
conjugates with proteins and lipids. Glycobiology is the study of the structure, 
biosynthesis, biology, and evolution of sugar chains or glycans that are widely 
distributed in nature (Varki et al. 2009). Glycobiology has been one of the fastest 
growing areas in natural sciences in the last number of years. This is due to the 
increase in knowledge about the attachment of carbohydrates onto many proteins 
especially those involved in secretion or insertion into cell membranes.   
 
1.12.2 Glycosylation  
 
Glycosylation is the process of enzymatically attaching carbohydrate molecules to 
protein or lipid substrates (Rakus et al. 2011). Glycosylation is a class of post-
translational modification, which occurs on both proteins and lipids and it is more 
prevalent than phosphorylation, methylation, or acetylation. It is thought that the 
majority of proteins in eukaryotic cells are glycosylated. Abberant glycosylation has 
been observed in diseases such as congenital disorders of glycosylation, and also in a 
number of pathological states, including inflammation and cancer (Varki et al. 2009). 
It is important to emphasize that unlike protein sequences, which are primary gene 
products, glycan chain structures are not encoded directly in the genome and are 
secondary gene products. Small changes in the environment of the cell can cause 
dramatic changes in glycans. It is this variable and dynamic nature of glycosylation 
that makes it a powerful way to generate biological diversity and complexity. Of 
course, it also makes glycans more difficult to study than nucleic acids and proteins 
(Varki et al. 2009). 
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The complexity of carbohydrate structures in an organism is a result of several 
carbohydrate characteristics. The first is the ability of different types and numbers of 
sugar residues to form glycosidic bonds with one another. The second is the 
structural characteristics of these molecules, the type of linkage, the position and the 
absence or presence of branching (Ghazarian, Idoni, and Oppenheimer 2011). 
Glycans have the ability to encode a considerable amount of biological information 
even though they are not encoded by the genome (Varki et al. 2009). However the 
genome does encode for the enzymes that act on glycans such as glycosyltransferases 
and glycosidases. These enzymes come together in the endoplasmic reticulum (ER), 
the Golgi apparatus, and on the cell surface to determine the glycosylation patterns of 
glycoproteins and glycolipids (Sharon, 1980). There are two main types of 
glycosylation N linked and O linked glycosylation.   
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1.13 N – Linked and O – Linked Glycosylation in Eukaryotes  
 
Glycans can form glycosidic bonds with proteins by two types of linkage, the first 
(N-linked) is the binding of N-acetylglucosamine to the amide side chain of 
asparagines. The second (O-linked) involves the addition of a C- 1 of N-
acetylgalactosamine to the hydroxyl of serine or threonine (Ghazarian, Idoni, and 
Oppenheimer 2011). 
 
 
1.13.1 N - Linked Glycan Synthesis 
 
The N – linked glycosylation pathway is the best understood route to protein 
glycosylation. N-linked glycosylation can be used to demonstrate general principles 
of glycoconjugate structure and biosynthesis (Taylor and Drickamer 2006). Even 
though N-linked glycans are diverse they all have a common core structure. These 
attach to glycoproteins via the amide nitrogens of asparagine side chains. The glycan 
usually linked to an asparagine residue in animal cells is GlcNAc and this linkage is 
always in the β configuration (GlcNAcβ1-Asn) (Varki et al. 2009; Taylor and 
Drickamer 2006) (See figure 1.9). N-linked glycan synthesis can be divided into 
three stages. 1) The formation of a lipid-linked precursor oligosaccharide which 
takes place in the endoplasmic reticulum (ER). 2) en bloc transfer of the 
oligosaccharide to the polypeptide and 3) Processing of the oligosaccharide which 
takes place in the Golgi apparatus. These processing steps may include trimming 
some of the sugar residues and the addition of new sugars at the non-reducing 
terminal of the glycan (Taylor and Drickamer 2006).  
 
The donor that initiates N-linked glycan synthesis is a Glc3Man9GlcNac2 structure 
attached to the lipid dolichol through a pyrophosphate linkage. The assembly of a 
glycan on the dolichol head group takes place in two phases. The first phase occurs 
on the cytoplasmic side of the ER and the second phase takes place in the lumen 
(Varki et al. 2009; Taylor and Drickamer 2006) (See figure 1.8). The enzymes that 
catalyse the attachment of the two GlcNAc residues and the first five mannose 
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residues use the nucleotide sugar donors UDP-GlcNAc and GDP-Man. The lipid – 
linked glycan is then translocated across the membrane and becomes inaccessible to 
cytoplasmic enzymes. Further sugars are added by dolichol – linked sugars once the 
glycan chain is exposed on the luminal side of the ER membrane. Transfer of the 
completed glycan to emerging polypeptides also occurs on the luminal side of the 
ER. The dolichol-linked precursor oligosaccharide can be now transferred to 
asparagine residues of polypeptides. Glycosylated asparagine residues are almost 
invariably found in the sequences Asn-Xaa-Ser or Asn-Xaa-Thr, where Xaa can be 
any amino acid except proline. N – linked glycans are found at the surfaces of 
proteins while N-glycosylation is only initiated in the lumen of the ER, therefore 
target asparagine residues are found in secretory proteins and in some parts of 
transmembrane proteins. Oligosaccharyltransferase can then catalyse the transfer of 
the completed dolicol-bound precursor glycan to a polypeptide.  
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Figure 1.8: Overview of the synthesis of the common core in N-linked glycan in 
eukaryotes. 1. Dolichol phosphate (Dol-P) on the cytoplasmic face of the ER 
membrane receives GlcNAc-1-P from UDP-GlcNAc in the cytoplasm to generate 
Dol-P-P-GlcNAc. 2. Dol-P-P-GlcNAc is extended to Dol-P-P-GlcNAc2Man5 and 
then is flipped across the ER membrane to the lumenal side. 3. On the lumenal face 
of the ER membrane, four mannose residues are added from Dol-P-Man and three 
glucose residues from Dol-P-Glc (Varki et al. 2009). 
3 
2 
1 
Synthesis started 
with the Dol-P 
27 
 
 
Following the transfer to the polypeptide, the N-linked glycan is processed, first by 
the removal of some of the sugar residues by glycosidases. This happens while the 
polypeptide is in the ER. Glucosidase I removes terminal α1-2 linked glucose and 
glucosidase II removes the inner α1-3 linked glucose. The removal of glucose signals 
the glycoprotein to move from the ER to the Golgi apparatus. The glycoprotein is 
now subject to the action of a series of mannosidases that remove some or all of the 
four mannose residues in α1-2 linkages. Some of these proteins remain in this state 
and are high – mannose oligosaccharides, others become complex oligosaccharides 
and also hybrid oligosaccharides (Varki et al. 2009). 
 
 
 
Figure 1.9: Types of N-glycans. Three general types of N-glycans can be attached 
to a mature glycoprotein: oligomannose, complex, and hybrid. Each N-glycan 
contains the common core Man3GlcNAc2Asn (Varki et al. 2009).  
 
 
28 
 
Complex glycans are therefore built on a core that consists of just three mannose 
residues and two GlcNAc residues which are attached to the glycoprotein. GlcNAc-
transferase I initiates re-elongation by the addition of a GlcNAc residue to the 1-3 
arm of the core. Following this mannosidases in the golgi remove two additional 
mannose residues from the 1-6 arm of the core. GlcNAc additions are then added by 
GlcNAc-transferase and give the glycan its formation by defining a branch structure 
that is built onto the core. The branched structures may be extended by the addition 
of a single galactose and sialic acid residue. Galactosyltransferase and 
sialytransferases are responsible for these steps and are located further along in the 
secretory pathway. The galactose residue is usually β1-4 linked while the sialic acid 
is either α2-3 or α2-6 linked. If mutations are made in the dolichol pathway in 
knockout mice to prevent synthesis of the core oligosaccharide, it generates cells that 
lack N-linked glycosylation (Varki et al. 2009). Even though cells can be made 
which have no N-linked glycosylation these cells cannot form an organism. For 
example, embryos lacking N-linked glyans die shortly after implantation. This shows 
the importance of N-linked glycosylation and how understanding glycans and their 
regulation remains a key objective for the future. 
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1.13.2 O-linked glycosylation  
 
O-glycosylation is a relatively common covalent modification of serine and 
threonine residues of mammalian glycoproteins. The properties of two groups of 
glycoproteins, mucins and proteoglycans, are dominated by the large number of O-
linked sugars that are on their surface (Varki et al. 2009). The purpose of mucins is 
to retain water at the cell surface to which they are exposed and therefore mucins 
must be present at the surfaces of the digestive, genital tracts and the respiratory 
system. The addition of sialylated glycans to serine and theronine residues results in 
regions of strong negative charge which allows the mucins bind large amounts of 
water (Tabak 1995). Mucin glycosylation is based on a set of core structures in 
which GalNAc is linked to the side chain of serine or threonine and has a single β1,3-
linked Gal residue to form a core 1 structure (Varki et al. 2009). To date there are 
about 20 genes so far that have been cloned which encode mucins (Varki et al. 2009). 
As well as water retention mucins give lubrication and also help protect from 
invasion by microorganisms (Bektas and Rubenstein 2011). The mucin polypeptides 
are very long and can contain as many as 1000 amino acids, they can be membrane 
bound or secreted (Varki et al. 2009). They contain tandem repeats of amino acid 
sequences rich in serine and threonine. The mucin genes, their transcripts, the 
resulting mucin proteins, and the attached GalNAc glycans all display large 
variability. The mucin genes are often polymorphic as different numbers of repeats 
are observed in different individuals (Varki et al. 2009).  
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Table 1.2: Structures of O-glycan cores found in mucins (Varki et al. 2009).  
 
O-Glycan Structure 
 
Core 
 Tn antigen GalNAcαSer/Thr 
 Sialyl-Tn antigen Siaα2-6GalNAcαSer/Thr 
 Core 1 or T antigen Galβ1-3GalNAcαSer/Thr 
 Core 2 GlcNAcβ1-6(Galβ1-3)GalNAcαSer/Thr 
 Core 3 GlcNAcβ1-3GalNAcαSer/Thr 
 Core 4 GlcNAcβ1-6(GlcNAcβ1-3)GalNAcαSer/Thr 
 Core 5 GalNAcα1-3GalNAcαSer/Thr 
 Core 6 GlcNAcβ1-6GalNAcαSer/Thr 
 Core 7 GalNAcα1-6GalNAcαSer/Thr 
 Core 8 Galα1-3GalNAcαSer/Thr 
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1.13.3 O-glycan structures 
 
The Tn antigen is one of the simplest mucin O-glycan structures. It consists of a 
single N-Acetylgalactosamine linked to a serine or threonine. This glycan is often 
antigenic and does not normally occur in O-glycosylated proteins (Brockhausen 
2006; Hollingsworth et al. 2004). The most common O-glycan is Galβ1-3GalNAc-, 
this is the core 1 glycan (T antigen) as it forms the core of many other longer glycans 
(see figure 1.10) and like the Tn antigen is antigenic (Brockhausen 2006). The Tn 
and T anitgen may be modified by sialic acid to form sialylated-Tn or -T antigens. 
Core 2 is an N-acetylglucosamine attached to the core 1 (Varki et al. 2009). Linear 
core 3 and branched core 4 have O-GalNAc glycans and have only been found in 
mucin secreting tissues such as bronchi, colon, and salivary glands (Perez-Villar and 
Hill, 1999). The core structures 5-8 do not occur very often. Mucins with core 5 
occur in human meconium and intestinal adenocarcinoma tissue, whereas core 6 
structures have been found in human intestinal mucin and ovarian cyst mucin (Varki 
et al. 2009, Brockhausen 1999). All of these structures can be sialylated, however 
only cores 1–4 and core 6 have been shown to occur as extended, complex O-glycans 
that carry antigens such as the ABO and Lewis blood group determinants (Varki et 
al. 2009). 
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Figure 1.10: Examples of complex O-GalNAc glycans with extended core 1, 2, 3 
and 4 (Varki et al. 2009).  
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1.13.4  O – Glycosylation synthesis    
 
O-glycosylation uses glycosyltransferases that are analogous to those in the N-linked 
biosynthesis pathway. However, the organisation of these enzymes is very different. 
Firstly sugars are added one at a time in a stepwise series of reactions, which start 
with GalNAc attached to a serine or threonine residue (Varki et al. 2009). There is no 
en bloc transfer and there is no target sequence as in N-glycosylation. This is because 
there are numerous transferases that attach GalNAc to serine and threonine residues. 
There are at least 21 polypeptide-N-acetylgalactosaminetransferases (ppGalNAcT-1-
21). N-acetyl-galactosaminyltransferase (ppGalNAcT) catalyzes the first step of 
mucin O-glycosylation and transfers GalNAc from UDP-GalNAc to serine or 
threonine residues (Tabak 1995). These transfers take place post-translationally in 
the Golgi. Subsequently, with the addition of the next sugar, different mucin O-
glycan core structures are synthesized (Varki et al. 2009). During the extension of the 
core GalNAc, no lipid-linked intermediates are involved, and there are no 
glycosidases involved in the processing of O-GalNAc glycans within the Golgi 
(Perez-Villar and Hill 1999). The first sugar GalNAc added to the protein creates the 
Tn antigen (GalNAc-Ser/Thr), which is uncommon in normal mucins, but is often 
found in mucins derived from tumors (Brockhausen 1999). Another common cancer-
associated structure found in mucins is the sialyl-Tn antigen, which contains a sialic 
acid residue linked to C-6 of N-acetylgalactosamine (Brockhausen 2006).   O-
Acetylation of the sialic acid residue stops anti-sialyl-Tn antibodies recognising the 
sialyl-Tn. To date, no other sugars are known to be added to the sialyl-Tn antigen. 
There are eight O-Glycan core structures, and most of these can be substituted with 
other sugars, such as sialic acid, galactose. 
 
 
1.14 Prokaryotic glycosylation  
 
It is now known that protein glycosylation is a phenomenon shared by all domains of 
life. A lot of progress has been made in understanding prokaryotic glycosylation 
since the general N-glycosylation system was discovered in Campylobacter jejuni 
(Wacker, Linton, and Hitchen 2002). Recently novel general O-glycosylation 
systems have been observed in pathogenic and symbiotic bacteria (Dell et al. 2010). 
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Bacterial glycans include peptidoglycan, periplasmic glycans, lipopolysaccharide, 
glycans of surface layer proteins (SLPs), and extracellular polysaccharides which 
make up capsules and biofilms (Varki et al. 2009). Prokaryotes produce a variety of 
glycoconjugates and polysaccharides which can vary in their structural diversity and 
complexity. These glycans include many sugars not found in eukaryotes, such as 
Kdo (3-deoxy-D-manno-octulosonic acid), heptoses, and modified hexoses 
(Schäffer, Graninger, and Messner 2001). The resulting glycans have important roles 
in the biology, and the pathogenicity, of bacterial cells.  
Bacteria are divided into Gram-positive and Gram-negative organisms depending on 
the nature of their cell wall. In Gram-negative bacteria such as Escherichia coli, the 
cell wall consists of inner and outer membranes separated by the periplasm. 
Peptidoglycan is the major structural component of the periplasm, and it is made up 
of a polysaccharide covalently cross linked by short peptides (van Heijenoort 2001). 
In Gram negative bacteria the periplasmic space may also contain β-glucans, while 
the outer layer mostly contains lipopolysaccharide (Varki et al. 2009) (see figure 
1.11 and 1.12). The cells of mucoid strains are surrounded by a polysaccharide 
capsule, which is thought to play a role in virulence. Gram-positive bacteria do not 
have the outer membrane, instead they have a much thicker peptidoglycan layer 
modified with the addition of teichoic acids (Schaffer et al. 2005).  
Although much more remains to be discovered regarding the biosynthetic pathways 
of protein glycosylation in prokaryotes, genetic information so far shows that these 
pathways vary in complexity (Zarschler et al. 2010). In Campylobacter jejuni, a 
cluster of 12 genes - the pgl locus, is responsible for the synthesis of a 
heptasaccharide GalNAcα1–4GalNAcα1–4(Glcβ1–3)GalNAcα1–4GalNAcα1–
4GalNAcα1–3Bac. The transfer of this chain en bloc to asparagine residues in a 
protein involves the same consensus sequence found in eukaryotic glycoproteins 
(Wacker, Linton, and Hitchen 2002). Oligosaccharyltransferase-mediated O-
glycosylation is frequent in gram-negative bacteria, but has not yet been proven to 
occur in gram-positive bacteria. While cytoplasmic O-glycosylation seems to be 
more common in Gram-positive bacteria (Weerapana et al. 2006).     
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Figure 1.11: Cell wall from Gram-negative bacteria. Diagram of the cell wall of 
Gram-negative bacteria showing layers of polysaccharides and glycoconjugates 
(Varki et al. 2009). 
 
 
 
 
Figure 1.12: Cell wall from Gram-positive bacteria. Gram-positive bacteria lack 
the outer membrane and lipopolysaccharide (LPS) that is present in Gram-negative 
organisms. However the peptidoglycan layer is thicker and contains teichoic acids 
(Varki et al. 2009). 
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1.15 Significance of Glycosylation  
 
Glycocosylation has proven to be of fundamental importance to many biological 
processes (Varki et al. 2009). Correct glycosylation plays a role in immune defence, 
cell growth, cell-cell adhesion, inflammation and fertilisation. Attachment of glycan 
moities to proteins/glycoproteins functions to stabilise proteins against denaturation 
and proteolysis, confer structural rigidity, enhance solubility, increase blood 
retention time and reduce immunogenicity (Varki et al. 2009; Taylor and Drickamer 
2006). However, our understanding of the significance of glycans to biological 
processes arises from the study and genetic engineering of abnormal glycosylation 
and disease states. The general affect of glycosylation on physiochemical and 
biological functions are summarised in table 1.3.  
 
Table 1.3: Affect of glycosylation on physiochemical and biological functions. 
Type Function 
Physiochemical  Modify solubility, electrical 
charge, mass, size and viscosity in 
solution 
 Control protein folding 
 Stabilise protein conformation 
 Confer thermal stability and 
protection against proteolysis 
Biological  Regulate intracellular traffic and 
localisation of glycoproteins 
 Determine lifetime of 
glycoproteins in circulation 
 Determine time of glycoproteins 
in circulation 
 Modify immunological properties 
 Modulate activity of enzymes and 
hormones 
 Act as cell surface receptors for 
lectins, antibodies, toxins 
 Participate in cell-cell interactions 
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1.16 Lectins  
Lectins are proteins that have the ability to bind to glycans and glycoproteins. 
Glycans, as discussed previously, can mediate a wide variety of biological roles by 
virtue of their mass, shape, charge, or other physical properties. However, many of 
their more specific biological roles are mediated via recognition by Carbohydrate 
Binding Proteins (GBPs). There is considerable diversity in glycans expressed in 
organisms because of evolving proteins to recognise glycans that mediate specific 
physiological or pathological processes (Varki et al. 2009). Lectins were first 
discovered in plants more than 100 years ago and they are now known to be present 
in every organism (Kwan and Bun 2011) see Table 1.3. Lectins are found throughout 
the microbial world where they are described as toxins, hemagglutinins and adhesins 
(Varki et al. 2009; Taylor and Drickamer 2006). Plant Concanavalin A (Con A), was 
the first pure lectin to be isolated from the Jack Bean (Canavalia ensiformis) and to 
have its sugar specificity demonstrated by James and Stacey in 1936. They suggested 
that the hemaglutination induced by Con A might be a consequence of a reaction 
from the plant protein with carbohydrates on the surface of the red cells. Later it was 
discovered that Con A binds to α1-3 linked mannose residues (see Figure 1.13) Plant 
lectins are the most commercially available and applied lectins for glycoprotein and 
glycan research (Kwan and Bun 2011).  
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Figure 1.13: Examples of N-glycans recognized by ConA and GNA. 
Concanavalin A from Canavalia ensiformis and Galanthus nivalis agglutinin (GNA) 
(Varki et al. 2009).  
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Table 1.4: Examples of types of lectins from different organisms (Varki et al. 
2009). 
Lectin Family Lectin Abbreviation Sugar specificity  
Plant Lectins    
Legume lectins  Concanavalin A  ConA  Man/α1-Me  
 
Griffonia simplicifolia                    
 
lectin 1 GSLI α-gal 
Griffonia simplicifolia lectin II  
 
GSLII β1-4 GlcNAc 
Cereal lectins  Wheat germ 
agglutinin  
 
WGA  NeuNAc, GlcNAc  
 
Plant toxins  Ricin  RCA  β-gal/ lactosamine  
Bulb lectins  
 
Snowdrop lectin  GNL  Man  
Animal lectins    
Galectins  Galectin 1  Gal-1  Lactose  
Galectin 2  Gal-2              Fucose 
Galectin 3  Gal-3   Fucose 
P-type lectin  Mannose-6 
phosphate receptor  
M6P  Man-6 phosphate  
Bacterial lectins    
P. aeruginosa  Lectin 1 PA-IL β-gal 
P. aeruginosa  
 
 Lectin 1  PA-IIL 
 
Fucose/Man  
             
Bacillus thuringiensis Cry toxins    Cry1Ac GalNAc 
 
Viral lectins    
Influenza  Hemagglutinin  HA  NeuNAc  
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1.17 Methods used for the detection and separation of glycans and 
glycoproteins 
1.17.1 Commercial lectins 
To date, hundreds of plant and animal lectins have been identified and characterised 
(Varki et al. 2009). Lectins from many plants have been studied because of their 
abundance in seeds and tissues (Kwan and Bun 2011). These lectins have been 
analysed in detail and used for practical research on glycans (Varki et al. 2009). 
Thus, although monoclonal antibodies might be more specific for glycan epitopes, 
plant and animal lectins have useful specificities and affinities, are usually less 
expensive, are better characterised with respect to binding specificity, and are more 
stable. The availability of the plant lectins and their specificity for complex glycans 
has helped to expand the field of glycobiology (Varki et al. 2009). Figure 1.14 shows 
some important examples of the uses of lectins. Lectins with well defined specificity 
are excellent tools for several analytical and preparative purposes. Lectins may be 
used to identify and characterise the structure of glycans (Kwan and Bun 2011). 
They can be used when there is not enough biological material for techniques, such 
as mass spectrometry or nuclear magnetic resonance and they can also be used as a 
quantitative method as they can distinguish between subtle differences in 
oligosaccharide structure (Wu et al. 2009). Disadvantages of using plant lectins 
include; batch to batch variation depending on the purification method and high costs 
due to the low yield of lectin (Varki et al. 2009). 
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Figure 1.14: Examples of the various uses of plant and animal lectins and 
antibodies in glycobiology. They can be used to detect glycan structures in all of the 
formats shown (Varki et al. 2009). 
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1.17.2 Enzyme Linked Lectin Assay 
The Enzyme Linked Lectin Assay (ELLA) is useful technique employed for the 
generation of glycan profiles. The ELLA which is similar to an ELISA has proven to 
be important for glycan and lectin profiling (Matsumoto, Shinzaki, and Narisada 
2010; Lambre et al. 1991; Andrade et al. 1988; McCoy, Varani, and Goldstein 1983). 
In an ELLA a protein-glycan conjugate is immobilised onto the surface of a 96 well 
plate. After this the plate is blocked with appropriate blocking solution and the lectin 
is added. The binding of the carbohydrate and lectin can be detected using 
colorimetric techniques (Figure 1.15).   
 
 
 
Figure 1.15: Enzyme linked lectin assay (ELLA). A protein carbohydrate 
conjugate is immobilised on the bottom of a 96 well plate. The plate is blocked with 
appropriate blocking solution. The glycan complex is probed with labelled lectin(s). 
The lectins are detected using specific, peroxidase labelled antibodies. The antibody-
peroxidase conjugate can be detected using colormetric techniques (Thompson et al. 
2011). 
In the ELLA the proteins do not need to be denatured or go through harsh chemical 
steps. Exposure of underlying residues and specific linkages can be achieved by the 
glycosidase-mediated trimming of terminal glycans and the use of sugar and linkage 
specific lectins and neo-glycoproteins. As the lectin-glycan interactions are very 
specific, high concentrations of glycan are not needed. In addition, lectins can also be 
applied to in vitro and in vivo studies. Commercial lectins can be used to localise 
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specific glycans in cells by conjugating them to probes or fluorescent tags e.g. Green 
fluorescent protein (GFP) (Wanchoo, Lewis, and Keyhani 2009; Krist et al. 2004; 
Fitches et al. 2001), and radiolabelling (Smart et al. 2002). However the biggest 
disadvantage in the use of lectins is the cost and limited availability of fully 
characterised lectins (Kwan and Bun 2011). 
 
1.17.3 Lectin affinity chromatography 
 
Lectin affinity chromatography is very useful when a heterogeneous glycan mixture 
is passed over a lectin column. The glycans may be tightly bound to the column, 
requiring haptenic sugars for elution depending on the relative affinity of the lectin 
for sugars, therefore separating them from the unbound material (Geyer and Geyer 
2006). This is a great technique that can be used in conjunction with MS and NMR 
where a sample needs to be separated or enriched. This technique can be expanded 
using multiple columns with several specificities represented.  
 
1.17.4 Two dimensional (2D) gel electrophoresis  
 
Two Dimensional (2D) gel electrophoresis is one of the most efficient protein 
separation and analytical techniques and is often the first step in glycan analysis. 
This technique can be used to separate proteins, reflecting both size and/or isoelectric 
points (Geyer and Geyer 2006). Once separated the glycosylation of the proteins 
blotted on a membrane can be characterised by probing with carbohydrate-specific 
stains, lectins or antibodies. A major drawback to this technique is the frequent 
under-representation of membrane proteins, due to the high degree of insolubility in 
the solubilisation detergents (Geyer and Geyer 2006). Another disadvantage is that 
this technique gives an indication of whether glycans are present or not, it does not 
give a quantitative analysis of the glycans or any information on their 
oligosaccharide structure.  
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1.17.5 High Pressure Liquid Chromatography (HPLC)      
 
Due to their structural heterogeneity, glycoproteins represent often complex mixtures 
of closely related isomeric compounds. HPLC has proven to be good at separating 
and profiling glycans due to the wide range of adsorbents and solvent systems 
available, in addition to the speed and reproducibility of the separation (Geyer and 
Geyer 2006) (See Figure 1.16). Anion exchange chromatography may be used to 
separate glycans predominantly on the basis of the number of charged groups 
present. Similar systems can be used to separate glycans on the basis of 
hydrophilicity (Neutral phase NP-HPLC) and hydrophobicity (Reverse phase RP-
HPLC) (Geyer and Geyer 2006). One of the advantages of this technique is the 
ability to predict possible glycan structures through the comparison of elution times 
with standard glucose oligomers using only pico moles of sample. A HPLC database 
for glycans/sugar maps has been constructed based on a large number of well-
defined standard oligosaccharides, 
http://www.gak.co.jp/ECD/Hpg_eng/hpg_eng.htm (Geyer and Geyer 2006).  
 
 
Figure 1.16: An example of a HPLC-HILIC profile of N-glycans released from 
heavy chain human serum IgG. The scale of glucose units (GU) is based on the 
elution of a 2-AB–labeled glucose ladder. Only the major species have been shown 
in this particular figure, but the whole nested family of 36 different structures, 
including arm-specific isomers, can be identified using this technique (Marino et al. 
2010). 
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1.17.6 Mass Spectrometry (MS)  
 
Mass spectrometry is a technique that detects molecules that can be converted to gas-
phase ions. The resulting ions are accelerated out of the ionisation source into a mass 
analyser, where they are separated according to their mass to charge ratio and 
detected to produce a mass spectrum (Hitchen and Dell 2006) (See figure 1.17). 
Mass spectrometric identification of glycoproteins has proven to be an important tool 
due to its high degree of sensitivity. It can be used to resolve the components of a 
glycan mixture and derive information about the structures of individual glycans. 
(Taylor and Drickamer 2006).  
Unlike the HPLC method, a substantially larger amount (~10-20 times) of glycan is 
normally required for a single MS spectrum. Matrix-assisted laser 
desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is the most 
widely used MS technique (Tsarbopoulos, Karas, and Strupat 1994). The information 
gained by using MALDI MS is mass weight, which can be used to assign putative 
monosaccharide structures present in a pure oligosaccharide since the mass of a 
monosaccharide is measured with a high degree of accuracy (Tsarbopoulos, Karas, 
and Strupat 1994).  
For mass determination, glycans must first be separated from the protein backbone. 
Separation is usually carried out using enzymatic or chemical techniques. Enzymes 
such as trypsin and PNGaseF, glycosidase that cleaves between the innermost 
GlcNAc and asparagine residues of N-linked glycans, are most often used to separate 
glycans prior to analysis. There are disadvantages with both techniques in that the 
enzymatic release of glycans is dependent on the protein-glycan linkage and that not 
all glycans may be released, while chemical release may lead to the destruction of the 
non-carbohydrate parts of the protein backbone. When there are multiple 
glycosylation sites in a single protein the information as to the specific site and the 
exact protein-glycan linkage will be lost (Dalpathado and Desaire 2008, Budnik, Lee 
and Steen 2006). 
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Figure 1.17: An example of MALDI-TOF mass spectra. (A) Man-3 glycan, (B) 
Man-8 glycan, and (C) NA4 glycan. (www.sigmaaldrich.com)  
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1.17.7 Nuclear Magnetic Resonance (NMR)  
 
NMR analysis of glycoproteins is based on the fact that a glycan distorts in a 
magnetic field (Budnik, Lee and Steen 2006). It is a non-destructive technique and 
can provide full structural information. Therefore, NMR is a great source to get 
definitive information on glycan structures. However there are some limitations 
associated with this technique, which include the high cost of equipment and trained 
personnel and the amount of glycan required, concentrations of 3-4 orders of 
magnitude (10-100 ng) of the purified glycan compared to other techniques (Budnik, 
Lee and Steen 2006). Although NMR can provide information that cannot be 
obtained from other approaches and is well suited to the analysis of small sugars, it is 
not suited to the analysis of mixtures of glycans and the interpretation of the spectra 
can be made difficult by the similar environments of many of the protons (Taylor and 
Drickamer 2006). 
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1.18 Project Aims and Objectives 
As explained previously there is a need for novel carbohydrate binding proteins for 
the detection and analysis of glycans and glycoproteins. In particular there is a need 
for the detection of cell surface glycans in disease states such as cancer. O-
glycosylation has been shown to be affected in many cancers and it would be 
beneficial to be able to detect these changes. It was thought that the Cry toxins from 
Bacillus thuringiensis may be a good source of novel lectins. The aims of this project 
were to;  
1. Clone a truncated Cry1Ac protein that could be expressed as a soluble active 
protein, which would have specificity to GalNAc 
2. Clone the third domain of tCry1Ac to examine if the third domain on its own 
would have carbohydrate specificity 
3. Produce a large yield of both proteins, by expression in E. coli and 
purification by Immobilised Metal Affinity Chromatography (IMAC) for 
downstream applications 
4. Examine both proteins binding specificities for glycoproteins and 
carbohydrates by ELLA 
5. Determine whether tCry1Ac or CryD3 have carbohydrate binding 
specificities and whether those specificities may be altered by mutagenesis   
6. Determine whether Cry toxins from Bacillus thuringiensis are a good source 
of novel carbohydrate binding proteins.  
Cry1Ac from Bacillus thuringiensis, kursatki HD-73 was selected for this study. 
Bioinformatic and structural analysis of the protein were carried out to examine the 
best cloning strategy for Cry1Ac (tCry1Ac) and domain III of Cry1Ac (CryD3). 
Recombinant proteins were produced in Escherichia coli based expression systems, 
with particular focus on the selection of an appropriate  strain of E. coli and vector 
system for each, capable of producing soluble, active protein. Following successful 
expression of these molecules, protocols were developed to yield relatively large 
quantities of highly purified protein, for glycan binding characterisation studies. As 
stability is of particular important if these proteins are to be used for bioanalytical 
platforms, a comprehensive study on optimising their stability was carried out. 
tCry1Ac and CryD3 were also mutated within the proposed sugar-binding site to 
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confirm if the sugar specificity of these proteins could be manipulated and ultimately 
altered. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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2.1 Bacterial strains, primers sequences and plasmids 
 
Table 2.1: Bacterial strains 
 
Strain Genotype Features Source 
Escherichia coli  
 
JM109 
 
 
 
FtraD36, proAB+ lacIq, lacZ 
M15 endA1 recA1 hsdR17(rk-, 
mk+) mcrA supE44- gyrA96 
relA, (lacproAB) thi-1 
 
 
 
All purpose cloning 
strain. Produces 
stable plasmid DNA 
 
 
 
Sigma 
 
KRX 
 
[F’, traD36, ∆ompP, proA+B+, 
lacIq, ∆(lacZ)M15] ∆ompT, 
endA1, recA1, gyrA96, (Nalr), 
thi-1, hsdR17 (rk-, mk+), relA1, 
supE44, ∆(lac-proAB), 
∆(rhaBAD)::T7 RNA 
polymerase 
 
Expression strain Promega 
BL21 (DE3)  
 
FΔ dcm ompT hsdSB(rB-,mB-) 
gal 
Expression strain Novagen 
Bacillus 
thuringiensis  
 
Serovar kursaki HD-73 
 
Cry1Ac USDA, ARS 
Culture 
Collection in 
Peoria,I, 
USA 
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Table 2.2: Plasmids 
 
Plasmid Description Source 
Vector   
pQE60 Amp
R
 Expression vector for C terminus Histidine tag proteins, 
T5 promoter/lac operon 
Qiagen 
Constructs   
ptCry1Ac pQE60 with truncated cry1Ac This project 
ptCry1AcN521A pQE60 containing tCry1Ac with N521A mutation This project 
ptCry1AcQY487A pQE60 containing tCry1Ac with QY487A mutation This project 
ptCry1AcN480A pQE60 containing tCry1Ac with N480A mutation This project 
 
pCryD3 
 
pQE60 with lectin domain of cry1Ac 
 
This project 
CryD3PAV16A pQE60 containing CryD3 with PAV16AAA mutation This project 
CryD3N45A pQE60 containing CryD3 with N45A mutation This project 
CryD3QY52A pQE60 containing CryD3 with QY52A mutation This project 
pCryD3N86A pQE60 containing CryD3 with N86A mutation This project 
 
 
Table 2.3: Primer Sequences  
 
(Synthesised by Sigma-Aldrich, UK and integrated DNA technologies) 
Name Primer Sequence (5’-3’) TM 
(°C) 
Cry1Ac P60Df ATCGATCATGATGGATAACAATCCGAACATCAATG 52.3 
Cry1Ac P60Dr ATCGAAGATCTAACTGGAATAAATTCAAATCT GTCTA 50.1 
D3cry_ f ATCGATCCATGGGTAATAATATAATTGCATCGGATAGTAT 60 
D3cry_r ATCGAAGATCTAATAAATTCAAATCTGTCTATTATCAC 60 
 
mutPAVf /5Phos/CTC AAA TCG CAG CAG CAA AGG G 
 
60 
mutPAVr /5Phos/TAA TAC TAT CCG ATG CAA TTA TAT TA 
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Name Primer Sequence (5’-3’) TM 
(°C) 
Mut480f /5Phos/TTA AAT AGT AGT GGA GCT AAC ATT 
 
50 
Mut480r /5Phos/TCT AAC TAA GTC CCC ACC AGT AA 
 
55 
mutQYf /5Phos/AAG TTC CAA TTC ACT TCC CAT CGA 
 
57 
mutQYr /5Phos/CAA TAG CCC CTC TAT TCG CAA TG 
 
56 
Mut521f /5Phos/TTA ATT GGG GTG CTT CAT CCA TT 55 
Mut521r /5Phos/CGT TGA GGT GAA TCG GGG TTA 57 
D3cry_ f ATCGATCCATGGGTAATAATATAATTGCATCGGATAGTAT 60 
D3cry_r ATCGAAGATCTAATAAATTCAAATCTGTCTATTATCAC 60 
 
Sequencing 
Primers 
  
QE-F CCCGAAAAGTGCCACCTG 61.6 
QE-R GTTCTGAGGTCATTACTGG 53.5 
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Figure 2.1: The pQE60 vector. The 3431bp pQE60 vector from Qiagen contains 
the following features. The multiple cloning site is located before the 6x histidine 
amino acid sequence (blue) which allows for the expression of C-terminally 6x 
histidine tagged proteins. This is under control of the T5 promotor/lac operon 
(yellow). The bla gene encodes beta-lactamase which confers ampicillin resistance to 
the bacteria (red). This image was generated using pDRAW32. 
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2.2 Microbiological Media 
 
Bacteriological agar, tryptone and yeast extract were supplied by Lab M Ltd. All 
other chemicals were supplied by Sigma-Aldrich Co. All media was sterilised by 
autoclaving at 121
O
C and 15lb/in
2
 for 20 minutes. 
 
Luria Bertani (LB) Broth 
Used for culturing Escherichia coli and Bacillus thuringiensis strains 
 Tryptone 10g/L 
 NaCl  10g/L 
 Yeast Extract 5g/L 
 pH  7.0 
 
For LB agar, 15g/L bacteriological agar was included. 
 
SOB medium 
Tryptone 20g/L 
Yeast Extract 5g/L 
NaCl  0.5g/L 
KCL  2.5mM 
pH  7.0 
 
The solution was sterilised and allowed to cool to 55
O
C. Filter sterilised solutions of 
1m MgCl2 and 1M MgSO4 were added to final concentrations of 10mM each. 
 
 
SOC medium  
After making SOB medium as described above, filter sterilised 50% glucose was 
added to a final concentration of 20mM. 
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TB Medium 
Tryptone       12g/L 
Yeast extract 24g/L 
Glycerol        4mls 
Make up to 900mls and sterilise. Allow to cool and add 100mls of Potassium 
phosphate buffer 
 
 
2.3 Solutions and Buffers 
 
All Chemicals and solutions were obtained from Sigma Aldrich unless otherwise 
stated. 
 
RF1 
RbCl                        100mM 
CaCl2                       10mM 
Potassium Acetate   30mM 
Glycerol                   15% 
pH                            5.8 
When the pH had been adjusted with HCl MnCl2 was added to a final concentration 
of 50mM. The solution was filter sterilised through a 0.22µm filter membrane and 
stored at 4°C. 
 
7% Agarose 
 Agrose  
 TAE Buffer (1X) 
 
TE Buffer 
 Tris-HCL 10mM 
 Na2- EDTA 10mM 
      pH   8.0 
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TAE Buffer (50X)  
 Tris   242g/L 
 Glacial Acetic Acid 5.71% (v/v) 
 EDTA   50mM (from 0.5M Stock 
 pH   8.0 
The solution was diluted to 1X with dH2O before use 
 
Solutions for 1, 2, 3 Method of Plasmid Preparation (Birnboim and Doly 1979) 
Solution 1 
 Glucose  50mM 
 Na2-EDTA 10mM (from 0.5M stock) 
 Tris-HCl 25 mM (from 1M stock) 
 pH  8.0 
 
Solution 2 
NaOH  200mM (from 1M stock) 
SDS  1% (w/v) 
 
Solution 3 
Potassium Acetate  3M 
pH   4.8 
 
To 60ml of 5M potassium acetate, 11.5ml of glacial acetic acid and 28.5ml of dH2O 
was added. The resulting solution was 3M with respect to potassium and 5M with 
respect to acetate. 
 
Western Blot Transfer Buffer  
Tris   25 mM  
Glycine  150 mM  
Methanol  10% (v/v) 
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TBS Buffer  
Tris   20 mM  
NaCl   150 mM  
CaCl2   1 mM  
MgCl2  1 mM  
pH   7.6  
 
When the pH had been adjusted with HCl MnCl2 was added to a final concentration 
of 1mM. For TBST, the detergent Triton X-100 was added to a final concentration of 
0.1% (v/v) 
 
PBS (10x)  
Na
2
HPO4   10.9 g/L  
NaH
2
PO4   3.2 g/L  
NaCl    90 g/L  
 
A 1X has a pH of 7.2. For PBST, the detergent Triton X-100 was added to a final 
concentration of 0.1% (v/v)  
 
 
Agarose Gel Loading Dye (6X) 
 Bromophenol Blue  0.25% (w/v) 
 Xylene Cyanol  0.25% (w/v) 
 Ficoll (Type 400)  15% (w/v) 
Made in dH2O and sterilised by autoclaving 
 
Ethidium Bromide Stain 
 
A 10mg/ml solution of ethidium bromide was stored at 4
O
C in the dark. For the 
staining of agarose gels, 100ul of this stock was mixed with 1L of dH2O. The 
solution was kept in a plastic tray and covered to protect against the light. Fresh stain 
was made every 1-2 weeks. Used ethidium bromide stain was collected and ethidium 
bromide was removed by mixing with a de-staining bag (GeneChoice) overnight. 
The clear liquid was disposed of routinely, while the ethidium waste was incinerated.  
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SDS-PAGE Sample (Laemmli) Buffer (5X) (Laemmli 1970) 
 Glycerol   50% (v/v) 
 2-mercaptoethanol  5% (v/v) 
 SDS    2% (w/v) 
 Bromophenol Blue  0.1% (w/v)  
 Tris-HCl, pH 6.8  62.5mM 
 
SDS-PAGE Running Buffer (5X) 
 Tris  125mM 
Glycine 960mM 
SDS  0.5% (w/v) 
pH  8.3 
 
Coomassie Blue Stain for SDS-PAGE Gels 
 Methanol  45% (v/v) 
dH2O   45% (v/v) 
 Glacial Acetic Acid 10% (v/v) 
 Coomassie Blue 0.25% (w/v) 
To make destaining solution for coomassie blue stained gels, the coomassie blue was 
omitted. 
 
Buffers for Ni-NTA purification of histidine tagged proteins 
 
Lysis Buffer  
NaH2PO4   50 mM  
NaCl    300 mM  
Imidazole  40 mM  
pH   8.0 
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Wash buffer 
NaH2PO4   50 mM 
NaCl    300 mM 
Imidazole   100 mM 
pH    8.0 
 
Elution buffer 
NaH2PO4   50 mM 
NaCl    300 mM 
Imidazole   300 mM 
pH   8.0 
 
Column Stripping Buffer  
NaH2PO4   50 mM  
NaCl    300 mM  
EDTA    50 mM  
pH     8.0 
 
 
Table 2.4 Antibiotics 
Antibiotic Stock Conc Prepared in Working conc. 
(Solid media) 
Working conc.  
(Liquid media) 
Ampicillin 100mg/ml dH2O 100ug/ml 100ug/ml 
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2.4 Storing and Culturing of Bacteria 
 
Glycerol stocks were prepared in duplicate for each strain by picking a colony from a 
streak plate and inoculating 5ml of LB broth with a specific antibiotic if required 
overnight at 37
O
C. A 0.5ml aliquot of this exponentially growing culture was added 
to 1.0ml of sterile 80% (v/v) glycerol in a cryogenic tube. Stocks were stored at -
20
O
C and the duplicate stored at -80
O
C. Working E. coli and B. thuringiensis stocks 
were stored on agar plates at 4
O
C. 
 
2.5 Isolation and purification of DNA 
 
2.5.1 Preparation of Total Genomic DNA using the Wizard Genomic DNA Kit 
 
The kit was used according to the manufacturer’s instructions (Promega) with some 
modifications. An overnight culture of the appropriate organism (Bacillus 
thuringiensis) was prepared in LB and a 1ml aliquot of this culture was pelleted by 
centrifugation at 13,000rpm for 2 minutes. As Bacillus thuringiensis is Gram positive 
some extra steps were required for lysis. The supernatant was removed and the pellet 
was resuspended in 450µl of 50mM EDTA and 120µl of lysozyme at 10mg/ml. The 
suspension was then incubated at 37
O
C for 60 minutes to break down the bacterial 
cell wall. This was then centrifuged for 2 minutes at 13,000rpm and the supernatant 
was removed. The pellet was resuspended in 600µl of nuclei lysis solution.  The 
suspension was then incubated at 80
O
C for 5 minutes to lyse the cells and then 
cooled to room temperature. 3ul of RNase solution was added to the cell lysate. The 
tube was inverted several times to mix and incubated at 37
O
C for 60 minutes. To 
remove the protein in the sample, 200µl of protein precipitation solution was added 
and vortexed for 20 seconds. The sample was then incubated on ice for 5 minutes 
and centrifuged at 13,000rpm for 3 minutes. A phenol choloroform extraction was 
then carried out.  
600µl of the sample supernatant was taken and 400µl of phenol was added. This 
solution was inverted and centrifuged at 13,000g for 5 minutes. This step was 
repeated. The supernatant was decanted and transferred to a clean 1.5ml tube. 450µl 
chloroform was added to this sample and the solution was inverted this was then 
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centrifuged at 13,000g for 5 minutes. 600µl of isopropanol was added to the solution 
and inverted, this was then centrifuged at 13,000g for 5 minutes. The pellet was then 
kept from the last step and washed with 100µl 70% ethanol. This was centrifuged for 
3 minutes at 13,000g. The pellet was then air dried and 50µl of DNA rehydration 
solution was added and incubated overnight at 4 degrees. 
 
 
2.5.2 Isolation of plasmid DNA 
 
Two procedures for the isolation of plasmid DNA were used. The 1-2-3 method was 
used for convenient plasmid isolation from large numbers of samples in screening. 
The Hi Yield plasmid mini Kit from ISIS was used to prepare consistently pure 
DNA. 
 
2.5.2.1 1-2-3- Method 
 
Bacterial growth was taken off an agar plate with a sterile loop and re-suspended in 
200 µL of Solution 1. Alternatively, 1.5 mL of a bacterial culture in a microfuge tube 
was centrifuged at 13,000rpm for 2 minutes to collect the cells. The supernatant was 
discarded and the cell pellet re-suspended in 200 µL of Solution 1. The re-suspension 
was left for 5 minutes at room temperature. 200 µL of Solution 2 was added and the 
tube was mixed by inversion and left for 5 minutes at room temperature. Finally 200 
µL of Solution 3 was added, the tube was mixed by inversion and left at room 
temperature for 10 minutes. Cell debris was collected by centrifugation at 13,000rpm 
for 10 minutes. The supernatant was transferred to a fresh microfuge tube and a 
phenol chloroform extraction was carried out. 500 µL of phenol chloroform 
isoamylalcohol (25:24:1) was added to the tube and mixed briefly by vortexing. This 
was then centrifuged at 13,000rpm for 5 minutes. The top aqueous layer was 
removed and an equal volume of isopropanol was added and mixed by inversion. 
The tube was centrifuged at 13,000rpm for 5 minutes to pellet the plasmid DNA. The 
pellet was washed with 70% ethanol and then air dried or dried briefly in a Speed 
Vac (Savant) vacuum centrifuge. The plasmid DNA was resuspended in 30 µL of TE 
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buffer and 1 µL of Ribonuclease A was added to digest RNA. The plasmid DNA was 
stored at -20° C.  
 
 
 
2.5.2.2 High Yield Plasmid Mini Prep Kit (BBC Bioscience) 
 
The kit was used according to the manufacturer’s instructions with some alterations. 
1.5 mL of bacterial culture was added to a microfuge tube and this was centrifuged at 
13,000rpm for 1 minute to pellet the cells. Also bacteria can be collected from an 
agar plate with a sterile loop and resuspended in 200 µL of PD1 buffer. The 
respuspended cells were then lysed by adding 200 µL pf PD2 buffer and mixed 
gently by inverting the tube 10 times. The mixture was left to stand for 2 minutes at 
room temperature until the lysate clears. 300 µL of PD3 buffer was added to 
neutralise the PD2 and the sample was inverted 10 times. This was then centrifuged 
for 2 minutes at 13,000rpm. The supernatant was then transferred to a PD column 
and centrifuged at 13,000rpm for 30 seconds. The flow through was discarded and 
the PD column returned to the 2mL collection tube. To wash the DNA, 400 µL of 
W1 buffer was added to the PD column and this was centrifuged for 30 seconds at 
13,000rpm. The flow through was again discarded and 600 µL of wash buffer 
(ethanol) was added to the PD column. The column was centrifuged at 13,000rpm for 
30 seconds and the flow through discarded. The column was then dried by 
centrifugation again at 13,000rpm for 10 minutes. The dried column was then 
transferred to a fresh microfuge tube. 50 µL of elution buffer or ddH2O was directly 
added onto the centre of the membrane. The walls of the column were avoided to 
stop residual buffer adhering to them. This was then allowed to stand for 2 minutes 
until the liquid is absorbed. The column was then centrifuged at 13,000rpm for 2 
minutes to elute the purified DNA. 
 
 
 
 
 
64 
 
2.5.3 Agrose Gel Electrophoresis 
 
DNA was analysed by electrophoresis in agarose gels in a BioRad horizontal gel 
apparatus. Samples were run on a 0.7-1.0% agrose gel at 120V for 25-30 minutes. 
Agarose was prepared by adding the required amount to TAE buffer and dissolved 
by boiling. Agarose was stored at 60°C until needed. TAE was used as the running 
buffer. Agarose gel loading dye was mixed with the DNA samples to help loading of 
the DNA into the gel and to give an indication of migration distance during 
electrophoresis. After running the gels for 25-30 minutes the gels were then put into 
a bath of ethidium bromide for approximately 15-20 minutes so that an image of the 
gel could be obtained using a UV transilluminator coupled with an image analyser. 
On every gel 0.5 µg of 1 Kb Plus DNA ladder (Invitrogen) was run as a molecular 
size marker. 
 
2.5.4 Isolation of DNA from agarose gels 
 
The Hi Yeild
TM
 Gel/PCR DNA extraction kit from RBC Bioscience was used to 
isolate DNA from agarose gels. The kit was used according to the manufacturer’s 
instructions: The DNA band to be isolated from the agarose gel was excised using a 
scalpel. Up to 300mg of a gel slice was transferred to a microfuge tube. 500 µL of 
DF buffer was added to the sample and mixed by vortexing. The sample was 
incubated at 55-65°C for 10-15 minutes, inverting every 2-3 minutes until the gel 
slice was completely dissolved. A DF column was placed into a collection tube and 
up to 800 µL of the dissolved gel sample was transferred to the DF column. The DF 
column was centrifuged at 13,000rpm for 30 seconds. The flow through was 
discarded and 500 µL of wash solution was added to the DF column which was 
centrifuged again at 13,000rpm for 30 seconds. The flow through was again 
discarded and the column was dried by centrifugation at 13,000rpm for 10 minutes. 
30 µL of elution buffer or ddH2O was added to the DF membrane. The column was 
left to stand for 2 minutes and then centrifuged at 13,000rpm for 2 minutes to elute 
the isolated DNA. The DNA was stored at -20°C. 
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2.6 Preparation of high efficiency competent cells by the RF method 
 
5mL of LB broth containing the relevant antibiotics was inoculated with a single 
colony of E. coli from a plate and cultured overnight at 37°C. A 1L flask with 
200mL of SOB broth was inoculated with 2mL of the overnight culture and 
incubated at 37°C shaking at 180-220rpm. When the culture had reached an OD600 of 
0.5 the flask was cooled in ice water. All subsequent steps took place at 4°C. The 
culture was transferred to a sterile centrifuge bottle. The cells were collected by 
centrifugation at 3,000rpm for 5 minutes (using a Beckman JA-14 rotor). The 
supernatant was decanted and the cells gently re-suspended in 60mL of chilled RF1 
buffer. The suspension was left on ice for 90 minutes. The cells were again collected 
by centrifugation at 3,000rpm for 5 minutes. The supernatant was decanted and the 
cells gently re-suspended in 8mL of chilled RF2 buffer. Aliquots of 400 µL were 
prepared in sterile 1.5mL microfuge tubes and flash frozen using -80°C metal blocks. 
The competent cells were stored at -80°C. 
 
 
2.6.1 Transformation of competent cells 
 
An aliquot of competent cells was thawed on ice. 2 µL of plasmid DNA was mixed 
with 200 µL of the cell suspension in a sterile 1.5mL microfuge tube. The mixture 
was incubated on ice for 30 minutes. The cells were heat shocked at 42°C for 45 
seconds and placed back into ice for 2 minutes. After this 800 µL of LB broth was 
added to the cells and they were incubated for 1 hour at 37°C. 200 µL of the sample 
was spread on LB agar and incubated at 37°C overnight.  
 
2.6.2 Determination of cell efficiency 
 
Competent cell efficiency depends on the number of colonies formed per µg of 
transformed plasmid DNA. A 10 ng/ µL stock of pUC18 plasmid DNA was diluted 
to 1ng/ µL, 100pg/ µL and 10 pg/ µL. 1 µL of each dilution was transformed as 
described above. The cell efficiency was calculated from the number of colonies 
obtained, taking into account the dilution factor and the fraction of culture transferred 
to the spread plate.  
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2.7 Enzymatic reactions 
 
All enzymes and relevant buffers were obtained from Invitrogen Life technologies, 
New England Biolabs, Sigma Corporation or Bioline and were used according to the 
manufacturer’s instructions.  
 
2.7.1 Polymerase chain reaction 
 
PCR reactions (Mullis and Faloona 1987) were carried out using a Veriti 
Thermocycler (Applied Biosystems) 
 
2.7.1.1 Standard PCR reaction mixture 50 µL 
Buffer (5X)       10 µL 
Primers (10µM)  1 µL of each 
dNTP’s               1 µL 
Template DNA   1 µL 
dH2O                   35 µL 
Taq polymerase    1 µL 
 
2.7.1.2 Standard PCR programme cycle for Velocity taq polymerase reactions 
Stage 1: Step 1: 95°C for 10 minutes 
Stage 2: Step 1: 95°C for 30 seconds 
               Step 2: Annealing temperature for 30 seconds 
               Step 3: 72°C for 30 seconds per kb to be synthesised 
Stage 3: Step 1: 72°C for 10 minutes 
Stage 2 was carried out for 30 cycles. A 1:3 dilution of velocity Taq polymerase was 
carried out before use in PCR. 
 
2.7.2 Restriction Digests 
DNA/PCR               8 µL 
Buffer                      1 µL 
Enzyme                    1 µL 
Reactions were incubated for 3 hours or overnight at 37°C. 
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2.7.3 Ligation reaction 
PCR product            6 µL 
Vector                      10 µL 
T4 DNA ligase         1 µL 
Ligase buffer(10X)  2 µL 
dH2O                        1 µL 
Reactions were incubated for 3 hours at room temperature of 16 hours at 4°C. 
 
2.7.4  Site specific mutagenesis  
 
Mutations were introduced into open reading frames on plasmid constructs by PCR 
amplification using complementary phosphorylated primers carrying the desired 
mutation. A standard PCR reaction mixture as show in Section 2.7.1.1 was set up. 
The PCR was carried out using the high fidelity Velocity Taq polymerase. The 
standard program cycle for Velocity Taq polymerase (Section 2.7.1.2) was used. 
Typically an extension time of 2 min was used to amplify plasmids of 3.5-4 kb. The 
template DNA was eliminated by digestion with DpnI restriction endonuclease. 
DpNI is biased towards a methylated recognition sequence. It selectively digests the 
template DNA from dam+ E. coli strains over the newly synthesized DNA. The 
amplified plasmid, with the incorporated mutation, is circularized by ligation which 
was facilitated by the use of phosphorylated primers. 
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2.8 DNA sequencing  
 
Recombinant clones were verified by DNA sequencing. Commercial sequencing 
services were provided by MWG Biotech/Eurofins and Source BioScience gene 
service. Suitable sequencing primers for standard vectors were sent with samples to 
be analysed. Samples were sent as plasmid preparations 
 
 
2.9 In silico analysis of DNA sequences 
 
DNA sequences for the strains used in this study were obtained from the following 
sequencing studies;  
DNA and protein sequences were aligned using the ClustalW, available at 
http://www.ebi.ac.uk/Tools/clustalw/ and Gendoc programme, available to download 
at http://www.nrbsc.org/. DNA sequences were analysed for restriction sites using 
Webcutter 2.0 programme.  
 
2.10 Protein modelling using I-Tasser and Pymol 
Protein sequences were sent to the I-Tasser server in fasta format 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/). An e-mail with the predicted 
protein structure models was sent by the I-Tasser server to the user. Predicted protein 
models and their scores were given along with any enzyme and lectin binding 
domain similarity. The protein data files were downloaded and were used as the basis 
for PyMol modelling. PyMol was downloaded from the PyMol website 
(http://www.pymol.org/). PyMol interface was opened and the protein data file of the 
protein of interest was uploaded by the molecular graphics system file > open > data 
file(.pdb). The protein structure was observed on the PyMol viewer in stick molecule 
formation. The protein was then modelled using the PyMol viewer command system 
and the PyMol molecular graphics system. The protein could be rotated and areas 
selected using the mouse on the PyMol viewer.  
 Display a white background for pictures (Display > background > white). 
 Obtain the colours for publication (Display > colour space > CMYK for 
publications). 
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 Change the protein structure from stick molecules to cartoon ribbons. (Hide 
all > show cartoon ribbons) 
 Show the surface of the protein (select all > show surface) 
 Colour the helical and beta barrel structures. (colour > by ss > Helix, sheet, 
loop) 
 Colour selected regions (select region > colour > select colour) 
 Mutate regions or amino acids, the sequence was added to the PyMol viewer 
so residues could be selected with ease (display > sequence). For mutagenesis 
(wizard > mutagenesis > pick a residue > no mutation, select residue change 
> apply > done.  
 Obtain a high resolution picture (Ray) 
 Save the session (file > save session as > file name) 
 Save the model as a image (file > save image as > PNG > file name) 
 
 
2.11 Data analysis of ELLA results 
 
An ELLA was read on the spectrometer at 450nm. The data was transferred into a 
excel file for analysis. Each sample was carried out in triplicate and the average of 
the three samples was taken. The averages of the negative controls, PBS and TBST 
were taken away from the average of the samples. Standard deviation was obtained 
using the custom standards from the averages of each sample. A column graph was 
used to graph the ELLA results while concentration ELLA results were graphed 
using xy scatter plot. The standard deviation was added to the graphs as custom error 
bars. All ELLAs were carried out an average of three times to confirm conststant 
results. 
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2.12 Standard expression culture 
 
An LB plate with the appropriate antibiotic was streaked from a glycerol stock of the 
strain containing the expression plasmid. A colony was used to inoculate 10 mL of 
LB broth containing the appropriate antibiotic, and grown over night at 37°C while 
shaking at 200rpm. A 1 L baffled clonical flask containing 500 mL of LB broth was 
inoculated with 5 mL of the overnight culture and the appropriate antibiotic was 
added. The culture was incubated at 37°C, shaking at 200rpm, until an optical 
absorbance (a600) of 0.4-0.6 was reached. IPTG was added to a final concentration of 
50µM to induce expression. The culture was incubated at 20°C -30°C overnight. The 
culture was then centrifuged at 4,000rpm for 10 minutes (using a Beckman JA-14 
rotor) to collect the cells. The supernatant was autoclaved and discarded, and the 
pellets were stored at 20°C.  
 
 
2.13 Preparation of time course expression samples  
 
2.13.1 Culture growth and sampling 
 
5mL of an overnight culture was used to inoculate 500mL of LB broth to which the 
appropriate antibiotic had been added. The culture was incubated at 37°C until the 
OD600 has reached 0.5-0.6. An initial 6mL aliquot (time zero) was taken and placed 
on ice for 30 minutes prior to harvesting of the cells by centrifugation. IPTG was 
added to the culture to a final concentration of 50µM and 6mL aliquots were taken 
every hour for an additional 5 hours (samples time 1 to time 4). All of the samples 
were placed on ice for at least 30 minutes prior to harvesting by centrifugation. The 
culture was allowed to grow overnight and a final sample was withdrawn. Having 
been incubated on ice for 30 minutes all samples were harvested by centrifugation at 
4000 rpm for 10 minutes and the cell pellets re-suspended in 6mL of PBS. 
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2.13.2 Clarified media samples for SDS PAGE – monitoring extracellular 
protein 
 
A sample of the clarified media was retained for SDS PAGE analysis. Therefore a 
500ml aliquot was spun at 13,000rpm for 10 minutes to ensure removal of all cells. 
The clarified media was transferred to a fresh tube and frozen for analysis on SDS 
PAGE. 
 
2.13.3 Growth curve preparation  
 
Cell pellets were re-suspended in 6mL of buffer and readings taken at 600nm to 
enable the construction of growth curves. The readings were also used to calculate 
the volume of culture required for preparation of samples for SDS-PAGE analysis.  
 
 
2.13.4 Sample preparation for total protein analysis 
 
The volume of each time course sample needed to prepare samples for total protein 
analysis was calculated using the following equation. 
(0.7/OD600nm) x 300 = Volume of culture to be harvested (µL) 
The cells were harvested by centrifugation in microfuge tubes at 13,000rpm and were 
re-suspended in 50µL of 1x SDS-PAGE loading buffer. 20 µL of each sample was 
then run on SDS-PAGE. 
 
2.13.5 Sample preparation for soluble and insoluble protein analysis 
 
The volume of the time course samples that were harvested to prepare samples for 
soluble and insoluble protein analysis was calculated using the following equation 
(0.7/OD600nm) x 2400 = volume of culture to be harvested (µL) 
The harvested pellet was then re-suspended in 40 µL of 1x cell lytic (prepared from a 
10x stock). The re-suspended cells were left to lyse overnight at 4°C or at room 
temperature for at least 1 hour. Once the cells were lysed the insoluble cell debris 
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was pelleted by centrifugation at 13000rpm for 20 minutes and the soluble fraction 
removed to a fresh tube. 
 
2.13.5.1 Soluble protein analysis 
 
For analysis of soluble protein the soluble fraction was diluted at least 1:5 prior to 
running on SDS-PAGE, as the components of the cell lytic have a negative impact on 
the protein separation. Samples were prepared by mixing 5 µL of the soluble fraction 
with 15 µL of the appropriate buffer and then 5 µL of 5x SDS-PAGE loading dye. 
The entire sample was loaded onto the SDS-PAGE gel. 
 
2.13.5.2 Insoluble protein analysis 
 
For analysis of insoluble protein the pelleted insoluble material was re-suspended in 
50 µL of 1x SDS PAGE loading dye and heated for 10 minutes at 95°C. The samples 
were centrifuged at 13,000rpm for a few seconds and 15-20 µL was run on the SDS-
PAGE gel. 
 
2.14 Preparation of cleared lysate for protein purification  
 
Cell lysis was carried out using a cell disruptor. 
 
2.14.1 Cell lysis by cell disruption (constant cell disruption ltd) 
 
A cell pellet from a 500mL expression culture was re-suspended in 10% of the cell 
pellet weight in lysis buffer containing 20-40mM imidazole, pH 8.0. 1% Antifoam 
was added to the cell mixture to prevent foaming in the cell disruptor. 200mL lysis 
buffer was put over the cell disruptor at 15kpsi to equilibrate the machine. The cell 
mixture was passed through the machine at 15kpsi to lyse the cells and this was 
followed by the same amount of lysis buffer to wash any reside from the system. The 
lysed mixture was collected and spun at 13,000rpm for 50 minutes at 4°C to separate 
the insoluble and soluble fractions. The cleared lysate was transferred to a fresh 
container and then passed through a 0.2 µM filter to remove any remaining cell 
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debris and stored at 4°C. The cell disruptor was cleaned by passing through 500mL 
of Ethanol followed by 500mL of distilled water at 15-20kpsi. 
 
 
2.15 Protein Purification 
 
2.15.1 Protein purification by standard IMAC procedure 
 
Protein purification of 6x histidine tagged proteins was carried out by IMAC. A 1mL 
Ni- Sepharose Fast flow column was washed with 5-10 column volumes of dH2O. 
The column was equilibrated with 5-10 column volumes of lysis buffer containing 
20-40mM imidazole. The cleared lysate was gently mixed with the nickel resin in a 
column. The column was washed with 10 column volumes of lysis buffer containing 
20-40mM imidazole. A gradient of imidazole in lysis buffer was used to elute 
contaminating proteins from the column. The target protein was eluted from the 
column using a high concentration of imidazole in lysis buffer (120-500mM 
imidazole). The column was washed with 5-10 column volumes of water followed by 
3-5 column volumes of 20% ethanol. Samples were taken at each step and analysed 
on SDS-PAGE electrophoresis.  
 
2.15.2 Cleaning and recharging of IMAC resin 
 
The column was routinely recharged and cleaned prior to re-use of the Ni-NTA resin. 
The used resin was poured into a column and washed with 5 columns of dH2O. The 
resin was then stripped by washing with 5 column volumes of stripping buffer. 
Ionically bound proteins were removed by washing with 5 column volumes of 1.5M 
NaCl. Precipitated proteins, hydrophobically bound proteins, lipoproteins and lipids 
were removed by washing with 5 column volumes of 1M NaOH, contact time 1-2 
hours, followed by 10 column volumes of dH2O. Remaining impurities were 
removed by washing with 10 column volumes of 30% isopropanol for 30 minutes, 
followed by 10 column volumes of dH2O. The resin was charged by adding 2 column 
volumes of 100mM NiSO4. The resin was washed again with 2 column volumes of 
dH2O before storage in 20% ethanol.  
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2.15.3 Protein purification by Size exclusion Chromatography  
 
The separation of protein contaminants from recombinant proteins under native 
conditions was done by size exclusion chromatography. Size exclusion 
chromatography was carried out using FPLC. Before attachment of the gel filtration 
column to the AKTA purifier the maximum back pressure was set according to the 
manufacturer’s instructions. The column storage valve was disconnected from the gel 
filtration column, and the top was attached to pump outlet no 1. The bottom of the 
column was attached directly to the FPLC. To remove the column storage buffer 
(20% ethanol) two column volumes of water were pumped through the column at a 
flow rate of 1 mL/min (unless otherwise stated). The column was then equilibrated 
with 5 column volumes of sample buffer, at the same flow rate, before sample 
application. 
 
 
2.15.3.1 Toyopearl HW-55S  
 
With pump A attached to a reservoir of degassed sample buffer 10ml of the protein 
sample was applied through the sample injection port. The run commenced, with a 
flow rate of 1 mL/min of buffer A and a maximum back pressure of 0.5 MPa. 
Following sample injection 2.5 column volumes of buffer was passed through the 
column. The proteins retention time was measured using the online Monitor U-900 
(GE Healthcare), which read the eluent absorbance at 280 nm. 
 
2.15.4 Protein purification by Ion Exchange Chromatography 
 
Ion exchange chromatography was carried out to separate proteins by charge. At a 
pH lower than a proteins PI the protein will be positively charged and so it binds to a 
cation exchanger. Toypearl CM sepharose was used as a weak cation exchanger. 
PBS at a particular pH, generally between the PI of both proteins, was used to 
equilibrate 0.5ml of CM sepharose in triplicate. The protein sample was buffer 
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exchanged into PBS at the appropriate pH in triplicate. Both samples were mixed 
gently overnight at 4°C. The CM sepharose was spun at 13,000rpm for 5 minutes and 
the PBS supernatant was taken off. The protein sample was added to the CM 
sepharose and gently mixed for 1 hour at 4°C. The sample was then spun again at 
13,000rpm for 5 minutes and the supernatant extracted. This contained the negatively 
charged proteins that did not bind to the resin. The protein that bound to the CM 
sepharose was eluted by adding PBS that has a higher pH than the protein’s PI and 
mixing gently for one hour. The sample is spun at 13,000rpm for 5 minutes and the 
supernatant extracted. Analysis of the protein samples was carried out on SDS 
PAGE.  
 
 
2.15.5 Purification of proteins using detergent: Triton X100 
 
During the cell disruption and IMAC process a concentration of Triton X100 ranging 
from 1 to 10% was added to the sodium phosphate buffer. IMAC was carried out as 
in section 2.21. The protein was then eluted in 300mM imidazole with added Triton 
X100.  The eluted protein was then analysed on SDS PAGE and buffer exchanged 
into PBS to be analysed on ELLAs.   
 
2.15.6 Purification of proteins by competing sugars 
 
The IMAC procedure was carried out as normal and during the washes 100mM of a 
sugar eg. Galactose was added to the Sodium phosphate buffer with imidazole. The 
column was again washed with sodium phosphate buffer and imidazole and then the 
protein was eluted in 300mM imidazole. The eluted protein was analysed on SDS 
PAGE and buffer exchanged to remove any residual imidazole and sugar. 
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2.16 Examining the stability of a protein 
 
The protein stability was analysed through these steps and then examined by protein 
quantification and on ELLA’s. The pH was tested in steps of one pH unit in between 
pH 2 and 10. The salt stability was tested with 0.2M NaCl and 0-2M (NH4) 2 SO4 in 
steps of 0.5M. Acetonitrile and methanol was tested in 10% steps between 0 and 
50%. The temperature stability was tested in +10°C steps from 4°C to 40°C. The 
stability and occurrence of proteolytic activity was tested by leaving an aliquot of the 
sample at room temperature overnight. The aliquot was then centrifuged and the 
activity and UV absorbance at 280nm was measured in the supernatant.  
 
 
2.17 Protein quantification by 280nm readings 
 
The quantification of protein concentration by 280nm reading is based on the 
proteins ability to absorb ultraviolet light in solution with the absorbance of 280nm. 
Prior to reading all samples were spun down at 13,000rpm for 10 minutes to 
minimize any debris present in solution that may interfere in absorbance readings. 
The UV lamp was set to 280nm and the absorbance was calculated with buffer 
solution. The absorbance of the protein solution was read in triplicate. The 
concentration of the protein was then calculated using Beer-Lambert law; 
A=Ɛcl 
Equation: Beer – Lambert equation for the quantitative determination of protein 
concentration from absorbance readings at 280nm. A=absorbance at 280nm, 
Ɛ=molecular extinction coefficient, c=concentration (in units corresponding to Ɛ) and 
l=path length.  
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2.18 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
2.18.1 Preparation of SDS gels 
 
Protein samples were analysed by Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE), based on the method outlined by Laemmli (Laemmli 
1970).  
10%, 12.5% and 15% gels were prepared as outlined in the table  
 
Table 2.5: Preparation of SDS gels 
Resolving Gel 10% 15% 4% 
30% Acrylamide (mL) 2.501 3.750 0.325 
H2O (mL) 3.007 1.758 1.540 
1.5M Tris-HCl pH8.8 
(mL) 
1.875 1.875 - 
0.5M Tris-HCl pH 8.8 
(µL) 
- - 625 
10% APS (µL) 37.5 37.5 12.5 
10% SDS (µL) 75 75 25 
Temed (µL) 3.75 3.75 2.5 
 
 
 
2.18.2 Sample Preparation 
 
20 µL of the protein sample was added to 5µL of 5x SDS-PAGE loading buffer. 
Samples were boiled for 5 minutes and applied to wells that had been flushed of un-
polymerised acrylamide.  
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2.18.3 Sample application  
 
10-15 µL of the prepared sample was loaded to each SDS-PAGE well. One lane on 
each gel was kept for the molecular weight protein marker (figure 2.1). A 20 µL 
aliquot of the marker was loaded to the gels for coomassie staining. For a western 
blot, the NEB pre-stained and colour plus pre-stained protein markers were used.   
 
                                             
Figure 2.2: A; NEB broad range protein marker, B; Pre-stained protein marker 
and C; Colour plus pre-stained protein marker. Representative images of the 
NEB broad range protein marker, pre-stained protein marker and colour plus pre-
stained protein marker used in this study. Images obtained from www.NEB.com. 
 
 
 
 
 
 
 
 
 
 
 
 
C B 
A 
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Table 2.6: NEB Protein marker, representative bands. 
 
Protein Source Molecular Weight 
(daltons) 
Myosin rabbit muscle 212,000 
MBP-β-galactosidase E. coli 158,194 
β-Galactosidase E. coli 116,351 
Phosphorylase b rabbit muscle 97,184 
Serum albumin bovine 66,409 
Glutamic dehydrogenase bovine liver 55,561 
MBP2* E. coli 42,710 
Thioredoxin reductase E. coli 34,622 
Triosephosphate 
isomerase 
E. coli 26,972 
Trypsin inhibitor soybean 20,100 
Lysozyme chicken egg 
white 
14,313 
Aprotinin bovine lung 6,517 
Insulin A bovine 
pancreas 
3,400 
B chain bovine 
pancreas 
2,340 
 
 
2.18.4 Gel analysis 
 
Polyacrylamide gels were removed from the electrophoresis box and washed with 
dH2O. Gels were stained for one hour with coomassie blue stain solution. An 
overnight de-stain followed using coomassie blue de-stain solution. The gels were 
then put into dH2O to enhance the protein bands further. 
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2.19 Western blot 
 
A SDS-PAGE gel was run using NEB pre-stained molecular weight markers. Four 
pieces of blotting paper and a piece of nitrocellulose membrane were cut to the same 
dimensions as the SDS-PAGE gel. The blotting paper, nitrocellulose and the gel 
were soaked in transfer buffer, and arranged on the semi-dry electroblotter. Transfer 
then occurred at a constant 20V for 15 minutes. For the detection of recombinant 6x 
histidine tagged proteins, the membrane was blocked with 3% BSA-TBST for one 
hour. The membrane was washed four times for 5 minutes with TBST, and then 
incubated with 1:10,000 murine anti-His antibody- HRP in 3% BSA-TBST. The 
membrane was washed four times for 5 minutes with TBST and incubated in 15mL 
dH2O containing sigmafast 3,3-diaminobenzidine tablets. dH2O was used to stop the 
development. 
To detect glycoproteins the membrane was blocked with Carbo-Free blocking 
solution (Vector Laboratories), diluted to the correct concentration in PBS. The 
membrane was washed four times for 5 minutes in TBST then incubated for 1 hour 
with a 1 μg/ml solution of a biotin labelled lectin of choice in TBST. The membrane 
was washed again then incubated with 1:10,000 horseradish peroxidase (HRP) 
labelled murine anti-biotin antibody in TBS. After a final washing the membrane was 
developed using 15 ml of dH2O containing a SIGMAFAST Ô 3,3_-diaminobenzidine 
tetrahydrochloride tablet. The developed blot was washed with dH2O. 
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2.20 Protein identification by MS peptide mapping and sequencing 
analysis 
 
The protein samples were reduced and alkylated with iodoacetamide, i.e. 
carbamidomethylated, and subsequently digested with trypsin that cleaves after 
lysine and arginine residues. The resulting peptides were spotted onto an anchorchip 
target for analysis on a Bruker Autoflex Speed MALDI TOF/TOF instrument. The 
peptide mixture was analyzed in positive reflector mode for accurate peptide mass 
determination. MALDI MS/MS was performed on 15 peptides for peptide 
fragmentation analysis. The MS and MS/MS spectra were combined and used for 
database searching using the Mascot software. The data are searched against in-
house protein databases downloaded from NCBI, including the NRDB database 
containing more than 20 million known non-redundant protein sequences. The data 
can also be searched against a custom database containing specific protein 
sequences. The Mascot software finds matching proteins in the database by their 
peptide masses and peptide fragment masses. The protein identification is based on a 
probability-scoring algorithm (www.matrixscience.com).  
 
 
 
2.21 Enzyme linked lectin assay 
 
50µL of a glycoprotein was immobilised in a well of a NUNC MaxiSorp ELISA 
plate at 4°C overnight. Each sample was done in triplicate, at a concentration of 
5µg/mL. The plate was inverted to remove any unbound glycoprotein and the wells 
were blocked with 200 µL 3% BSA in PBS for two hours at 25°C. The plate was 
inverted to remove the solution and the plate was washed with TBST four times. A 
50 µL aliquot of lectin in TBST was added at a concentration of 5µg/mL and 
incubated at 25°C for one hour. This was removed by inverting the plate and washed 
four times with TBST. 50 µL of 1:10,000 murine anti-histidine-HRP or anti-biotin 
antibody-HRP was then added to the wells. Antibody was diluted fresh each time 
with TBST and the plate was incubated for an hour at 25°C. Unbound antibody was 
removed by inversion and the plate was washed four times with TBST and once with 
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PBS. 100 µL of TMB substrate was added to each well and the reaction was left for 
10 minutes. The reaction was stopped by the addition of 50 µL of 10% H2OS4. The 
absorbance could then be read on a plate reader at 450nm. 
 
 
2.3 The ELLA assay methodology. (a) Lay down lectin or carbohydrate binding 
protein (e.g. tCry1Ac), (b) block with BSA, (c) incubate with neo-glycoprotein 
(GalNAc-BSA), (d) incubate with antibody, (e) detect antibody and colour change at 
Abs 450nm. 
 
  
 
 
 
 
 
Chapter 3 
Bioinformatic analysis and structural 
modelling of Cry1A Toxins; Cloning of 
the Cry1Ac derivatives tCry1Ac and 
CryD3 
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3.1 Overview 
 
This chapter describes the bioinformatic analysis and structural modelling carried out 
on the Cry1Ac toxin from Bacillus thuringiensis kursatki HD-73, for the design and 
subsequent cloning of two recombinant genes, encoding tCry1Ac, a truncated 
Cry1Ac and CryD3, the third domain of Cry1Ac. It was hypothesised that soluble 
active proteins would be expressed in E. coli for both tCry1Ac and CryD3.  The gene 
encoding tCry1Ac was designed from the gene encoding the activated Cry1Ac toxin 
that binds to the insect cell membrane (Bravo et al. 2007). The expressed protein if 
active should bind to N-acetylgalactosamine (GalNAc). Bioinformatic and structural 
analysis of Cry1Ac domain III, revealed that this domain alone may yield an active 
protein that would potentially bind to galactose. The gene encoding CryD3 would 
result in a protein that encodes only the third domain of Cry1Ac. A recombinant 
expression system developed in E. coli, using the plasmid pQE60 which encodes a 
C- terminal 6 x histidine tag, was used for protein purification.  
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3.2 Analysis of the Cry1Ac protein sequence 
 
A blast search was carried out on the protein sequence of Cry1Ac to identify 
homologues of the three domains and in particular to compare domain III of Cry1Ac 
with carbohydrate binding proteins (Figure 3.1). The sequence identity was highly 
conserved between Cry1Ac and related Cry toxins. The blast search revealed the 
approximate location of the three domains of Cry1Ac, domain I (aa 10-250), domain 
II (aa 250-460) and domain III (aa 460-640). The similarity of domain III to a lectin 
superfamily Carbohydrate binding module family 6 (CBM6) was also observed 
(Figure 3.1)  
CBM6, is also known as cellulose binding domain family VI (CBD VI), and has 
related CBMs, CBM35 and CBM36. These carbohydrate binding families are non-
catalytic carbohydrate binding domains found in a range of enzymes that display 
activities against a diverse range of carbohydrate targets, including mannan, xylan, 
beta-glucans, cellulose, agarose, and arabinans (http://blast.ncbi.nlm.nih.gov). The 
function of the domain is to facilitate the strong binding of the catalytic modules to 
their dedicated, insoluble substrates. Many of these CBMs are associated with 
glycoside hydrolase (GH) domains. CBM6 is an unusual CBM as it represents a 
chimera of two distinct binding sites with different modes of binding: binding site I 
within the loop regions and binding site II on the concave face of the beta-sandwich 
fold (Varki et al. 2009).  CBM36 comprises a group of calcium-dependent xylan 
binding domains. Members of CBM35 display conserved specificity through 
extensive sequence similarity, but divergent function through their appended 
catalytic modules. The alignment model in figure 3.2 also contains the C-terminal 
domains of bacterial insecticidal toxins, as they may be involved in determining 
insect specificity through carbohydrate binding functionality (NCBI blast search). 
A diagram of the full Cry1Ac, the activated Cry1Ac (tCry1Ac) and domain III of the 
activated toxin (CryD3) is shown in Figure 3.3. It highlights the domains and the 
regions that are cleaved prior to activation. Domain III represents the binding region 
of Cry1Ac. 
A multiple sequence alignment was performed on Cry1Aa, Cry1Ab and Cry1Ac 
using ClustalW and Genedoc. Figure 3.4 highlights the few areas where there was 
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sequence divergence. Overall the sequences were highly conserved in the N and C 
termini, non conserved blocks were mostly confined to domains II and III (Figure 
3.4). From amino acids 470 to approx 620 there is a lot of variation between the 
sequence of Cry1Ac and Cry1Aa. However the main differences are found in the 
lengths, orientations, and sequences of the loops (Pigott and Ellar 2007). The 
importance of these differences is evident with Cry1Aa and Cry1Ac, where a loop 
extension in Cry1Ac creates a unique GalNAc binding pocket involved in receptor 
binding (Pigott and Ellar 2007). 
This sequence divergence in domain III accounts for the variety in receptors for the 
Cry toxins. A maximum likelihood method was employed to detect evidence of 
adaptive evolution in Cry proteins by Wu et al. (2007). They identified positively 
selected residues, which are all located in Domain II or III, revealing that the Cry 
toxins are adapting and evolving in these regions (Figure 3.5). This is possibly the 
reason for multiple receptors, variation in targeted species of insects among toxins 
and the recent increase in Cry toxin susceptibility among nematodes and mosquitoes. 
Therefore the sites under positive selection could prove interesting targets for 
structural and functional analysis in relation to receptor binding, in particular 
carbohydrate recognition moieties. Multiple sequence alignments were preformed on 
Cry1Ac and other related toxins which revealed similar results. The rooted 
phylogenetic tree, of the sequence alignment reveals that Cry1Ac diverged earlier 
from Cry1Aa, Cry1Ab and also Cry1Ad (Figure 3.6).  
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Figure 3.1: Hierarchy of the functions of related proteins to domain III from the 
blast search result. The hierarchy shows all the families related to the CBM6 
family. This is a tree that starts with the highest related families down to the lowest 
similarities. Domain III shows similarity to the CBM6-CBM35-CBM36 
superfamilies, the members of which have related structures and functions to 
xylanase, agarose, cellulose galactosidase, and delta endotoxin proteins (Marchler-
Bauer et al. 2013, NCBI blast search). 
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Figure 3.2: Blast search results of Cry1Ac. (a) The blue box from ~10-250, represents domain I, the green ~250-460, domain II, and 
the red, ~460-620, domain III. (b) Domain III has a specific hit with endotoxin C, while also showing similarities to a lectin superfamily 
CBM6-CBM35-CBM6. 
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Figure 3.3: Diagram of (A) Cry1Ac complete toxin, (B) Activated Cry1Ac toxin (tCry1Ac) and (C) Domain III (CryD3).  (A) 
Cry1Ac complete toxin contains domain I, domain II and domain III. This protein is not activated and is protected by the cysteine 
residues in domain III and some in domain I, these parts of the protein are highlighted yellow. (B) The activated toxin (tCry1Ac) which 
has been cleaved to yield, domain I, domain II and partial domain III. There are no cysteine residues in the protein and it can now induce 
binding and toxicity in insects. (C) Only the activated part of domain III makes up CryD3. It contains the binding site but cannot induce 
toxicity in insects.  
Cry1Ac complete toxin 
A 
Domain III Domain II Domain I 
Activated Cry1Ac 
(tCry1Ac) 
B 
 
CryD3 
Domain III Domain II Domain I 
C 
Domain I Domain II Domain III 
Domain III 
14 Cysteine residues  2 Cysteine residues  
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Figure 3.4: Multiple sequence alignment of Cry homologous proteins. The alignment shows the large sequence homology of 
Cry1Aa, Cry1Ab and Cry1Ac. The sequence is almost identical for each domain I which spans from approx 1-250 amino acids. Domain 
II spans from approx 250-460 amino acids and shows a considerable sequence similarity between Cry1Ab and Cry1Ac. The active part 
of Domain III spans 460-620 and shows the dissimilarity of this region in Cry1Ac compared to Cry1Aa and Cry1Ab.   Alignment 
created using ClustalW and Genedoc 2.7. 
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Figure 3.5: Multiple sequence alignment of homologous Cry proteins, focusing on specific residues in domain III. Domain III in 
each toxin has considerable sequence similarity; however there are some differences especially between the Cry1Ac sequence and the 
other two sequences. The black arrow represents the amino acid known to be involved in GalNAc binding (Xiang et al. 2009). The green 
arrow points out the amino acid that is involved in GalNAc binding and is under positive selection for adaptive evolution (Wu et al. 
2007). The red arrows highlight the residues that are under positive selection for adaptive evolution, as observed by Wu et al. (2007). 
Alignment created using ClustalW and Genedoc 2.7. 
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Figure 3.6: Rooted phylogenetic tree from the results of the sequence alignment 
of Cry1Aa, Cry1Ab, Cry1Ac and Cry1Ad. Cry1Ac diverged early from Cry1Aa, 
Cry1Ab and Cry1Ad, even though these toxins all form a group distinguishable from 
other Cry toxins. Alignment and phylogenetic tree created using ClustalW. 
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3.3 Designing the recombinant proteins tCry1Ac and CryD3  
The design of tCry1Ac was based on the activated form of Cry1Ac, as described in 
Figure 3.3, which binds to the insect gut intestine (Figure 3.8). This design 
eliminated all the cysteine residues in Cry1Ac shown in Figure 3.7, which cause an 
insoluble protein. It is predicted that tCry1Ac would bind to GalNAc. CryD3 was 
designed around domain III of tCry1Ac. (Figure 3.9) It was proposed that if CryD3 
would be produced as a soluble protein with a similar structure to that of domain III 
in Cry1Ac, it may also have carbohydrate binding abilities. CryD3 therefore would 
not have the toxin domain but it still may bind carbohydrates. Previously, Cry 
proteins would have been harvested as inclusion bodies and extracted using methods 
such as cell-free extract for excreted toxins and autolysis, sonication, French press, 
freeze/thaw for Bacillus expressed proteins. The inclusion bodies were then purified 
by density gradient or recrystallization and the crystals were solubilised using pH 
and activated by proteolytic enzymes.  The toxins were further purified using 
methods such as precipitation and dialysis. Making the proteins soluble and more 
amenable to expression in E. coli allows them to be readily produced for use as 
carbohydrate binding lectins for various applications.   
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Figure 3.7: Complete protein sequence of Cry1Ac.  The amino acids underlined 
were not cloned.  tCry1Ac, the region that is not underlined, represents the active 
toxin. Cystine residues are highlighted in pink, domain III is highlighted in blue, 
and the residues thought to play a role in GalNAc binding are highlighted in yellow. 
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Figure 3.8: Protein sequence of tCry1Ac, a truncated form of Cry1Ac. This 
protein is predicted to express as a soluble active protein, similar to that which is 
activated in the intestine of insects. A 6x histidine tag was added to the C terminus of 
the recombinant protein. 
 
 
 
Figure 3.9: Protein sequence of CryD3, the third domain of tCry1Ac.  CryD3 is 
153 amino acids long, and encoding a 6x histidine tag at the C terminus of the 
recombinant protein. This protein would not have the toxin capabilities of Cry1Ac 
but it may have kept the ability to bind GalNAc. 
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3.4 Structure predictions of tCry1Ac and CryD3 using I-TASSER  
The protein sequences of tCry1Ac and CryD3 were submitted to the online service I-
Tasser. The I-Tasser server is an internet service for protein structure and function 
predictions. It automatically generates high-quality predictions of 3D structure and 
biological functions of protein molecules from their amino acid sequences (Roy, 
Alper, and Yang 2010; Roy, Jianyi, and Yang 2012; Zang, 2008). Figure 3.10 shows 
how the server generates structure and function predictions by first retrieving 
templates of proteins that have similar secondary structure from the Protein Data 
Bank (PDB) library by a threading approach. In the second step, the continuous 
fragments excised from the PDB templates are reassembled into full-length models 
by replica-exchange Monte Carlo simulations with the threading of unaligned 
regions built by ab initio modeling. In the third step, SPICKER (a clustering 
algorithm to identify the near-native models from a pool of protein structure decoys) 
assembles the fragments again to refine the clusters and remove steric clash. The 
decoys generated in the second simulations are then clustered and the lowest energy 
structures are selected. The final full-atomic models are obtained by REMO which 
builds the atomic details from the selected I-TASSER decoys through the 
optimization of the hydrogen-bonding network (Figure 3.10) (Roy, Alper, and Yang  
2010; Roy, Jianyi, and Yang 2012; Zang, 2008). I-Tasser then send the predicted 
protein structures, models and protein data files to the user.  
Figure 3.11 shows three different views of the predicted structure of tCry1Ac by I-
Tasser. These models show a very similar structure to other Cry toxins, (De maagd, 
et al. 2001) which would predict that tCry1Ac would fold into an active protein. The 
predicted structure of CryD3 is shown in Figure 3.12, while also highlighting the 
predicted binding site in the protein. This predicted binding site was in a different 
position than the expected binding site in domain III of Cry1Ac. I-Tasser predicted 
residues P14, A15 and V16 to be involved in galactose binding. It also showed how 
CryD3 would fit into the Cry toxin protein model. This structure for CryD3 is very 
similar to that of domain III in tCry1Ac however it does have some small differences 
and this could affect the binding site. Therefore further analysis on these protein 
models and predicted binding sites was done using PyMol. 
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Figure 3.10: I-Tasser protocol for protein structure and function predictions 
(Roy, Alper, and Yang 2010). 
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Figure 3.11: Predicted structure of tCry1Ac from I-Tasser. A and B show the 
helical domain I in pink and domains II and III in yellow. C) Domain I is in blue 
(beta barrels), domain II is shown in green while domain III is shown in red. Models 
from I-Tasser.  
 
 
B A 
C 
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Figure 3.12: Predicted structure models of CryD3 by I-Tasser. A) Predicted 
structure of CryD3, helical formation in pink, beta sheets in yellow. B) Predicted 
structure of CryD3 with highlighted residues for the galactose binding site, 6x 
histidine tag and C terminus shown in red, N terminus shown in blue. Models from I-
Tasser. 
 
 
Figure 3.13: Predicted structure of CryD3 fitting into the Cry toxin model. This 
predicts that CryD3 will have a similar structure and, possibly, function to that of the 
third domain in Cry1Ac. 
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3.5 Modelling of tCry1Ac and CryD3 structures using PyMOL 
After tCry1Ac and CryD3 were submitted to I-Tasser a protein data file was 
generated for the two proteins. This protein data file was then inputted to PyMOL. 
PyMOL is a user-sponsored molecular visualization system on an open-source 
foundation, which allows the user to download the software to visualise, render and 
animate 3D molecular structures. Protein models for both tCry1Ac and CryD3 were 
made (Figures 3.14 and 3.15). The binding site of GalNAc in domain III was then 
investigated. Previously, Burton et al. (1999) and Xiang et al. (2009) have shown 
residues N506, Q509, Y513 and N546 to be involved in GalNAc binding. PyMOL 
allowed regions of the protein to be highlighted and examined in more detail for both 
tCry1Ac and CryD3 (Figure 3.16). Examination of the region in CryD3 that I-Tasser 
predicted as the carbohydrate binding site was also carried out (Figure 3.15). 
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Figure 3.14: Predicted protein structure of tCry1Ac, edited using PyMOL. For all structures domain I is coloured red, domain II, 
green and domain III, purple. The 6x histidine tag is blue and the predicted binding site is yellow. A) A ribbon cartoon of tCry1Ac 
showing the three domains, the α-helical structure of domain I is  shown in red, while the β-sheets of domains II and III are shown in 
green and purple respectively. This structure is very similar to other Cry1A toxin structures. B) and C) show the cartoon surface of 
tCry1Ac as it is easier to identify potential binding sites. C) 180° turn to the left revealing the residues N480, Q583, Y587 and N521 in 
yellow. These residues are examined in more detail in Figure 3.15.  
180° 
A B C 
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Figure 3.15: Predicted protein structure of CryD3, edited using PyMOL. A) Cartoon ribbon structure of CryD3, N terminus 
highlighted yellow and the 6x histidine in red. B) Cartoon ribbon of CryD3 showing the surface, N terminus highlighted yellow and the 
6x histidine in red. C) CryD3 turned 180° and angled towards the predicted carbohydrate binding site from I-Tasser, which is coloured 
green. The 6x histidine tag is blue and the N terminus is yellow.  
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Figure 3.16: Models of tCry1Ac and CryD3 showing expected binding site of GalNAc. A) tCry1Ac, domain I in red, domain II in 
green and domain III in purple with highlighted residues believed to be involved in GalNAc binding, N480- orange, Q483-cyan (buried 
in this structure), Y487 – pink, N521- yellow. B) CryD3 in purple with highlighted residues that relate to tCry1Ac, N45 – orange, Q48 – 
cyan, Y52 – pink, N86 – yellow. The 6x histidine tag in both proteins is red. These protein structures are from the same sequence 
however some structural differences are predicted. The residues that are highlighted are located in different positions in the different 
proteins. In tCry1Ac, the domains I and II may be supporting domain III and cause its structure to change slightly.  
B 
A 
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3.6 Cloning of cry1Ac and cryd3 from Bacillus thuringiensis 
 
The most effective systems in terms of simplicity and reproducibility for protein 
expression are generally considered to be prokaryotic systems. Over expression of 
specific proteins in the natural prokaryotic host cell however can be difficult to 
achieve. Escherichia coli a gram negative bacterium is the most widely used host for 
expression of recombinant proteins. This is mainly due to its simplicity, safety, and 
rapid high density growth rate on inexpensive substances, allowing for large scale 
protein expression. 
There are of course a number of different E. coli strains and also a broad range of 
cloning and expression vectors, which can all help to increase the expression or 
amount of soluble protein. Depending on the expression system, fusion tags can be 
incorporated onto the protein, to facilitate downstream purification and analysis.  
An E.coli expression system will be used for the expression of tCry1Ac and CryD3. 
The Qiagen vector pQE60 (Figure 3.17) was used as the main expression vector. 
This vector has been designed to produce high amounts of recombinant protein. This 
is due to an optimised promoter, the phage T5 transcriptional promoter, a lac 
operator sequence, extensive multiple cloning sites, and a tag site designed to 
introduce a 6x histidine at the C terminus of a protein expressed from an insertion in 
the multiple cloning sites. The pQE60 vector confers on the host ampicillin 
resistance as it expresses the β-lactamase gene. 
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Figure 3.17: pQE60 vector from Qiagen. pQE60 contains a PT5 promoter for 
increased expression of the gene of interest, a lac operator to allow control of 
expression with IPTG, a multiple cloning site with restriction sites and codons for a 
6xHis tag that will be added to the C terminus of the expressed protein.  
 
The B. thuringiensis stain kurstaki HD73 was obtained from USDA, ARS Culture 
Collection in Peoria, IL. The strain kurstaki HD73 itself is not sequenced, however 
the sequence for the related organism kurstaki str. T03a001 (Accession no 
NZ_ACND00000000.1) was used for designing the primers for the DNA region 
encoding tCry1Ac. Primers Cry1Ac P60Df and Cry1Ac P60Dr were designed to 
amplify a truncated region of cry1Ac which would be cloned into the pQE60 vector. 
The primers used for the amplification of the truncated region of the gene contained 
BspHI and BglII restriction sites (see section 2.1). Genomic DNA was extracted 
from B. thuringiensis strain kurstaki HD73 (see section 2.5.1) and PCR was carried 
out using the primers Cry1Ac P60Df and Cry1Ac P60Dr. The PCR product was 
analysed by agarose gel electrophoresis and the DNA band corresponding to the 
expected size was present (Figure 3.20). The PCR products were then restricted 
T5 promoter/lac operator 
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using BspHI and BglII, gel extracted and ligated to the NcoI-BglII digested pQE60 
vector (Figure 3.18). Following transformation of E .coli JM109 cells, plasmid DNA 
was isolated and screened for inserts using gel electrophoresis and restriction 
analysis. The presence of a correct insert was confirmed by DNA sequencing.  
This plasmid was named ptCry1Ac and was then used to amplify the DNA region 
encoding the CryD3 domain. The plasmid ptCry1Ac DNA was isolated using a High 
Yield Plasmid Mini Prep Kit (see section 2.5.2.2). The DNA was then used for PCR 
along with the primers Cryd3f and Cryd3r (see section 2.1), which incorporated 
restriction sites for NcoI and BglII respectively. The PCR product was analysed and 
a DpnI restriction digest was carried out to remove any double stranded plasmid 
DNA (see section 2.7.2). The PCR product was then restricted using NcoI and BglII 
and ligated to pQE60 (Figure 3.19). E. coli JM109 was transformed with ligated 
DNA (see section 2.6.1). Plasmid DNA was isolated and screened for inserts using 
gel electrophoresis and restriction analysis. The presence of a correct insert was 
confirmed by DNA sequencing.  
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Figure 3.18: Cloning strategy for the region encoding tCry1Ac in the expression 
vector pQE60. The PCR product was restricted using the enzymes BspHI and BglII. 
The NcoI site in the PCR product prohibited the use of this enzyme to cut the product 
for cloning. Restriction with BspHI results in compatible ends for ligation with NcoI. 
The pQE60 vector was restricted using NcoI and BglII. The products were then 
ligated to form ptCry1Ac. 
T5 promoter/lac operator 
tCry1Ac DNA 
fragment from 
PCR 
pQE60 restricted with 
NcoI and BglII  
Restricted with 
BspHI and BglII 
T5 promoter/lac operator 
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Figure 3.19: Cloning strategy for the DNA region encoding the CryD3 domain in 
the pQE60 vector. PCR on ptCry1Ac DNA using primers for the region encoding the 
target domain was carried out. The product was cleaned and digested using DpnI to 
eliminate any double stranded DNA in the reaction. The PCR fragment and pQE60 were 
both digested using NcoI and BglII. They were then ligated to form pCryD3. 
T5 promoter/lac operator 
pQE60 restricted with 
NcoI and BglII 
DNA fragment 
restricted with NcoI 
and BglII 
PCR with primers to 
amplify the DNA region 
encoding the Cryd3 
domain 
T5 promoter/lac operator 
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Figure 3.20: 1% DNA agrose gel electrophoresis on plasmids pQE60, pCryD3 
and ptCry1Ac. Lane 1; 1Kb DNA Plus ladder, 2; pQE60, 3; and 4; pCryD3, 5-7; 
ptCry1Ac. 
The linear DNA fragments in the ladder are used for confirmation of staining and for 
comparative analysis of migration. They are not used for direct size calculation of the 
closed circular plasmid molecules. 
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3.7 Discussion 
 
This chapter has described the bioinformatic analysis of the Cry1Ac protein 
sequence, the design of two recombinant proteins tCry1Ac and CryD3, the extensive 
structural modelling of these proteins by I-Tasser and PyMOL and the subsequent 
cloning of these genes into the pQE60 vector.   
The blast search revealed the high sequence homology between Cry1Ac and closely 
related toxins such as Cry1Aa and Cry1Ab. It also showed where the three domains 
were located on Cry1Ac and this was important information for the design of 
tCry1Ac and CryD3. This blast search revealed Domain III of Cry1Ac has similarity 
to the CBM6-CBM35-CBM36 superfamilies, which is an important indicator that the 
third domain of Cry1Ac may have carbohydrate binding abilities.  
A multiple sequence alignment was carried out on Cry1Ac, Cry1Aa and CryAb to 
examine the sequences for any differences particularly in the third domain. This 
sequence alignment showed considerable homology between the sequences 
especially in the N and C terminus. However, there was a great deal of variation 
particularly in Cry1Ac domain III, from amino acid 480 to 620. The altered sequence 
may give Cry1Ac its receptor binding capacity for GalNAc. From the results of the 
sequence alignment between Cry1Aa, Cry1Ab, and Cry1Ac a rooted phylogenetic 
tree showed that Cry1Ac diverged early from Cry1Aa, Cry1Ab and Cry1Ad giving 
an indication as to why Cry1Ac has carbohydrate specificities but Cry1Aa, Cry1Ab 
and Cry1Ad do not.  
The recombinant proteins tCry1Ac and CryD3 were then designed based on the 
Cry1Ac activated toxin when it has been processed following ingestion by insects 
(Bravo et al. 2007) and from the highlighted domains on the blast search of Cry1Ac. 
These proteins were designed so that they would be expressed as soluble active 
proteins with 6x histidine tags on their C termini. Therefore this would limit the 
downstream experiments which would be needed for solubilisation or activation of 
the proteins. This would be the first time any Cry toxins would be cloned in this way 
and if they can be expressed and purified in E. coli as active proteins it could be used 
as a model going further for analysing Cry toxins.  
Further analyses were carried out on tCry1Ac and CryD3 by using I-TASSER to get 
structure predictions of both proteins. These structures were very similar to Cry1Ac 
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and the third domain of Cry1Ac. There were a few slight differences which could be 
due to the structure predictions of the proteins in I-TASSER or the slight alteration in 
protein folding. PyMol was used to model the structures of tCry1Ac and CryD3 and 
examine the predicted binding sites further. By using PyMol the expected binding 
site of GalNAc was mapped on tCry1Ac and the corresponding sites were 
highlighted in CryD3. This showed some differences in the binding site and so 
CryD3 may have a different binding specificity than tCry1Ac, or it could have a 
higher or lower affinity for GalNAc.  
Cloning of tCry1Ac and CryD3 and the construction of ptCry1Ac and pCryD3 was 
carried out using the pQE60 vector. Positive clones were identified and the plasmid 
inserts sequenced. These plasmids were then available for the expression and 
characterisation of the recombinant proteins tCry1Ac and CryD3, described in 
Chapter 4.  
This work has shown conclusively that Cry1Ac domain III has protein sequence 
homology to lectins in the superfamilies, CBM6-CBM35-CBM36 and backs up 
previous research which showed the structure of domain III has similarities to lectins 
(Bravo et al. 2012). The residues of tCry1Ac previously shown to have an effect in 
GalNAc binding were mapped on tCry1Ac and CryD3 and they show the potential 
binding site for GalNAc on the protein. This may allow for further mutagenesis 
studies on this protein to elucidate the binding site for GalNAc on Cry1Ac and 
whether tCry1Ac and CryD3 have carbohydrate binding specificities also.  
 
  
  
 
 
 
Chapter 4 
Optimisation of tCry1Ac and CryD3 
protein expression and purification 
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4.1 Overview 
This chapter describes the optimisation of the expression and purification of tCry1Ac 
and CryD3 and the separation of these proteins from a persistent contaminating 
protein from E. coli. tCry1Ac was expressed in low amounts in small scale 
expression and purification. CryD3 had relatively good expression yields but there 
were contaminating proteins in the purified samples. To assess tCry1Ac and CryD3 
binding specificities for different glycoproteins they were examined by Enzyme 
Linked Lectin Assay (ELLA). This revealed that tCry1Ac bound to GalNAc while 
CryD3 had specificity towards galactose. These results correlated with the structural 
modelling and predictions described in chapter 3. However the relative affinity of 
CryD3 for galactose was lower than the affinity tCry1Ac had for GalNAc. The 
expression of tCry1Ac was optimised, by varying the host cell choice (i.e. the strain 
of E. coli), the type of medium and the temperature used during expression. 
Optimisation of the purification of tCry1Ac and CryD3 was carried out by increasing 
imidazole concentrations during the elution phase of Immobilized Metal Affinity 
Chromatography (IMAC). Instability of the purified protein and relative sensitivity to 
proteases were thought to be a problem and so optimisation of the conditions during 
purification were also varied and tested. Contaminating proteins continued to be a 
problem throughout the purification process with the main contaminant being 
identified by MS peptide mapping and sequencing analysis. This contaminating 
protein was found to be a cAMP regulatory protein from E. coli. Various purification 
systems were examined to remove the persistent contaminating proteins. These 
included ion exchange chromatography, gel filtration, IMAC purification with added 
detergents and the addition of galactose washes. These modifications ultimately 
succeeded in greatly improving the purification and stability of the proteins. 
Functional analysis of the pure tCry1Ac and CryD3 proteins were then carried out by 
use of the ELLA.  
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4.2 Small scale expression of tCry1Ac and CryD3 proteins 
 
The proteins tCry1Ac and CryD3 were expressed in E. coli JM109 from ptCry1Ac 
and pCryD3 respectively as described in section 2.10. The cell lysates from 100ml 
cultures were examined by SDS-PAGE.  From the protein sequence the predicted 
protein size of tCry1Ac and CryD3 was determined by ExPASY. tCry1Ac was 
predicted at 69kDa and CryD3 was less than 20kDa. A protein at approx 69kDa was 
observed on the SDS PAGE gel for tCry1Ac (see Figure 4.1 b). However, over 
expression of the protein was not obvious. Therefore, a western blot was carried out 
to probe for the 6x histidine tag on the C terminus of tCry1Ac (Figure 4.1 a). A 
protein was observed in low amounts on the western blot in the soluble fraction. 
Thus optimising the expression of tCry1Ac was needed to obtain a higher yield of 
recombinant protein for functional analysis. CryD3 expression was also examined on 
SDS-PAGE gels, as the protein is approx 20kDa it is difficult to view on 15% gels. 
An increased expression of a 20kDa protein was observed in the overnight soluble 
samples (see Figure 4.2).  The overnight cultures of tCry1Ac and CryD3 were then 
lysed by cell disruption and the soluble fraction taken for preliminary IMAC 
purification. 
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Figure 4.1: SDS PAGE and western blot analysis of small scale expression of 
tCry1Ac in E. coli JM109. (A) 1 and 6; protein ladder, 2; 2 hours post induction, 3; 
3 hours post induction, 4; 4 hours post induction, 5; overnight post induction. (B) 
Western blot, 1; protein marker, 2; pQE60, 3; not induced ptCry1Ac total protein, 4; 
induced ptCry1Ac total protein, 5; not inducted ptCry1Ac soluble protein, 6; induced 
ptCry1Ac soluble protein, 7; not induced ptCry1Ac insoluble, 8; induced ptCry1Ac 
insoluble.   
 
 
Figure 4.2: SDS PAGE analysis, soluble and insoluble expression of CryD3 in E. 
coli JM109.1 and 12; Broad range protein marker, 2-6; soluble post induction at time 
1hr, 2hr, 3hr, 4hr and overnight respectively, 7-11; insoluble post induction at time 
1hr, 2hr, 3hr, 4hr and overnight respectively. White arrow represents CryD3 
expression.  
B 
A 
1      2     3     4      5      6   
1    2   3    4     5     6      7    8 
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4.3 Preliminary Purification of tCry1Ac and CryD3 by Immobilised 
Metal Affinity Chromatography (IMAC) 
Affinity chromatography separates proteins on the basis of a reversible interaction 
between a protein and a specific ligand coupled to a chromatography matrix. The 
technique is ideal for a capture or intermediate step in a purification protocol and 
may be used whenever a suitable ligand is available for the protein of interest. This 
method potentially gives high selectivity, high resolution, and high capacity for the 
protein of interest. The target protein may then be collected in a purified, 
concentrated form. 
The 6x histidine tag is one of the most common affinity tags used to facilitate the 
purification and detection of recombinant proteins. Polyhistidine tags such as 4x 
histidine or 10x histidine are also used. They may provide useful alternatives to 6x 
histidine for improving purification results. For example, since 10x histidine binds 
more strongly to the affinity medium, a higher concentration of eluent (imidazole) 
can be used during the washing step before elution. This may facilitate the removal 
of contaminants which may otherwise be co-purified with a 6x histidine fusion 
protein.  
Chelating Sepharose, when charged with Ni2+ ions, selectively binds proteins if 
complex forming amino acid residues, in particular histidine, are exposed on the 
protein surface. 6x histidine fusion proteins can be easily bound and then eluted with 
buffers containing imidazole. tCry1Ac and CryD3, each with the histidine tag fusion 
were purified from the soluble fraction by IMAC on two separate columns. As 
described in section 2.13.1 the soluble fraction was added to the resin and washed 
with 40, 60 and 70mM imidazole to elute any contaminating proteins. Both proteins 
were eluted using 250mM imidazole. Samples were taken from each fraction to be 
analysed on SDS PAGE. Figure 4.3 presents the results obtained from the 
preliminary analysis of IMAC purification, revealing tCry1Ac at 69kDa in the 
elution fractions. From the SDS PAGE gel it is clear that tCry1Ac does not express 
very well and further optimisation of expression is needed. Figure 4.4 shows CryD3 
as a large band at approximately 20kDa. There are also some contaminating bands on 
the gel; therefore optimisation of purification was needed for CryD3.   
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Figure 4.3: SDS PAGE analysis of the preliminary purification of tCry1Ac by 
IMAC. 1;SigmaMarker Wide Range , 2; lysate, 3; flow through, 4 and 5; 60mM and 
70mM imidazole washes, 6 and 7; 250mM imidazole elutions, 8; protein marker. The 
white arrow indicates tCry1Ac. 
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Figure 4.4: SDS PAGE analysis of the preliminary purification of CryD3 by 
IMAC. 1; broad range protein marker NEB, 2; elution of CryD3 in 250mM 
imidazole, 3; broad range protein marker. The white arrow represents CryD3.  
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4.4 Buffer exchange of tCry1Ac and CryD3 
 
Buffer exchange and desalting are important steps following IMAC purification. This 
is because downstream processes, such as protein quantification and subsequent 
assays can be affected by the presence of imidazole. Both desalting and buffer 
exchange may be carried out simultaneously using viva spin columns. This also helps 
to concentrate low concentrations of tCry1Ac protein which facilitates its analysis by 
ELLA. tCry1Ac and CryD3 were concentrated and buffer exchanged into PBS. 
These protein samples were then be used for binding analysis using the ELLA. 
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4.5 Examining Lectin binding of tCry1Ac and CryD3 using the ELLA 
 
The Enzyme Linked Lectin Assay (ELLA) method (which is outlined in section 2.21 
and figure 4.5) is similar to the ELISA. The primary antibody in an ELISA is 
replaced by a carbohydrate-binding protein and the target is the glycans of the 
glycoprotein. The 6x histidine affinity tag which was engineered into tCry1Ac and 
CryD3 allow for the detection of the interaction between tCry1Ac and the 
glycoprotein by use of an anti-His antibody. The relative affinities and specificities 
of recombinant carbohydrate-binding proteins may be studied through the 
comparison with biotinylated commercial plant lectins. The dependency of tCry1Ac 
and CryD3 on metal ions is not known, but many plant lectins require calcium, 
magnesium and manganese for the function of the binding pocket. 
Typically N-glycosylated glycoproteins are used in the ELLA’s to study binding 
specificity. However as tCry1Ac binds to GalNAc, a glycoprotein with GalNAc on 
its surface was needed for the assay. Therefore a neoglycoprotein was obtained as 
this consists of numerous GalNAc linked onto BSA. The binding of tCry1Ac to the 
neoglycoprotein with a GalNAc surface and also to an array of glycoproteins was 
investigated. The commercial lectins used in this assay were ECL, SBA, RCA, PNA 
and DBA (see figure 4.6). The results presented in Figure 4.6, seem to demonstrate 
that the purified tCry1Ac displayed a strong specificity for GalNAc in comparison to 
the plant commercial lectins. A dilution series of the neoglycoprotein and tCry1Ac 
were carried out in order to examine the relative affinities of tCry1Ac to GalNAc. 
(Figures 4.7 and 4.8) This further analysis showed a linear affinity of tCry1Ac for 
GalNAc and binding at low concentrations of tCry1Ac. 
CryD3 was predicted to have Galactose specificity. Various glycoproteins with 
galactose on the terminus were used in the ELLA such as asialofetuin and a Galα1-3, 
Gal neoglycoprotein. The GalNAc neoglycoprotein was also used to assess if CryD3 
had any GalNAc specificity. The commercial lectin ECL was used as a positive 
control for Galactose, while tCry1Ac was used as a positive control for GalNAc. 
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Figure 4.9 shows the dilutions of CryD3 to asialofetuin, the affinity is not very strong 
as it correlates to the drop after each dilution.  
4.5.1. ELLA Assay Methodology 
 
  
 
Figure 4.5: The ELLA assay methodology. (a) Lay down lectin or carbohydrate 
binding protein (e.g. tCry1Ac), (b) block with BSA, (c) incubate with neo-
glycoprotein (GalNAc-BSA), (d) incubate with antibody, (e) detect antibody and 
colour change at Abs 450nm. 
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Figure 4.6: Comparison of tCry1Ac and commercial plant lectin binding 
profiles by ELLA analysis. ELLA analysis of tCry1Ac 10 µg/ml and commercial 
lectins binding to GalNAc linked BSA, ELLA samples averaged in triplicate and 
ELLA experiment carried out three times. The legend shows the specificity of each 
commercial lectin. Interestingly tCry1Ac showed strong binding to GalNAc-BSA 
compared to the commercial plant lectins. The black arrow shows the binding of 
tCry1Ac to GalNAc-BSA.  
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Figure 4.7: ELLA analysis showing binding of tCry1Ac, CryD3 compared to the 
commercial lectin ECL. ELLA of tCry1Ac10µg/mL, CryD310µg/mL, and the 
commercial lectin ECL10µg/mL to neo-glycoprotein GalNAc-BSA, the glycoprotein 
asialofetuin and neo-glycoprotein Gal,α1-3Gal-BSA. ELLA samples averaged in 
triplicate and ELLA experiment carried out three times. tCry1Ac shows binding to 
GalNAc-BSA. Significantly CryD3 has specificity for asialofetuin and galactose α1-
3. 
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Figure 4.8: Effect of increasing concentrations of GalNAc-BSA on tCry1Ac 
binding activity by ELLA analysis. GalNAc-BSA concentration from 1µg/mL – 
8µg/mL, concentration of tCry1Ac 10µg/mL. ELLA samples averaged in triplicate 
and ELLA experiment carried out three times. The graph is a linear correlation of the 
affinity between GalNAc-BSA and tCry1Ac.  
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Figure 4.9: Effect of decreasing concentrations of tCry1Ac protein on binding to 
5µg/mL GalNAc-BSA by ELLA analysis. The working concentration of tCry1Ac 
was 100µg/mL, 1 is 20 µg/mL, 2 is 15 µg/mL, 3 is 10 µg/mL, 4 is 5 µg/mL and 5 is 
2.5 µg/mL. ELLA samples averaged in triplicate and ELLA experiment carried out 
three times. The affinity here is slightly better showing a slower drop in signal with 
each dilution. 
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Figure 4.10: Effect of increasing concentrations of CryD3 on the binding to 
asialofetuin by ELLA analysis. CryD3 in concentrations of 20 µg/mL, 15 µg/mL, 
10 µg/mL,  and 5µg/mL was tested against 5µg/mL of asialofetuin in order to assess 
the affinity of their binding. ELLA samples averaged in triplicate and ELLA 
experiment carried out three times. 
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4.6 Optimisation of expression of recombinant tCry1Ac 
 
As the expression of tCry1Ac was low in the soluble fraction, optimisation of the 
expression was carried out to obtain a higher yield of protein. Expression studies on 
various factors that influence expression of a recombinant protein, such as strain of 
E. coli, temperature, IPTG concentration and media were carried out. Time-course 
expression was carried out for each condition and the resulting soluble and insoluble 
fractions were analysed on SDS PAGE gels.  
 
4.6.1 Choice of host strain for tCry1Ac 
 
Two strains of E. coli were examined JM109 and KRX for tCry1Ac protein 
expression. JM109 and KRX are both strains designed for protein expression type 
strains. KRX has been modified to protect the expressed protein from degradation. 
Although the KRX cells grew faster than JM109 after induction (Figure 4.11) there 
was some increase in expression of tCry1Ac in the overnight soluble fraction of 
JM109 when compared to KRX. Therefore it was decided to use JM109 for 
expression of tCry1Ac (Figure 4.12).  
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Figure 4.11: Comparasion of E. coli strains under expression conditions.  The 
growth curve of E. coli strains JM109 and KRX were compared, while expressing 
tCry1Ac. The graph shows pQE60 in JM109, tCry1Ac in JM109 and tCry1Ac in 
KRX. Timepoints were taken post induction with IPTG.  
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Figure 4.12: SDS PAGE of soluble expression of tCry1Ac in different expression 
E. coli strains, JM109 and KRX. C represents JM109 pQE60 as the control, J 
represents JM109 tCry1Ac, and K represents KRX tCry1Ac.  
Panel A: 1 and 11; broad range protein marker, 2; Control, time of induction, 3; 
tCry1Ac JM109, time of induction, 4; tCry1Ac KRX, time of induction, 5; Control, 1 
hour post induction, 6; tCry1Ac JM109, 1 hour post induction, 7; tCry1Ac KRX, 1 
hour post induction, 8; Control, 2 hours post induction, 9; tCry1Ac JM109, 2 hour 
post induction, 10; tCry1Ac KRX, 2 hour post induction. 
Panel B: 1 and 12; broad range protein marker, 2; Control, 3 hours post induction, 3; 
tCry1Ac JM109, 3 hours post induction, 4; tCry1Ac KRX, 3 hours post induction, 5; 
Control, 4 hour post induction, 6; tCry1Ac JM109, 4 hour post induction, 7; tCry1Ac 
KRX, 4 hour post induction, 8; Repeated, tCry1Ac KRX, 4 hour post induction 9; 
Control, overnight, 10; tCry1Ac JM109, overnight, 11; tCry1Ac KRX,  overnight. 
The red box indicates tCry1Ac JM109, overnight. 
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4.6.2 IPTG concentration optimisation during expression of tCry1Ac 
IPTG controls the lac promoter by inducing expression, therefore a higher 
concentration of IPTG will give a higher level of expression and in turn a higher 
protein yield. However too much IPTG could be inhibitory to the cells and may limit 
protein production. Therefore different IPTG concentrations were used to induce the 
cultures. The gel (Figure 4.14) shows that there was no significant increase in 
expression over 50µM. The graph (Figure 4.13) shows that 50µM was the optimal 
amount of IPTG as it produced no quantifiable decrease in growth rate or cell 
number when compared to 5µM, an amount that does not induce gene expression. 
Therefore 50µM was chosen as the best concentration to induce tCry1Ac protein 
expression. 
 
Figure 4.13: Expression growth curve of E. coli JM109 with tCry1Ac in varying 
concentrations of IPTG. At higher concentratation than 50µM IPTG the cells do 
not grow as well and have a slower growth rate.  
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Figure 4.14: Time course study of the expression of tCry1Ac using varying 
concentrations of IPTG by SDS PAGE Analysis. 
Panel A: 1, 12; broad range protein marker, 2; 5µM, 2 hours post induction, 3; 
50µM, 2 hours post induction, 4; 100µM, 2 hours post induction, 5; 500µM, 2 hours 
post induction, 6; 1000µM, 2 hours post induction, 7; 5µM, 3 hours post induction, 
8; 50µM, 3 hours post induction, 9; 100µM, 3 hours post induction, 10; 500µM, 3 
hours post induction, 11; 1000µM, 3 hours post induction. 
Panel B: 1, 12; broad range protein marker, 2; 5µM, 4 hours post induction, 3; 
50µM, 4 hours post induction, 4; 100µM, 4 hours post induction, 5; 500µM, 4 hours 
post induction, 6; 1000µM, 4 hours post induction, 7; 5µM, overnight, 8; 50µM, 
overnight, 9; 100µM, overnight, 10; 500µM, overnight, 11; 1000µM, overnight. Red 
box indicates tCry1Ac at 50µM overnight. 
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4.6.3 Temperature optimisation of expression of tCry1Ac  
Temperature is an important factor for expression. The growth of E. coli is optimal at 
37°C. However, the stability of a protein may be increased by lowering the 
temperature to 30°C when induced with IPTG. Expressing the Cry toxins in E. coli at 
a lower temperature of 20-25°C may yield a higher level of stable protein in the 
soluble fraction. Therefore, expression of tCry1Ac was carried out and compared at 
30°C and 20°C. Figure 4.15 shows that there is a slightly higher expression of 
soluble tCry1Ac at 20°C. Therefore, protein expression was carried out at 20°C post 
induction. As tCry1Ac is a large protein at about 69kDa. E. coli may have some 
difficulty over expressing the protein. Slowing the growth rate down by lowering the 
expression temperature to 20°C gives the cells more time to produce the protein.  
 
Figure 4.15: Time course study of the expression of tCry1Ac using varying 
temperature by SDS PAGE analysis.  
(A) 1, 12; broad range protein marker, 2; 20°C, one hour post induction, 3; 20°C two 
hour post induction, 4; 20°C three hour post induction, 5; 20°C four hour post 
induction, 6; 20°C overnight, 7; 30°C one hour post induction, 8; 30°C two hour post 
induction, 9; 30°C three hour post induction, 10; 30°C four hour post induction, 11; 
30°C overnight. 
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4.6.4 Comparison of TB and LB for the expression of tCry1Ac 
The two types of bacterial growth media used here were LB and TB. LB is a medium 
used routinely for growing E. coli. TB is a highly nutritious medium that is used for 
protein expression. E. coli grows very well in this media and continues to grow and 
produce protein to a higher OD when compared to LB (Figure 4.16). The results 
presented in Figure 4.16 and in Figure 4.17 clearly show that there is higher 
expression of tCry1Ac in the overnight TB than in the overnight LB. TB was thus 
chosen as the media for the expression of tCry1Ac and CryD3 at 20°C. 
 
 
Figure 4.16: Growth curve comparasion, TB and LB media expressing tCry1Ac. 
Comparasion of growth of tCry1Ac JM109 in TB and LB broth. 
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Figure 4.17: SDS PAGE analysis of the time-course expression of tCry1Ac in TB 
and LB growth medium.  
1 and 10; Broad range protein marker, 2; LB 2 hours post induction, 3 LB 3 hours 
post induction, 4; LB 4 hours post induction, 5; LB overnight, 6; TB 2 hours post 
induction, 7; TB 3 hours post induction, 8; TB 4 hours post induction, 9; TB 
overnight. 
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4.7 Further optimisation of the purification of the tCry1Ac and CryD3 
proteins 
 
The conditions for the expression of tCry1Ac were now optimised. The expression 
strain was E. coli JM109, the IPTG concentration used was 50µM, the temperature of 
expression was 20°C and the media used was TB. tCry1Ac was then purified by 
IMAC after expression with the new conditions. Figure 4.18 shows the purification 
of tCry1Ac by IMAC and reveals numerous protein bands in the eluted fractions. 
Even though stringent imidazole washes were carried out during tCry1Ac there was 
still a significant amount of contaminating proteins. At higher elution fractions there 
are many lower bands observed. Therefore a western blot was carried out to examine 
these elution fractions. As can be seen from figure 4.19, numerous bands are 
detected. These bands may represent cleaved fragments of tCry1Ac that have a 6x 
histidine tag. 
Previously, in the small scale expression of CryD3 contaminating proteins were 
evident in the elution fractions also. Figure 4.20 shows the results obtained from the 
optimised purification of tCry1Ac and CryD3. It shows a similar protein band pattern 
for both proteins. Remarkably, there is a higher protein band in the CryD3 
preparation which correlates with a band observed in the tCry1Ac preparation.  
These protein samples were analysed on an ELLA and neither of the protein 
preparations showed activity. This could be due to protein inactivity because of 
protease activity or interference by the contaminating proteins. CryD3 also fell out of 
solution and aggregated after one day of storage at 4°C. As both proteins were active 
and binding to GalNAc and galactose in section 4.5, it is clear that both proteins are 
being affected by the contaminating proteins or instability. Therefore the stability of 
both proteins and protease activity during purification were examined further.  
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Figure 4.18: SDS PAGE analysis of the tCry1Ac protein purified by IMAC with 
increasing imidazole washes. 1; Broad range protein marker, 2; flow through, 3; 
40mM imidazole wash, 4; 60mM imidazole wash, 5; 80mM imidazole wash, 6; 
100mM imidazole wash, 7-11; 300mM imidazole elution. The black arrow indicates 
tCry1Ac.  
 
 
Figure 4.19: Western blot analysis of the tCry1Ac protein following IMAC 
purification. To detect if the contaminating bands were cleaved parts of tCry1Ac a 
western blot was done to detect the 6x histidine tag on the C terminus of the protein. 
1; Prestained plus protein ladder, 2-6; Elutions of tCry1Ac from IMAC. The white 
arrow indicates tCry1Ac. 
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Figure 4.20: SDS PAGE analysis of the optimised purification by IMAC of 
tCry1Ac and CryD3. These purifications had washes of 100mM imidazole, the 
300mM imidazole elutions of tCry1Ac and CryD3 are shown on the gel. 1 and 12; 
Broad range protein marker, 2-5; tCry1Ac 300mM imidazole elutions, 6-11; CryD3 
300mM imidazole elutions. There is a one band that is common to both purifications 
at approx 30kDa.  White arrows indicate tCry1Ac and CryD3. There is a band that is 
common to both purifications at approx 30kDa (black arrow).  
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 Figure 4.21: ELLA analysis of tCry1Ac and CryD3 proteins compared to the 
commercial lectin ECL. The purified samples from the IMAC optimisation of 
tCry1Ac 10µg/ml (red) and CryD3 10µg/ml (green) were analysed on an ELLA. 
There was a very low signal for tCry1Ac (red) and CryD3 (green).  
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4.7.1 Examining the stability and degradation of tCry1Ac and CryD3 during 
IMAC purification  
SDS PAGE analysis of the tCry1Ac and CryD3 proteins both show similar patterns 
of contaminating protein bands following purification by the optimisation of the 
IMAC procedure. As these bands also showed up on the western blots (using anti-
His tag antibodies) they were thought to be histidine tagged C terminal cleaved 
protein fragments in the case of tCry1Ac and/or possibly aggregations of CryD3. 
Therefore, experiments were carried out to examine the stability of both proteins and 
how their degradation and/or aggregation could be reduced. Firstly protease 
inhibitors were introduced and the plasmid containing tCry1Ac was introduced into 
the protease resistant E. coli KRX strain as described in section 2.6.1. The protein 
was expressed and purified and compared to E. coli JM109 with no protease 
inhibitors. The results of the purifications may be seen in figures 4.22 and 4.23. It is 
apparent that the protease inhibitors and the KRX strain had no effect on protein 
degradation, and surprisingly, there were even more bands found in this purification 
over the original purification. ptCry1Ac and pCryD3 were used to transform E. coli 
strain BL21 to examine if the there was any difference in protein expression or 
purification. Figure 4.24 shows the purified samples of tCry1Ac and CryD3 
expressed in BL21 compared to JM109. There is no significant difference in protein 
expression, and the same protein band pattern is observed for both purifications. 
As stated earlier, temperature was found to have a significant effect on the protein 
expression as a change from 30°C to 20°C increased soluble protein expression. 
Figure 4.25 shows aliquots of CryD3 at various temperatures. The sample becomes 
cloudier at 30°C and at 37°C the protein was found to fall out of solution. Therefore, 
after the expression of the proteins, all experiments were carried out at 4°C. This 
improved greatly the quality of the protein, (see Figure 4.26.a). However, there were 
still some contaminating bands and consistently there was a band at about 30kDa in 
both protein preparations. Therefore, another western blot was carried out on these 
samples (see Figure 4.26. b). This western blot showed tCry1Ac at 69kDa and 
CryD3 at 20kDa. However, there was no protein at the 30kDa band to correspond to 
the SDS PAGE gel. Therefore, it was concluded that this protein is either a degraded 
part of the Cry protein that has bound to the purified proteins and so is co-purified, or 
is a contaminating protein from the host strain of E. coli. From this SDS PAGE gel 
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the two corresponding bands at 30kDa were excised and sent to Alphalyse to be 
identified by MS peptide mapping and sequencing analysis. 
 
 
Figure 4.22: SDS PAGE analysis of the purified of tCry1Ac, expressed in E. coli 
JM109. 1 and 12; Broad range protein marker, 2; flow through, 3; 100mM imidazole 
wash, 4-11; 300mM imidazole elution. The white arrow represents tCry1Ac.  
 
Figure 4.23: SDS PAGE analysis of the purified of tCry1Ac, expressed in E. coli 
KRX.1 and 11; Broad range protein marker, 2; Lysate, 3; Flow through, 4; 100mM 
imidazole wash, 5-10; 300mM imidazole elutions. The white arrow represents 
tCry1Ac. 
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Figure 4.24: Investigation of E. coli strain BL21 for the expression of tCry1Ac 
and CryD3. ptCry1Ac and pCryD3 were used to transform E. coli strain BL21 to 
investigate if there was any increased expression or differences in contaminating 
protein. Lane 1; broad range protein marker, 2; tCry1Ac from JM109, 3; tCry1Ac 
from BL21, 4; CryD3 from JM109, 5; CryD3 from BL21. It is clear that there was no 
difference in expression or any change in contaminating protein. The white arrow 
indicates tCry1Ac, the black CryD3 and the red the contaminating protein.  
 
 
Figure 4.25: CryD3 solubility tested at various temperatures. CryD3 at A: 4°C,  
B: 30°C,  C: 37°C. CryD3 starts to falls out of solution as the temperature rises. At 
30°C the solution is cloudy and at 37°C there is a visible white precipitation in the 
solution.  
A C B 
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Figure 4.26: SDS PAGE gel and western blot of tCry1Ac and CryD3 
purifications from JM109 at 4°C (A) SDS PAGE analysis of the purification of 
tCry1Ac at 4°C, 1; broad range protein marker, 3; tCry1Ac 300mM imidazole eluted 
sample. The black arrow represents tCry1Ac. (B) SDS PAGE analysis of the CryD3 
purification at 4°C, 1 and 7; broad range protein marker, 2; Lysate, 3; Flow through, 
4; 100mM imidazole wash, 5 and 6; 300mM imidazole elutions. The black arrow 
represents CryD3, (C) Western blot of SDS PAGE of purification of tCry1Ac and 
CryD3, 1; pre-stained protein marker, 2; tCry1Ac, 3; CryD3. The white arrow 
represents tCry1Ac while the black arrow indicated CryD3.  
C 
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4.8 Identification of the contaminating protein bands by MS peptide 
mapping and sequencing analysis 
The samples were extracted from the SDS PAGE gel in figure 4.26 and were sent to 
Alphalyse for protein analysis. The samples were identified by MS peptide mapping 
and sequence analysis as outlined in section 2.18. The results can be seen in table 
4.1, revealing the major contaminating protein to be a cAMP-regulatory protein also 
known as the catabolite gene activator (CRP) from E. coli. The standards used in the 
experiment were transferrin and BSA. The sequence of the protein can be seen in 
figure 4.27.  
The CRP protein complexes with cyclic AMP and binds to specific DNA near the 
promoter to regulate the transcription of several catabolite-sensitive operons (Aiba, 
1985). The protein induces a severe bend in the DNA and it acts as a negative 
regulator of its own synthesis as well as for adenylate cyclase (cyaA), which 
generates cAMP. Constitutively expressed, levels decrease in stationary phase. The 
structure of CRP with highlighted histidine residues was made using PyMol and can 
be seen in figure 4.28. It was not known how the CRP protein was co-purified with 
both tCry1Ac and CryD3. Investigation into various purification and separation 
techniques was then done to remove CRP from the protein samples.  
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Table 4.1: Results from the MS peptide mapping and protein identification. The 
unknown protein was a cAMP-regulatory protein from E. coli.  
 
Sample name  Protein found in 
database  
GI-number  MW  Score  Seq. cov.   
Cry unknown  cAMP-regulatory 
protein [Escherichia 
coli E24377A]  
 
gi|15715932
6  
23812  346  68%  
 
 
 
 
Quality control 
standards 
included in the 
analysis 
Standard  
 
 
Protein found in 
database  
 
GI-number  
 
MW  
 
Score  
 
Seq. cov.  
 
1 pmol transferrin  transferrin [Homo 
sapiens]  
gi|11539451
7  
79190  1020  57%  
62 fmol BSA  Chain A, Crystal 
Structure Of Bovine 
Serum Albumin  
gi|36746026
0  
68416  268  39%  
 
 
     
 
 
Figure 4.27: Protein sequence of cAMP- regulatory protein. Matched peptides 
shown in bold underline with 68% predictability match. 
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Figure 4.28: Protein structure of the catabolite gene activator. (A) Cartoon 
ribbon structure of CRP showing a dimer formation. (B) Cartoon model of the CRP 
surface with all histidine residues coloured in pink. Most of the histidines are 
exposed on the surface of the protein. Structure made using PyMol.  
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4.9 Purification of tCry1Ac and CryD3 from the catabolite gene activator 
 
As the CRP was identified as the consistent contaminating protein in tCry1Ac and 
CryD3 purifications, experiments were designed to separate and purify these proteins 
using various chromatography techniques. The three techniques further discussed are 
IMAC using both detergent and competing sugars, Gel filtration and Ion exchange 
chromatography (IEX). These techniques were chosen to remove the contaminating 
protein that was consistently found in the purified samples of tCry1Ac and CryD3 
and was postulated to be responsible for the loss of carbohydrate binding activities.  
 
 
4.9.1 Purification of tCry1Ac and CryD3 by Ion exchange chromatography 
 
Ion Exchange Chromatography (IXE) for the separation of biomolecules was 
introduced in the 1960s and continues to play a major role in the separation and 
purification of proteins, peptides, nucleic acids and other charged biomolecules 
(Yigzaw et al. 2009). It offers high resolution and group separations with high 
loading capacity. The technique is capable of separating molecular species that have 
only minor differences in their charge properties, for example two proteins differing 
by one charged amino acid. These features make IEX well suited for capture, 
intermediate purification or polishing steps in a purification protocol. IEX separates 
molecules on the basis of differences in their net surface charge. Molecules vary 
considerably in their charge properties and will exhibit different degrees of 
interaction with charged chromatography media according to differences in their 
overall charge, charge density and surface charge distribution. The charged groups 
within a molecule that contribute to the net surface charge possess different pKa 
values depending on their structure and chemical microenvironment. Since all 
molecules with ionizable groups can be titrated, their net surface charge is highly pH 
dependent. In the case of proteins, which are built up of many different amino acids 
containing weak acidic and basic groups, their net surface charge will change 
gradually as the pH of the environment change. IEX chromatography takes 
advantage of the fact that the relationship between net surface charge and pH is 
unique for a specific protein. In an IEX separation reversible interactions between 
charged molecules and oppositely charged IEX media are controlled in order to 
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favour binding or elution of specific molecules and achieve separation. A protein that 
has no net charge at a pH equivalent to its isoelectric point (pI) will not interact with 
a charged medium. However, at a pH above its isoelectric point, a protein will bind 
to a positively charged medium or anion exchanger and, at a pH below its pI, a 
protein will behind to a negatively charged medium or cation exchanger.  
 
Here cation exchange chromatography was employed to separate tCry1Ac while 
anion exchange chromatography was used to separate CryD3 (see section 2.13.5). 
The pI for CRP is 8.38, CryD3 is 9.39 and tCry1Ac is 6.96. For the separation of 
tCry1Ac from CRP a pH of 7.7 was utilised to give CRP an overall positive charge 
while tCry1Ac should have an overall negative charge. Therefore at this pH the CRP 
should bind to CM sepharose with the tCry1Ac should be eluted. To separate CryD3 
from CRP a pH of 8.8 was employed to give CRP a negative overall charge and 
CryD3 a positive overall charge. At this pH CryD3 should bind to the CM sepharose 
with the CRP remaining unbound. The CryD3 could then be eluted with a pH of 9.4. 
After both protein samples were purified and eluted they were analysed by SDS 
PAG. Figure 4.29 reveals that there was no significant improvement in tCry1Ac or 
CryD3 purification by the use of cation exchange chromatography. There was some 
retention of CryD3 on the CM sepharose but most of the protein did not bind to the 
column. CM sepharose is a weak exchanger therefore the experiment was repeated 
changing the pH to pH 7 and pH 8.5, for tCry1Ac and CryD3 respectively. The 
results show in Figure 4.30 show some improvement in protein purification but there 
are still some protein contaminants in the samples. An ELLA analysis of the eluted 
protein samples was carried out and the results displayed in Figure 4.31. This shows 
no binding activity for either tCry1Ac or CryD3. Overall, ion exchange 
chromatography did not effectively separate tCry1Ac and CryD3 from CRP. 
Therefore other methods of purification were examined. 
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Figure 4.29: SDS PAGE analysis of purified tCry1Ac and CryD3 by cation 
exchange chromatography - using pH 7.8 and 8.8 respectively. Lanes 1 and 11; 
Broad range protein marker, 2-4; tCry1Ac in triplicate from the Ion exchange, 5-7; 
CryD3 washes in triplicate, 8-10; CryD3 elution in triplicate. The white arrow 
represents tCry1Ac, the black arrow CryD3. 
 
Figure 4.30: SDS PAGE analysis of purified tCry1Ac and CryD3 by cation 
exchange chromatography - pH 7 and pH 8.5 respectively. Optimised pH to pH 7 
for tCry1Ac and pH 8.5 for CryD3 for stronger binding to the CM sepharose. Lane 1 
and 11; Broad range protein marker, 2-4; tCry1Ac elutions, 5-7; CryD3 washes, 8-
10; elutions of CryD3. The white arrow represents tCry1Ac, the black arrow CryD3. 
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Figure 4.31: ELLA analysis of tCry1Ac and CryD3 purified by cation exchange 
chromatography. The samples from the cation exchange chromatography at pH 7 
for tCry1Ac and pH 8.5 for CryD3. tCry1Ac (red) and CryD3 (green) were analysed 
on an ELLA and compared to the commercial lectin ECL. There is no significant 
binding for tCry1Ac (red) or CryD3 (green). 
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4.9.2 tCry1Ac purification using Gel filtration (size exclusion) chromatography 
Gel filtration or size exclusion chromatography separates proteins based on 
differences in size as they pass through a packed column. The larger proteins will 
pass through the matrix faster than smaller proteins, due to the retardation of lower 
relative molecular mass proteins within the porous beads of the gel filtration 
medium. This technique can be used to characterise proteins, separate them from 
contaminating proteins and also examine how the proteins interact in a non denatured 
environment. The separation of tCry1Ac (69kDa) from CRP (30kDa) was attempted 
using gel filtration as there is a sufficient difference in relative molecular masses.  As 
CryD3 (20kDa) is only approximately 10kDa smaller than CRP their separation 
would be difficult to achieve on this type of column. 
 
 
4.9.2.1 Investigation of the purification of tCry1Ac by Toyopearl HW-55S 
 
The Toyopearl SuperButyl-550 (HW-55S base bead) (Tosoh Biosciences, Germany) 
column matrix is composed of methyl-methacrylate. The compounds structure is 
displayed in Figure 4.32 and has no carbohydrate component. As a result, this matrix 
would be more suitable for the examination of carbohydrate binding molecules that 
might otherwise bind to a Sepharose matrix. 
 
 
Figure 4.32: Polymeric structure of methyl methracylate. The hydroxylated 
polymeric structure that forms the filtration matrix in the SEC column HW-55S. R is 
a hydroxylated aliphatic group. Image produced using Chemsketch. 
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tCry1Ac was applied to the Toyopearl HW-55S column as outlined in section 2.13.3 
and was run through the column. The results of that run are shown in figures 4.33 
and 4.34. Figure 4.33 presents the full elution profile. The elution profile shows 4 
protein peaks. The profile shows that there was some good separation of peak one 
and four in solution, however peak two and three did not separate very well as they 
similar in size. Figure 4.34 is magnified to show peaks 2, 3 and 4 on the elution 
profile. Further analysis of these proteins was carried out by SDS PAGE and ELLA. 
SDS PAGE (see Figure 4.35) indicates that peak one contains tCry1Ac with some 
contaminant proteins. Therefore this implies that these contaminating proteins are 
being co-purified with tCry1Ac as they cannot be separated by size exclusion 
chromatography. The results do show however that the two smaller bands in the 
tCry1Ac protein sample are not in peak one and so could be the proteins for peaks 
two and three on the elution profile. The results of the ELLA analysis, shown in 
Figure 4.36, show that peak one has a very low activity towards GalNAc but it is not 
significant. It is difficult to say how the CRP is binding to both tCry1Ac and CryD3. 
It could be due to hydrophobic bonds or even through the lectin domain. Therefore, 
further attempts to purify and separate tCry1Ac and CryD3 from the CRP were then 
carried out by IMAC in the presence of (a) detergent and (b) competing Galactose.  
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Figure 4.33: Elution profile of tCry1Ac in PBS pH 7.2 from the Toyopearl HW-55S SEC matrix. The elution profile of tCry1Ac 
using SEC with the Toyopearl HW-55S column. The optical density at OD280nm was plotted against the elution volume. There are 4 
main protein peaks in blue. 
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Figure 4.34: Peaks two, three and four from tCry1Ac elution profile. Magnified peaks 2, 3 and 4 from the elution profile of tCry1Ac 
by size exclusion chromatography. 
3 
4 
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Figure 4.35: SDS PAGE of the peaks from the size exclusion column. 1 and 8; 
Broad range protein marker, 2; tCry1Ac before being put over the column, 3; CryD3, 
4; Peak one, 5; Peak two, 6; Peak three, 7; Peak four. The white arrow represents 
tCry1Ac. The black arrow post to two small bands that are not in the elution fraction 
of peak one. 
 
Figure 4.36: ELLA analysis of the four peaks of the tCry1Ac sample produced 
by gel filtration. tCry1Ac peak 1, 2, 3 and, 4 were analysed on an ELLA in 
comparison with the ECL. There is a small amount of binding for tCry1Ac peak 1 to 
GalNAc. Overall there was no significant activity for tCry1Ac to GalNAc. 
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4.9.3 Separation of tCry1Ac and the Catabolite Gene Activator using IMAC in 
the presence of a non ionic detergent Triton X-100. 
As the other separation and purification protocols did not separate tCry1Ac or CryD3 
it was thought that the catabolite gene activator may be binding to tCry1Ac through 
hydrophobic interactions. Triton X-100 is the most characteristic example of a non-
ionic surfactant. Non-ionic detergents contain a headgroup that is uncharged and 
hydrophilic (see Figure 4.37). They are considered mild surfactants as they break 
protein-lipid, lipid-lipid but not protein-protein interactions and most of them do not 
denature proteins. Therefore, proteins are solubilised and isolated in their native and 
active form retaining their protein activity. This is their main advantage and preferred 
in isolation of membrane proteins. To test this theory tCry1Ac was expressed and 
purified using IMAC with the addition of 10% triton X100 in the lysis, wash and 
elution buffers. A significant reduction in protein yield was observed in the SDS 
PAGE gel (Figure 4.38) from the tCry1Ac compared to tCry1Ac with added Triton 
X100. There was a small band barely visible on the gel that corresponds to tCry1Ac. 
The eluted sample was examined on an ELLA (see Figure 4.39) but it did not show 
activity for tCry1Ac. Therefore purification by non ionic detergent was found not to 
yield positive results. 
 
Figure: 4.37: The structure of Triton X-100. Adapted from G- Biosciences. 
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Figure 4.38: SDS PAGE analysis of tCry1Ac purified by IMAC in the presence 
of 10% triton X 100. Lane 1 and 4; Broad range protein marker, 2; tCry1Ac, 3 
tCry1Ac with added Triton X100. The white arrow indicates tCry1Ac.  
 
 
Figure 4.39: ELLA analysis of tCry1Ac, purified by IMAC with 10% Triton 
X100. Analysis of the binding activity of tCry1Ac purified by IMAC with added 
triton X100. No increase in binding was detected for tCry1Ac to GalNAc. 
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4.9.4 Separation of CryD3 and Catabolite Gene Activator by competing 
Galactose 
As CryD3 has been shown to bind the sugar galactose, it was thought that adding 
free galactose during the IMAC washes may result in competition with CRP for the 
binding of CryD3. The experiment was carried out as described in section 2.13.7.  
Figure 4.40 shows a significant improvement in purification as the eluted fraction of 
CryD3 (after the galactose washes) revealed a single band for CryD3. However, 
there were some differences in the protein yield which means that the contaminant 
proteins may be potentially diluted. Therefore, the purification was repeated with and 
without galactose washes. Figure 4.41 shows the difference in contaminating 
proteins at approx 30kDa between CryD3 purified with 100mM galactose and CryD3 
purified without galactose.  Figure 4.42 shows the results from the ELLA analysis of 
the purified sample of CryD3. It is apparent from this graph that CryD3 is binding to 
asialofetuin and therefore is active. This would suggest therefore that CRP could be 
glycosylated. A lectin blot was carried out in order to detect any glycosylated protein 
in the sample.  
 
Figure 4.40: SDS PAGE analysis of CryD3 purification by IMAC with 
competing Galactose. Lane 1 and 5; Broad range protein marker, 2; CryD3 purified 
by IMAC, 3; wash with imidazole 100mM and galactose 100mM, 4; Elution of 
CryD3 with imidazole 100mM and galactose 100 mM. The white arrow indicates 
CryD3. 
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Figure 4.41: SDS PAGE analysis of CryD3 purification by IMAC with 
competing galactose compared to dilutions of CryD3 purified by IMAC with no 
Galactose. Lane 1 and 12; Broad range protein marker, 2; CryD3 purified by IMAC 
with galactose 100mM, 3-11; dilutions from 1/2 to 1/10 respectively of CryD3 
purified by IMAC with no galactose. The white arrow indicates CryD3 while the 
black arrow indicates the contaminating protein.  
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Figure 4.42: ELLA analysis of CryD3 purified by IMAC with added 100mM 
galactose washes. CryD3 was purified by IMAC and galactose was added to the 
washes with the resulting eluted protein analysed by ELLA. There was significant 
binding of CryD3 to asialofetuin. Interestingly, this correlation is related to the loss 
of the CRP protein.  
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4.10 Investigation of the possible glycosylation of the catabolic gene 
activator 
 
As competitve galactose washes (during the IMAC purification of CryD3) were 
found to prevent the CRP from binding to CryD3 it was proposed that CRP may be 
glycosylated. Therefore, a lectin blot using ECL to detect galactose residues was 
carried out on the purified samples of tCry1Ac and CryD3 with CRP (See section 
2.17). Figure 4.43 showed that no bands appeared on the lectin blot. While this 
would suggest that CRP may not be glycosylated, it is still interesting that galactose 
has the ability to separate CryD3 from CRP. Therefore there may be a type of 
glycosylation that does showing up on this type of lectin blot. 
 
Figure 4.43: Lectin blot using ECL of purified samples of tCry1Ac and CryD3 
with contaminating CRP protein. A lectin blot was carried out on the protein 
eluted from IMAC to possibly identify if CRP is glycosylated. 1; pre-stained protein 
ladder, 2-4; tCry1Ac eluted peaks, 5-7; CryD3 eluted peaks. 
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4.11 IMAC: Increasing imidazole washes for the removal of bound CRP 
to tCry1Ac and CryD3 
tCry1Ac and CryD3 both bound very well to the nickel resin of the IMAC via the 6x 
histidine tag on their C terminus. Even at 300mM and 500mM imidazole elutions it 
took several fractions to elute the proteins. It was proposed that as tCry1Ac and 
CryD3 are over expressed in the host expression strain E. coli there should be a lot 
more of these proteins than the CRP protein. Therefore, IMAC purification was 
carried out in the presence of increasing imidazole washes ranging from 100mM, 
120mM, 140mM 160mM, 180mM, 200mM and 300mM. It was postulated that the 
tCry1Ac-CRP  or CryD3- CRP ‘complexes’ would be significantly larger than the 
unbound proteins and would therefore elute from the column first, leaving the 
unbound tCry1Ac and CryD3 to come off the column last (assuming saturation of 
CRP). Figure 4.44 presents some interesting results as it shows a decrease in the CRP 
and contaminating bands corresponding with an increasing amount of eluting 
imidazole.  
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Figure 4.44: SDS PAGE analysis of the optimised IMAC purifications of 
tCry1Ac and CryD3 using higher imidazole elutions.  tCry1Ac and CryD3 were 
purified and imidazole washes of 200mM were used before the proteins were eluted 
in 1mL fractions with 300mM imidazole. 1 and 10; Broad range protein marker, 2; 
tCry1Ac 300mM elution, 3 and 5; CryD3 300mM imidazole elution, 6; tCry1Ac 
200mM imidazole wash, 7 and 9; 200mM imidazole wash. The white arrow 
represents tCry1Ac, the black arrow, CryD3 and the red arrow, the contaminating 
protein CRP. 
 
4.11.1 Optimising protein purification by IMAC using combined increased 
imidazole and sugar washes 
IMAC purification was carried out on tCry1Ac and CryD3 by combining both very 
high levels of imidazole washes with (a) a 100mM galactose wash for CryD3 and (b) 
a 100mM GalNAc wash for tCry1Ac. Figure 4.45 shows a single band for CryD3 
and tCry1Ac, revealing that the combined method of increased imidazole washes and 
a galactose/GalNAc wash results in a highly purified protein with no bound 
contamination from E. coli proteins. The yield of the proteins was 1mg/ml for CryD3 
and 500µg/ml for tCry1Ac. This degree of purity would allow the sugar specificities 
of tCry1Ac and CryD3 to be investigated more exactly. 
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Figure 4.45: SDS PAGE analysis of tCry1Ac and CryD3 purified by IMAC 
combined with high imidazole and galactose/GalNAc 100mM washes. tCry1Ac, 
CryD3 elutions after purification by IMAC and galactose/GalNAc washes. Lane 1; 
broad range protein marker, 2; CryD3 3; tCry1Ac. The white arrow indicates 
tCry1Ac and the black arrow indicates CryD3. 
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4.12 Investigation of glycan binding specificities of tCry1Ac and CryD3 
 
ELLA analysis was carried out on the purified samples of tCry1Ac and CryD3 to 
examine their binding and relative affinities for different glycoproteins. Firstly they 
were tested against GalNAc-BSA, the Tn antigen and asialofetuin. Figure 4.46 shows 
the results of this ELLA analysis. tCry1Ac showed specificity for GalNAc and the 
Tn antigen, while CryD3 displayed specificity for galactose. This would seem to 
indicate that without the interference of CRP both of these proteins have active 
glycan binding. Dilutions of tCry1Ac and CryD3 binding to GalNAc –BSA and 
asialofetuin respectively were examined by ELLA analysis. In figure 4.47 tCry1Ac 
displayed a relatively good affinity for GalNAc. Figure 4.48 reveals that CryD3 has a 
slightly lower affinity for galactose, as there is a steep drop in signal with each 
dilution. This demonstrates that even though CryD3 binds to galactose specifically it 
does not have a high affinity for galactose and therefore does not bind very tightly. In 
figure 4.49 tCry1Ac and CryD3 were tested against GalNAc, galactose, sialic acid 
and GlcNAc. tCry1Ac and CryD3 showed no activity towards sialic acid or 
invertase. This would seem to indicate that tCry1Ac and CryD3 are selective for 
binding to GalNAc and galactose respectively.  
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Figure 4.46: ELLA analysis of the purified tCry1Ac 10µg/ml and CryD3 
10µg/ml compared to the commercial lectins SBA 10µg/ml and ECL 10µg/ml. 
Neoglycoprotein GalNAc-BSA and the Tn antigen were used along with the 
glycoprotein Asialofetuin. ELLA samples averaged in triplicate and ELLA 
experiment carried out three times. The positive controls, SBA binding to GalNAc 
and the Tn antigen while ECL binds to Asialofetuin and GalNAc. The graph shows 
the increased activity of tCry1Ac (green) and CryD3 (purple), which correlates to the 
purification of the proteins from CRP. Interestingly tCry1Ac (green) shows very 
strong binding to the Tn antigen and GalNAc, while CryD3 (purple) is specific to 
Asialofetuin.  
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Figure 4.47: ELLA analysis of tCry1Ac affinity for GalNAc. A dilution series 
was done on tCry1Ac and analysed against GalNAc. ELLA samples averaged in 
triplicate and ELLA experiment carried out three times. tCry1Ac seems to have a 
good affinity for GalNAc as the slope of the line is gradual. tCry1Ac still binds with 
good specificity at 5µg/mL of tCry1Ac.  
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Figure 4.48: ELLA analysis of CryD3 affinity for galactose. Dilutions of CryD3 
were assayed against 5µg/mL of asialofetuin to examine the affinity of CryD3 for 
galactose. ELLA samples averaged in triplicate and ELLA experiment carried out 
three times. The affinity was an improvement from figure 4.10. Nevertheless the 
affinity is still slightly weak as the signal drops quickly after each dilution.  
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Figure 4.49: ELLA analysis of tCry1Ac and CryD3 specificity for various 
glycoproteins with different glycan epitopes. This ELLA analysed the binding 
specificity of tCry1Ac (green) and CryD3 (purple) to various glycoproteins which 
contained, GalNAc, galactose, sialic acid, and GlcNAc. ELLA samples averaged in 
triplicate and ELLA experiment carried out three times. 
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4.13 Discussion 
tCry1Ac and CryD3 were successfully expressed, purified and separated from a 
persistently contaminating protein, namely the cAMP regulatory protein (CRP). The 
purified proteins where then characterised for their sugar binding properties, in 
particular their ability to bind to GalNAc and galactose. Extensive optimisation of 
tCry1Ac purification was essential due to the amounts of purified protein required 
for characterisation. The ability to produce large amounts of recombinant protein is 
also a pre-requisite if this molecule was to be incorporated onto an affinity or protein 
microarray formats. Optimisation of protein purification was also required for 
tCry1Ac and CryD3 as there was a persistent contaminating protein from E. coli in 
the eluted samples. The contaminating protein also seemed to block or inhibit the 
binding activity of tCry1Ac and CryD3 proteins.   
A preliminary small scale expression and purification was carried on tCry1Ac and 
CryD3. The small scale expression revealed that tCry1Ac did not express well and 
therefore optimisation of expression was required. Contaminating proteins were 
observed in the purified sample of CryD3, and later in the optimised tCry1Ac 
expressions. This lead to a requirement of the optimisation of IMAC conditions for 
both proteins. The subsequent proteins were analysed on a preliminary ELLA to 
determine if tCry1Ac and CryD3 had sugar/glycan binding abilities. tCry1Ac was 
found to strongly bind to GalNAc while CryD3 was found to bind to galactose. This 
was a significant result as it showed that the Cry1Ac toxin could be cloned and 
expressed as a soluble toxin while still retaining its carbohydrate specificity. This 
finding supports previous research carried out on Cry1Ac, where it was found to 
have specificity for GalNAc (Xiang et al. 2009, Burton et al. 1999, Knowles, Knight, 
and Ellar 1991). Surprisingly CryD3 showed specificity to galactose. This finding 
has not been documented previously and shows that it is possible that domain three 
of Cry1Ac may be produced as a soluble protein and still retains carbohydrate 
specificity.  
 
 
 
170 
 
Following the successful expression of soluble tCry1Ac, expression optimisation was 
carried out as described in section 4.6. Two E. coli strains, KRX and JM109 were 
transformed with ptCry1Ac, to express C-terminally 6x histidine tagged tCry1Ac. 
The clones from each strain were submitted to expression analysis by SDS-PAGE, 
with JM109 selected as the most efficient clone for recombinant tCry1Ac expression. 
IPTG induction levels, incubation temperatures and growth media were all varied to 
optimise protein production. 
As IPTG concentrations and incubation temperature influence cell growth rate, 
cultures may not be directly comparable, due to different cell densities. To combat 
this, all cultures were inoculated from the same starter culture and samples were also 
diluted to the same OD prior to cell harvest and analysis by SDS-PAGE. The effect 
of induction with varying levels of IPTG was investigated by looking at the amount 
of soluble and insoluble product produced at certain stages of expression. It was 
concluded that increasing the IPTG concentration did not result in a significant 
increase in levels of recombinant protein expressing in the soluble protein fraction 
and that dramatically increasing the IPTG concentration had an adverse affect on the 
cells growth rate. 
The optimal temperature for expression was also investigated. It was determined that 
that optimal incubation at 20°C overnight, lead to an increased amount of protein per 
cell. A morning harvest time would also lend itself to immediate downstream 
processing, thus reducing any prolonged protein exposure to proteases. 
The media chosen for protein expression was TB (Terrific broth) which would 
enable the cells to continue to grow and produce protein overnight, at the reduced 
temperature of 20°C.  
Having evaluated the conditions for optimal expression of tCry1Ac from E. coli a 
purification optimisation was investigated for both tCry1Ac and CryD3. Due to the 
presence of the 6x histidine tag on the proteins C-terminus an IMAC purification 
strategy could be employed. Imidazole elution concentrations were investigated in 
order to establish an optimised strategy for IMAC purification of 6x histidine tagged 
tCry1Ac and CryD3. The optimised elution profile consisted of using a concentration 
of 40mM Imidazole in the binding buffer (wash buffer 1), followed by an 
intermediate wash step using 100 mM Imidazole (wash buffer 2), with a 
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concentration of 300 mM Imidazole used for the elution of tCry1Ac and CryD3 from 
the matrix. However, there were still some contaminants in the eluted samples of 
both proteins.  
A western blot analysis was carried out in order to determine if the contaminating 
bands were potentially cleaved fragments of the histidine tagged proteins. The 
histidine results seemed to indicate this to be the case. ELLA analysis on the proteins 
showed no sugar binding activity. Therefore analysis on the stability of tCry1Ac and 
CryD3 was carried out with particular attention to protease inactivation/sensitivity 
and temperature denaturation. The host strain was compared to KRX E. coli, which 
is a protease resistant strain and protease inhibitor tablets were added to the cell 
lysate prior to cell disruption. This surprisingly resulted in more protein bands on the 
purification gels. Expression of protein was then carried out at 20°C with the actual 
purifications being carried out at 4°C as CryD3 aggregated and fell out of solution at 
temperatures between 30°C and 37°C. Analysis of the resulting purified protein 
showed less contaminating bands. However, there was still one prominent band that 
consistently showed up in both tCry1Ac and CryD3 samples. A western blot analysis 
showed a single band for tCry1Ac and CryD3. This suggested that a protein was 
being co-purified and was having an effect on the activity and stability of both 
proteins.  
The 30kDa protein band was sent to be identified by MS. The results of this revealed 
that the protein was a cAMP regulatory protein from E. coli also known as the 
catabolite gene activator (CRP). It was not clear how CRP was being co-purified 
with tCry1Ac and CryD3. The next steps were to identify how this protein was being 
co-purified with these proteins, to ultimately separate it from both the tCry1Ac and 
CryD3 proteins.  
Ion exchange and gel filtration chromatography were both found to not have any 
significant effect on the removal of the contaminant protein. In order to test the 
possibility that the binding of tCry1Ac to CRP may be hydrophobic in nature 10% 
TritonX100 was added during the IMAC purification of tCry1Ac. This resulted in a 
very low yield of protein and it was difficult to tell if the CRP protein had been 
separated or diluted. The resulting ELLA showed the tCry1Ac protein to have little 
or no binding activity for GalNAc.  
172 
 
It was hypothesized that as both tCry1Ac and CryD3 lost the ability to bind glycans 
when CRP is to them bound, then it could be binding to their sugar recognition site. 
Therefore CryD3 was purified by IMAC with the addition of 100mM galactose 
washes. The resulting gel showed a band for CryD3, with a lower yield than normal 
but with no CRP band present. The CRP was found to be present in the purification 
with no galactose washes but was not present in the purification with galactose 
washes. This would indicate that the galactose might be competing with CRP 
binding. ELLA analysis showed that the CryD3 purified by IMAC and galactose was 
active and bound to asialofetuin.  
A lectin blot carried out on a sample containing CRP showed no glycosylation was 
present. A general feature of lectin binding sites is that they consist of a primary 
binding site that is capable of binding an individual monosaccharide unit, usually 
with a low affinity. This weak affinity is most often compensated for by the presence 
of multiple subunits (Loris 2002). Consequently, any disruption to the lectins 
quaternary structure may have a greater impact on the lectins ability to interact with 
its target molecule. Therefore even though CRP may not be glycosylated, how it 
binds to tCry1Ac and CryD3 has an effect on their sugar binding abilities. 
Investigation of IMAC conditions was again analysed and it was found that if the 
tCry1Ac and CryD3 in particular are eluted in 300mM imidazole fractions, the larger 
proteins tCry1Ac –CRP complex and the CryD3-CRP complex elute off the column 
first. Therefore, these can be discarded and the ‘unbound’ tCry1Ac and CryD3 may 
be eluted. Thus when a combined purification was carried out with increased 
imidazole washes and GalNAc/galactose washes, it resulted in a purified protein for 
both tCry1Ac and CryD3.  
The pure samples of tCry1Ac and CryD3 were then analysed on an ELLA, showing 
significant activity towards GalNAc and galactose respectively. Further ELLA 
analysis was carried out on these purified samples. These results indicate that 
tCry1Ac is specific for GalNAc and the Tn antigen while CryD3 is specific for 
galactose. These findings are consistent with those of the structural modelling and 
binding predictions carried out in chapter 3. These experiments confirm that tCry1Ac 
binds to GalNAc, while the third domain on its own binds to galactose. This provides 
new information that domain III of Cry1Ac binds to galactose when produced as a 
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soluble protein. Previous studies have not characterised the third domain and this 
study shows that it is possible to produce a soluble active protein, while also showing 
that the third domain can have altered carbohydrate specificity. (Xiang et al. 2009, 
Burton et al. 1999, Knowles, Knight, and Ellar 1991).  
 
 
  
 
 
 
 
Chapter 5 
 Site Directed Mutagenesis of tCry1Ac 
and CryD3 
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5.1 Overview 
This chapter describes the site directed mutagenesis of tCry1Ac and CryD3 in both 
the known and predicted binding sites for the substrates GalNAc and galactose 
respectively. Alanine scanning was used to examine the effect these amino acids 
have on the protein structure and function. The effects of altering the amino acids of 
the binding sites on specificity and affinity were then studied. The structural models 
of the proteins were examined by PyMol to observe the effect mutagenesis had on 
each protein. Whole vector amplification of tCry1Ac and CryD3 was used to 
introduce the mutations. The resulting proteins were named, tCry1AcN480A, 
tCry1AcQY487A, tCry1AcN521A, CryD3N45A, CryD3QY52A, CryD3N86A, CryD3PAV16A. 
Small scale protein expression and IMAC purification was carried out for each 
protein. Contaminating proteins were still an issue during purification. An ELLA 
investigating the sugar binding abilities of each protein was carried out. CryD3N86A 
was the only protein that demonstrated significant biological activity. Therefore 
CryD3N86A was selected to analyse further. CryD3N85A was purified to a high degree 
and displayed significant binding to GalNAc with residual binding to galactose. This 
finding could suggest that the binding site for GalNAc and galactose in tCry1Ac and 
CryD3 is located in the same region but altered due to changes in protein folding 
when CryD3 is isolated.  
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5.2 Site directed mutagenesis of tCry1Ac and CryD3 
tCry1Ac and the lectin domain CryD3 both display specificity for oligosaccharides 
tCry1Ac as expected showed specificity to GalNAc, while CryD3 bound to 
galactose. This may be because of a different binding site or an alteration in the 
binding region due to protein folding. Therefore alanine mutations on the known 
binding regions and expected binding regions were carried out to examine the 
binding specificities of both proteins. From previous studies on Cry1Ac sites N506, 
Q509 and Y513 and N546 were shown to have an essential role in binding (Xiang et 
al. 2009; Burton et al. 1999). These sites correspond to N480, Q483, Y487 and N521 
in tCry1Ac and N45, Q48, Y52 and, N86 in CryD3. From I-Tasser the predicted 
galactose binding site for CryD3 was around the region, P14, A15 and V16. 
Alanine scanning is the most commonly used technique to map functional epitopes 
(Moreira et al. 2007, Cunningham and Wells, 1989, Morrison and Weiss 2001, 
Wells, 1990). Alanine substitution nullifies the amino acid side chain without 
altering the main-chain conformation, nor does it impost extreme electrostatic or 
steric effects (Cunningham and Wells, 1989)   
Alanine residues were introduced to tCry1Ac and CryD3 via site directed 
mutagenesis using Velocity tac polymerase whole vector amplification as described 
in section 2.7 (see Figure 5.1). The residues that were targeted for mutagenesis were 
the known binding residues of tCry1Ac N480, Q483, Y487 and N521 and the 
respective residues in CryD3; N45, Q48, Y52 and, N86. (See section 3.4 and 3.5). 
Protein modelling showed the expected binding region of CryD3 to involve residues 
P14, A15 and V16 (Figure 3.15). Therefore a double mutant of PAV was altered to 
AAA. 
The resulting genes were named tcry1acN480A, tcry1acQY487A, tcry1acN521A, cryc3N45A, 
cryd3QY52A, cryd3N86A, cryd3PAV16A. The resulting proteins were named, tCry1AcN480A, 
tCry1AcQY487A, tCry1AcN521A, CryD3N45A, CryD3QY52A, CryD3N86A, CryD3PAV16A 
respectively. The construction of the mutants is outlined in Figures 5.2-5.5. The 
predicted impact to the protein structure is shown in Figures 5.6 to 5.10. The model 
that displayed the most promising results was CryD3N86A in Figure 5.9. Figure 5.9 
showed that when CryD3 is mutated from N86A, it opens up a possible binding site 
in CryD3.  
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Figure 5.1: Schematic of Velocity whole vector amplification site directed 
mutagenesis. Two primers are designed to amplify the entire expression plasmid, 
one of which contains the desired mutation. Following PCR (Section 2.7.1) a DpnI 
restriction digest can be carried out to restrict any of the methylated template DNA. 
The phosphorylated ends are then ligated. The ligation is subsequently transformed 
directly into an E. coli expression strain (Section 2.6). For the mutation of tCry1Ac 
the template plasmid was ptCry1Ac while CryD3 was pCryD3. 
 
Figure 5.2: Outline of construction of tCry1AcN480A and CryD3N45A . 
Representation of the position of the primers used for the mutation of tCry1AcN480A 
and CryD3N45A, Mut480f (blue), Mut480r (red) (Table 2.3) within the tCry1Ac and 
CryD3 sequence which creates the mutation N480A and N45A respectively. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined in bold. 
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Figure 5.3: Outline of construction of tCry1AcQY487A and CryD3QY52A. 
Representation of the position of the primers used for the mutations of 
tCry1AcQY487A and CryD3QY52A, Mut487f (blue), Mut487r (red) (Table 2.3) within 
the tCry1Ac and CryD3 sequence which creates the mutations Q483A, Y487A and 
Q48A, Y52A respectively. The nucleotides to be mutated are highlighted in yellow, 
with the nucleotides to be introduced on each primer underlined in bold. 
 
 
Figure 5.4: Outline of construction of tCry1AcN521A and CryD3N86A. 
Representation of the position of the primers used for the mutation of tCry1AcN521A 
and CryD3N86A, Mut521f (blue), Mut521r (red) (Table 2.3) within the tCry1Ac and 
CryD3 sequence which creates the mutation N521A and N86A respectively. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined in bold. 
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Figure 5.5: Outline of construction of CryD3PAV16A. Representation of the position 
of the primers used for the mutation of CryD3PAV16A, MutPAVf (blue), MutPAVr 
(red) (Table 2.3) within the CryD3 sequence which creates the mutation P14A, A15 
and V16A. The nucleotides to be mutated are highlighted in yellow and green, the 
pink is the highlighted alanine, with the nucleotides to be introduced on each primer 
underlined in bold.     
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Figure 5.6: PyMol 3D Protein models of tCry1Ac (partial view) and CryD3 
showing expected binding site of GalNAc and galactose. A) tCry1Ac, domain I in 
red, domain II in green and domain III in purple with highlighted residues believed to 
be involved in GalNAc binding, N480- orange, Q483-cyan (buried in this structure), 
Y487 – pink, N521- yellow. B) CryD3 in purple with highlighted residues that relate 
to tCry1Ac, N45 – orange, Q48 – cyan, Y52 – pink, N86 – yellow. The 6 x histidine 
tag in both proteins is red. These protein structures are from the same sequence but 
some structural differences are predicted. The residues that are highlighted are 
located in different positions in the different proteins. In tCry1Ac, the domains I and 
II may be supporting domain III and cause its structure to change slightly.  
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Figure 5.7: PyMol Protein models of tCry1AcN480A (partial view) and CryD3N45A. 
(A) tCry1AcN480A with highlighted residue in yellow that was mutated to alanine, 
domain III; purple, domain II; green, 6x histidine tag; blue. (B) CryD3N45A with 
highlighted residue in yellow that was mutated to alanine, 6x histidine tag 
highlighted in red.  
 
 
 
 
Figure 5.8: PyMol Protein models of tCry1AcQY487A (partial view) and 
CryD3QY52A.  (A) tCry1AcQY487A with highlighted residues in yellow that were 
mutated to alanine, domain III; purple, domain II; green, 6x histidine tag; blue.  (B) 
CryD3QY52A with residues that were mutated to alanine in yellow, 6x histidine tag 
highlighted in red.  
B A 
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Figure 5.9: PyMol Protein models of tCry1AcN521A (partial view), CryD3N86A. 
tCry1AcN521A, CryD3N86A and CryD3 with mutations to alanine in yellow. (A) 
tCry1AcN521A showing a partial view of  tCry1AcN521A with the third domain in 
purple, histidine tag in blue and N521A change in yellow. (B) CryD3N86A with 
histidine tag in red and mutation to alanine in yellow. (C) CryD3 with histidine tag in 
red and N86 in yellow. This shows that when CryD3 is mutated N86A, it opens up a 
possible binding site in the CryD3.  
 
 
 
 
C 
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Figure 5.10: PyMol Protein model of CryD3PAV16A and CryD3. (A)  CryD3PAV16A 
with mutations to alanine in yellow, 6x histidine tag highlighted in red. (B) CryD3 
with PAV highlighted in yellow and 6x histidine tag highlighted in red.  
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5.3 Preliminary expression and purification of mutants of tCry1Ac and 
CryD3 
Following successful construction of the tCry1Ac and CryD3 mutants, each plasmid 
was verified by sequencing and transformed into the E. coli JM109 expression strain. 
The optimised expression and purification by IMAC strategies for tCry1Ac and 
CryD3 were used for all derivatives. The only difference was that galactose was not 
added in the preliminary purification to examine CRP binding to the mutants. This 
was to examine if there was any difference in contaminating bands compared to 
tCry1Ac and CryD3. The SDS PAGE gels showing the protein expressions are 
presented in Figure 5.11. They show low expression yields for tCry1Ac mutants, 
while CryD3 mutants expressed well, especially CryD3N86A and CryD3PAV16A. 
Following this the producing cells were lysed by cell distruption and the mutant 
proteins purified by IMAC. The results obtained from the preliminary purification of 
the mutant proteins are presented in Figures 5.12, 5.13 and 5.14 respectively. While 
the gels show the purified proteins, there are several contaminating bands including a 
large band at 30kDa which correlates to the CRP protein from E. coli. 
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Figure 5.11: SDS PAGE gels of small scale protein expression of tCry1Ac and 
CryD3 mutants. The mutants; tCry1AcN480A, tCry1AcQY487A, tCry1AcN521A, 
CryD3N45A, CryD3QY52A, CryD3N86A, CryD3PAV16A were expressed in E. coli JM109 
and the total protein analysed on a SDS PAGE gel.   
(A) Expression of tCry1Ac mutants, 1; broad range protein marker, 2; tCry1AcN480A, 
3; tCry1AcQY487A, 4; tCry1AcN521A. The black arrow indicates tCry1Ac. 
(B) Expression of CryD3 mutants, 1; CryD3N45A, 2; CryD3QY52A, 3; CryD3N86A, 4; 
CryD3PAV16A, 5; non induced CryD3, 6; Broad range protein marker. The white arrow 
indicates CryD3. 
185 
 
 
Figure 5.12: SDS PAGE gels of the preliminary purification of CryD3N45A and 
CryD3QY52A. IMAC purifications on CryD3N45A and CryD3QY52A reveal strong 
expression for the mutants but there are a large number of contaminating bands in the 
purifications. 1 and 12; Broad range protein marker, 2; CryD3N45A lysate, 3; 
CryD3N45A flow through, 4 and 5; CryD3N45A elutions, 6; CryD3QY52A lysate, 7; 
CryD3QY52A flow through, 8-10; imidazole washes, 11; CryD3QY52A elution. White 
arrows indicate CryD3N45A and CryD3QY52A.  
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Figure 5.13: SDS PAGE gels of the preliminary purifications of CryD3N86A and 
CryD3PAV16A. IMAC purifications on CryD3N86A and CryD3PAV16A reveal strong 
expression for the mutants but there are a large number of contaminating bands in the 
purifications. 1; CryD3N86A lysate, 2; CryD3N86A flow through, 3; CryD3N86A 
imidazole wash, 4; CryD3N86A elution, 5; CryD3PAV16A flow through, 6; CryD3PAV16A 
imidazole wash, 7; CryD3PAV16A elution, 8; Broad range protein markers. White 
arrows indicate CryD3N86A and CryD3PAV16A. 
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Figure 5.14: SDS PAGE gel of the preliminary purifications of tCry1AcN480A, 
tCry1AcQY487A, and tCry1AcN521A. IMAC purifications on tCry1AcN480A, 
tCry1AcQY487A, tCry1AcN521A, show expression at 69kDa, with contaminating bands 
again at approx 30kDa and lower. 1; tCry1AcN480A elution, 2; tCry1AcQY487A elution, 
3; tCry1AcN521A elution, 4; broad range protein marker. Black arrow indicates 
tCry1AcN480A, tCry1AcQY487A, and tCry1AcN521A 
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5.4 Investigating glycan binding of tCry1Ac and CryD3 mutants 
 
To examine if either tCry1Ac or CryD3 mutants had specficity towards glycans on 
glycoproteins an ELLA was carried out as described in section 2.19. As can be seen 
from Figure 5.15, CryD3N86 was the only mutant that displayed binding activity to 
GalNAc. This is significant as CryD3 previously had specificity to galactose. It was 
therefore decided to repeat the IMAC purification of CryD3N86 with the addition of 
galacotse washes to produce a purer prepation of CryD3N86 with no contaminating 
proteins. 
 
 
Figure 5.15: Preliminary ELLA on purified mutants from tCry1Ac and CryD3 
compared to commercial lectins ECL and SBA.  ELLA on purified mutants from 
tCry1Ac and CryD3 compared to commercial lectins ECL and SBA. CryD3N86A 
showed specificity to GalNAc, while tCry1AcN480A showed a small amount of 
specificity to GalNAc also. The red arrow indicates CryD3N86A binding to GalNAc-
BSA. 
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5.5 Optimised purification of CryD3N86A by IMAC incorporating 
galactose washes 
As described previously the initial purification of CryD3N86A contained 
contaminating protein bands and its specificity to GalNAc was low. Therefore 
CryD3N86A was purified by IMAC purification with the addition of  galactose washes 
as described in section 2.13.7. This was expected to help purify CryD3N86A,  as the 
galactose would compete for the binding of CryD3N86A. This was shown to be 
sucessful for the purification of tCry1Ac and CryD3 with additional washes of 
GalNAc and galactose. Figure 5.16 shows a significant improvement of the 
purification with a single band for both CryD3N86A and CryD3 seen. This result also 
demonstrated that the purification method, incorporating imidazole and galactose 
washes, used for CryD3 also works for the protein CryD3N86A. These purified protein 
samples were both then re-examined on an ELLA.  
 
 
Figure 5.16: SDS PAGE of IMAC and galactose purification of CryD3 and 
CryD3N86A. CryD3 and CryD3N86A were purified by IMAC and galactose washes 
resulting in a single protein band for CryD3 and CryD3N85A. 1; CryD3 elution, 2; 
CryD3N86A elution, 3; broad range protein marker. Arrow indicates CryD3 and 
CryD3N86A. 
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5.6 Investigation of CryD3N86A specificity for glycoproteins 
 
CryD3N86A had previously shown binding to GalNAc in the ELLA (see figure 5.15). 
However, as this protein also contained contaminating proteins it was decided to 
optimise the purification. This purer sample of CryD3N86A was retested by ELLA. As 
can be seen in Figure 5.17 it is clear that CryD3N86A bound to GalNAc and 
asialofetuin (galactose). This contrasts with CryD3 which had specificity for 
galactose only. It is apparent that one change N86A may have a significant effect on 
the binding specificity of the protein. These results seem to indicate that the binding 
site for tCry1Ac and CryD3 could be very similar. However, slight alterations of the 
protein may have an effect on its specificity towards sugars. CryD3N86A continues to 
display relatively good affinity towards GalNAc-BSA as it becomes progressively 
diluted and examined by ELLA (Figure 5.18). Even at low concentrations (5µg/ mL 
and 2.5µg/ mL) CryD3N86A still displayed specificity to GalNAc. 
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Figure 5.17: ELLA of CryD3 and CryD3N86A compared to commercial lectins 
ECL and SBA. An ELLA was carried out on the purified samples of CryD3 and 
CryD3N86A to examine and compare their specificities. CryD3N86A (in green) has 
altered binding specificity to CryD3. It now binds to GalNAc-BSA, the Tn antigen 
and has some weaker binding to asialofetuin. The arrows indicate the activity of 
CryD3N86A. 
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Figure 5.18: The effect of CryD3N86A dilutions on the binding to GalNAc-BSA 
(5µg/mL) analysed by ELLA. CryD3N86A concentrations 15µg/mL, 10µg/mL, 
5µg/mL, 2.5µg/mL, 1.25µg/mL were assayed against GalNAc-BSA 5µg/mL to 
examine the affinity of CryD3N86A to GalNAc by ELLA as described in section 2.19. 
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5.7 Discussion 
 
The mutants of tCry1Ac and CryD3; tCry1AcN480A, tCry1AcQY487A, tCry1AcN521A, 
CryD3N45A, CryD3QY52A, CryD3N86A, CryD3PAV16A were successfully produced , 
cloned and expressed in E. coli JM109. The initial purifications showed each mutant 
with contaminating proteins in their preparations. This indicates that none of these 
mutations had an effect on the binding of CRP to domain III. This may suggest that 
the CRP is not “binding” to domain III near the GalNAc binding site; however as 
shown in chapter 4 the introduction of either GalNAc or galactose in the IMAC 
purifications eliminates CRP from the protein sample.  
ELLA analysis on the mutant proteins revealed that only CryD3N86A displayed sugar-
binding activity. Unfortunately, tCry1AcN480A, tCry1AcQY487A, tCry1AcN521A, 
CryD3N45A, CryD3QY52A, and CryD3PAV16A did not show any significant results in 
relation to sugar binding. Due to time limitations these proteins were not investigated 
further.  
The purification of CryD3N86A was optimised by the incorporation of galactose 
washes, which produced pure active protein. CryD3N86A displayed specificity to 
GalNAc and some specificity for asialofetuin. This result would indicate that the 
change N86A increases GalNAc binding. It was revealed by Xiang et al., (2009), that 
the residue N546 in β18– β19 loop of the Cry1Ac domain III played an essential role 
in its insecticidal activity and binding to insect BBMV. N546 in Cry1Ac corresponds 
to N86 in CryD3. This would strongly indicate that the binding site for galactose on 
CryD3 and for GalNAc on tCry1Ac is in the same region and this mutation N86A 
can alter the binding specificity from galactose to GalNAc. 
Additional ELLA testing is required to characterise CryD3N86A, in order to analyse 
its binding abilities in more detail. It is interesting to note that only one amino acid 
change gave rise to an altered specificity for this protein. This shows the potential of 
these Cry toxin domains as carbohydrate binding proteins as they can be manipulated 
to give various sugar specificities. Further mutations could be carried out to 
potentially produce a mutant with only GalNAc and Tn antigen binding activity. This 
would potentially give rise to 3 distinct proteins from the CryD3 domain with 
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specificities to GalNAc, galactose and the Tn antigen respectively. These proteins 
would be good candidates for incorporation into novel bioanalytical platforms that 
would have the potential for detection and separation of closely related glycoproteins 
or in the detection of cell surface glycans in disease states such as cancer (Ghazarian, 
Idoni, and Oppenheimer 2011, Brockhausen 2006, Dube and Bertozzi 2005). 
  
 
 
 
 
 
Chapter 6 
Conclusion and Discussion 
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Interest in the area of glycobiology and protein glycosylation has increased 
significantly in the past twenty years. This is due to an increasing understanding of 
the importance of glycosylation such as the study of changes in protein glycosylation 
found in disease states such as cancer, discovery of bacterial glycosylation, and the 
increase in the use of glycoprotein therapeutics by the newly emerging 
biopharmaceutical industry.  
Glycoproteins now represent a large percentage of marketed and clinical 
development phase therapeutic proteins (Hossler et al. 2009). Thus there is an 
increased need to understand the nature and function of the carbohydrate moieties on 
these proteins and the impact on their physiochemical properties, such as stability 
(half-life), solubility and immunogenicity. This is essential for discovering and 
developing safe and efficacious glycoprotein biopharmaceuticals. N and O linked 
glycosylation has a significant impact on the biological activity, pharmacokinetics, 
clearance, and immunogenicity of the therapeutic proteins (Li and d’Anjou 2009). 
New techniques are required to understand and study these glycoproteins and to 
investigate the impact carbohydrates have on the physiochemical properties of a 
protein.  
In many early stage cancers there are significant changes in protein glycosylation and 
these changes represent an area for the development of biomarkers (Ghazarian, Idoni, 
and Oppenheimer 2011, Dube and Bertozzi 2005). For example, in cancers such as 
colon and breast, mucin-type O-glycans such as the T and the Tn antigen are often 
found on the surface of cells (Brockhausen 2006).  
Carbohydrate binding proteins such as lectins, have huge potential here as they may 
be used to detect, separate and quantify glycans, glycoproteins and even closely 
related glycoforms (Ghazarian, Idoni, and Oppenheimer 2011, Kwan and Bun 2011). 
As discussed in the Introduction, it has become apparent that bacteria are an 
excellent source of novel lectins as many have evolved carbohydrate binding proteins 
to specifically target their host cells. Bacterial lectins are much more amenable to 
recombinant production than plant lectins and their specificities may be further 
altered or enhanced by mutagenesis. In addition to this bacteria have been found to 
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produce lectins with novel binding abilities with specific binding (Gilboa-Garber et 
al. 2011).  
The focus of this research was to investigate the protein based Cry toxins from 
Bacillus thuringiensis and their potential for use as lectins in the detection, separation 
and quantification of glycans and glycoproteins. Analysis of the tCry1Ac, CryD3 
and, CryD3N86A proteins (Cry1Ac toxin derivatives), revealed that each had 
specificity for glycans/oligosaccharides/carbohydrates and glycoproteins. tCry1Ac 
specifically bound to GalNAc, CryD3 bound to α1-3, galactose while CryD3N86A 
bound to GalNAc and galactose. This information provides us with good basis to 
conclude that the Cry toxins from Bacillus thuringiensis are potentially a good 
source of novel lectins and that they can have their carbohydrate specificity changed 
with relative ease by mutagenesis.  
The bioinformatics carried out on Cry1Ac gave a good insight into the protein 
sequence in comparison to other Cry toxins. It highlighted the three domains that 
enabled the design of tCry1Ac and CryD3. The protein derivatives tCry1Ac and 
CryD3 were designed from the blast search. tCry1Ac was based on the activated 
form of Cry1Ac and should bind to GalNAc. CryD3 is designed based on the binding 
domain (domain III) of tCry1Ac.  
The protein structures of tCry1Ac and CryD3 were predicted by I-TASSER and 
PyMol was used to model these predictions and to investigate any structural 
differences that could potentially affect binding. It was found that tCry1Ac had a 
very similar structure to the active Cry1Ac, while CryD3 had a slightly altered 
structure to domain III of tCry1Ac, which may affect its binding activity. The 
modelling of tCry1Ac and CryD3 gave a good insight into the protein folding and 
also the potential binding site for GalNAc. The residues thought to be involved in 
GalNAc binding were highlighted in both proteins, which would be useful for the 
design of the site directed mutagenesis in chapter 5. 
tCry1Ac and CryD3 were successfully cloned into the expression vector pQE60 
containing a C terminal 6x histidine tag, which allowed for downstream applications. 
Cloning both proteins in this way was significant as they would be expressed in E. 
coli as soluble active proteins. Previously Cry toxins have been expressed as a 
insoluble protoxins and various downstream processes were needed to activate the 
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toxins. This method allowed for less downstream processes and a higher yield of 
active protein produced by E. coli. 
tCry1Ac and CryD3 were expressed in E. coli JM109 and purified by IMAC in 
laboratory scale. Preliminary ELLA analysis on these proteins showed that tCry1Ac 
bound to GalNAc and CryD3 bound, with low affinity, to galactose. This was a 
significant result as the Cry toxins have never been examined on ELLA’s and it 
showed that tCry1Ac bound to GalNAc, compared to other commercial lectins, 
whole the carbohydrate specificity of the third domain of Cry1Ac had specificity for 
galactose. Both of these proteins showed good potential as CBP’s therefore 
optimisation of the protein expression and purification was carried out.  
Expression optimisation was carried out on tCry1Ac under various conditions which 
included altering the strains of E. coli, the concentration of the inducer IPTG, the 
temperature of expression and the type of growth medium. This optimisation of 
expression showed a significant increase in tCry1Ac expression. Optimisation of 
IMAC purification was then carried out for tCry1Ac and CryD3, in particular, the 
removal of persistent contaminating proteins. tCry1Ac and CryD3 protein 
purifications were carried out at 4°C to increase protein stability.  
The main contaminant protein was identified as CRP (cAMP regulatory protein) 
from E. coli. Various purification strategies to remove this contaminating protein 
were then examined. CryD3 was purified by IMAC with added galactose washes of 
100mM. tCry1Ac and Cry1Ac were then purified with high concentrations of 
imidazole 300mM and sugar washes 100mM (galactose and GalNAc). The 
purifications ultimately produced a pure protein for tCry1Ac and CryD3.  
When analysed on an ELLA, both proteins were found to have active binding to their 
corresponding glycans i.e. tCry1Ac binding to GalNAc while CryD3 bound to 
galactose. tCry1Ac and CryD3 showed relatively good affinity for GalNAc and 
galactose respectively. The glycoprotein binding specificities of tCry1Ac and CryD3 
were then investigated by ELLA analysis. tCry1Ac only showed specificity for 
GalNAc and the Tn antigen, while CryD3 had specificity for terminal α1-3, galactose 
residues, for example, asialofetuin. This result is significant as tCry1Ac binds 
specifically to GalNAc and the Tn antigen, which is a important cancer associated 
antigen. The ability to detect and quantify this antigen on cell surfaces would be of 
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great benefit in detecting and staging certain cancers (Brockhausen 2006). The 
finding that the third domain has a very specific binding to α1-3, galactose residues, 
is important as this protein can detect or separate glycoproteins with slight change at 
terminal galactose residues. The ELLA represents a new technique that can be 
employed for the analysis of Cry toxins specificity to carbohydrates. This assay is 
much more specific for carbohydrate binding compared to previous methods such as 
indirect toxin binding assays to BBMVs and light scattering assays (Carroll and Ellar 
1993, Hendrickx et al. 1990). 
Site directed mutagenesis was then carried out on tCry1Ac and CryD3 to investigate 
the important amino acids at their binding site and their binding characteristics. 
Alanine scanning was used to examine the effect certain amino acids have on the 
protein structure and function. The resulting proteins were named, tCry1AcN480A, 
tCry1AcQY487A, tCry1AcN521A, CryD3N45A, CryD3QY52A, CryD3N86A, CryD3PAV16A. 
These proteins were cloned, expressed in E. coli JM109 and purified by IMAC. An 
ELLA carried out on the proteins showed that only CryD3N86A had significant 
binding activity to GalNAc with some binding to galactose. The IMAC affinity 
purification of CryD3N86A was optimised with galactose washes at 100mM, which 
ultimately produced a pure preparation of CryD3N86A. When analysed on an ELLA, 
CryD3N86A was found to recognise and bind both GalNAc and galactose.  
Instead of cancelling out the galactose binding specificity on CryD3 N86A, altered 
the binding specificity to GalNAc. This result was significant as it showed that a 
single point mutation at N86A had the ability to change the proteins specificity from 
galactose to GalNAc and galactose. This suggests that the binding site for GalNAc 
and galactose in tCry1Ac and CryD3 are in the same region. It also indicated that 
N86 plays an important role in the structure and binding of the protein. This 
correlates to the study carried out by Xiang et al. (2009), where they revealed that the 
residue N546 in β18– β19 loop of the Cry1Ac domain III played an essential role in 
its insecticidal activity and binding to insect BBMV. N546 in Cry1Ac corresponds to 
N86 on CryD3, showing that this residue has an important role in the carbohydrate 
specificity and binding of this protein. Figure 6.1 shows the structure of tCry1Ac, 
CryD3 and CryD3N86A modelled using PyMol and the corresponding residue N86 
highlighted on each protein. This shows that N86 is located close to the predicted 
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binding site on each protein and therefore is predicted to have an effect on the 
carbohydrate specificity of each protein.  
 
 
Figure 6.1: Structural modelling of the third domain of tCry1Ac, CryD3 and 
CryD3N86A highlighting corresponding residue N86.  The third domain is shown in 
purple with the 6x histidine tag in red, and the residue N86 in yellow. The white 
arrow indicates the predicted binding site of GalNAc on tCry1Ac. The red arrow 
indicates the predicted binding site of galactose on CryD3. The yellow arrow 
indicates the predicted binding site of GalNAc and galactose on CryD3N86A. 
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While this study did not show that the CRP protein from E. coli was glycosylated, 
further analysis on the nature of the affinity of CRP to tCry1Ac, CryD3 and 
CryD3N86A is required. Limitations exist if tCry1Ac, CryD3 and CryD3N86A are able 
to bind to numerous proteins via protein interactions. This may affect the binding of 
tCry1Ac, CryD3 and CryD3N86A to glycans and they may give false positives or 
negatives if they were introduced into an assay with a multitude of glycoproteins. 
However, the fact that GalNAc and galactose compete with the binding of CRP to 
tCry1Ac, CryD3 and CryD3N86A suggest that the interaction is a glycan/sugar based 
one There have been many discoveries of bacterial glycosylation since the N-linked 
general protein glycosylation pathway in C. jejuni was published in 2002 (Young et 
al. 2002). This includes a potential novel glycosylation system in P.luminescens (Fox 
2011). Future work is needed to examine the possibility of E. coli having some type 
of glycosylation system. 
 
Further work is required to characterise tCry1Ac, CryD3 and CryD3N86A in detail. 
These proteins have shown that they (or their binding domains) could potentially be 
used as lectins and that their carbohydrate binding affinities and specificities may be 
altered by mutagenesis. The applications of such proteins could be very useful. The 
creation of various lectins from the Cry1Ac toxin displaying a wide variety of 
specificities and affinities would be highly advantageous in the field of glycobiology, 
specifically, in the manufacture of proteins and lectin microarrays. Arrays that 
consist of recombinant molecules from a common protein scaffold would mean that 
each CBP would have the same requirements for activity, such as temperature, pH 
and buffer. The ability to produce these proteins through recombinant production has 
various advantages. It would ensure consistent production (which is not seen with 
plant lectins) and it would allow incorporation of affinity tags into the protein 
enabling more direct orientation specific immobilisation strategies. This in turn 
would lead to a decrease in cost, and greater accessibility of recombinant prokaryotic 
lectins. 
tCry1Ac, CryD3 and CryD3N86A also have the potential to be used in various 
bioanalytical and separation platforms. CryD3 and CryD3N86A could be attached to 
cyanogen bromide (CNBr) activated matrices such as sepharose beads which could 
then be used in lectin affinity chromatography. They are smaller proteins than 
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tCry1Ac and they also bind their respective sugars with a lower affinity, which 
should enable an easier elution of the bound glycoproteins from the column with the 
corresponding free sugar. The coupling of molecules to CNBr-activated matrices is 
usually via amine groups. Therefore CryD3 and CryD3N86A could be coupled with 
CNBr sepharose via exposed lysine residues. Our laboratory is currently looking at 
the immobilisation of carbohydrate binding proteins to gold and silica nano-particles 
as well as carbon monoliths and PolyHIPE (poly High Internal Phase Emulsions) in 
order to develop novel bioanalyical platforms for glycoprotein separation and 
analysis. 
tCry1Ac could also prove useful for analysing cell surface glycoproteins in disease 
states by microscopy. tCry1Ac binds specifically to GalNAc and the Tn antigen, 
which is found on the surface of many cancer cells such as breast and colon 
(Brockhausen 2006). tCry1Ac could be coupled with a florescent tag which would 
facilitate the labelling and detection of the Tn antigen on the surface of cells by 
microscopy. Fluorescently labelled tCry1Ac, CryD3 and CryD3N86A could also be 
used in Fluorescence-activated cell sorting (FACS) to identify the glycoproteins on 
the cell surface. This may be also used to examine any changes in surface 
glycosylation that occur during apoptosis (programmed cell death) and to distinguish 
diseased from healthy cells.  
Previously Cry toxins were not cloned as soluble toxins. This study has shown that 
Cry1Ac can be cloned as a soluble protein and retain its activity to GalNAc. It also 
shows that the third domain of Cry1Ac can also be produced as a soluble protein, 
which has altered carbohydrate specificity to galactose, but can be returned to a 
GalNAc binder with the mutation N86A. 
The present study confirms previous findings that Cry1Ac binds to GalNAc and 
contributes additional evidence that suggests the Cry toxins may have their 
carbohydrate specificities and affinities altered with relative ease by mutagenesis 
(Xiang et al. 2009, Burton et al. 1999, Knowles, Knight, and Ellar 1991). However 
the finding that CryD3 binds to galactose has not been observed by any other studies 
carried out on Cry1Ac. This is most likely due to the design of the protein CryD3 and 
the folding of this protein without domain I and II for structural support, which 
seems to alter the carbohydrate specificity of the third domain.  
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There are hundreds of Cry toxins whose binding characteristics have yet to be 
identified and there are many areas where Cry toxins could prove useful if their 
binding was extensively investigated and documented.  Cry toxins potentially present 
a huge reservoir and variety of natural CBP’s to study and are amenable to 
recombinant production and modification. This work presents a model of how 
domain III of a Cry toxin could be potentially used as a sugar binding lectin. The 
work carried out on tCry1Ac and CryD3 may potentially be applied to other Cry 
toxins thereby increasing the library of carbohydrate binding protein ligands. 
 
 
 
6.2 Potential publications  
• Carbohydrate binding properties of Cry1Ac toxin and its future applications 
• Cry1Ac and its potential in glycoanalysis  
• Mutation N86A in domain III of Cry1Ac derivative, CryD3, gives altered 
carbohydrate binding specificity  
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